WO2004005281A1 - Inhibitors of tyrosine kinases - Google Patents

Inhibitors of tyrosine kinases Download PDF

Info

Publication number
WO2004005281A1
WO2004005281A1 PCT/EP2003/007198 EP0307198W WO2004005281A1 WO 2004005281 A1 WO2004005281 A1 WO 2004005281A1 EP 0307198 W EP0307198 W EP 0307198W WO 2004005281 A1 WO2004005281 A1 WO 2004005281A1
Authority
WO
WIPO (PCT)
Prior art keywords
lower alkyl
phenyl
amino
mono
compound
Prior art date
Application number
PCT/EP2003/007198
Other languages
French (fr)
Other versions
WO2004005281A8 (en
Inventor
Werner Breitenstein
Pascal Furet
Sandra Jacob
Paul William Manley
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32178870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004005281(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to GBGB0215676.8A priority Critical patent/GB0215676D0/en
Priority to SI200331512T priority patent/SI1532138T1/en
Priority to DE60324805T priority patent/DE60324805D1/en
Priority to EP03762632A priority patent/EP1532138B1/en
Priority to CNA2007101077481A priority patent/CN101045727A/en
Priority to CA002491632A priority patent/CA2491632C/en
Priority to NZ537396A priority patent/NZ537396A/en
Priority to AU2003249962A priority patent/AU2003249962C9/en
Priority to US10/520,359 priority patent/US7169791B2/en
Priority to MXPA05000328A priority patent/MXPA05000328A/en
Priority to JP2004518718A priority patent/JP4110140B2/en
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Priority to DK03762632T priority patent/DK1532138T3/en
Priority to BRPI0312464A priority patent/BRPI0312464B8/en
Priority to KR1020057000159A priority patent/KR100733639B1/en
Publication of WO2004005281A1 publication Critical patent/WO2004005281A1/en
Publication of WO2004005281A8 publication Critical patent/WO2004005281A8/en
Priority to ZA200410322A priority patent/ZA200410322B/en
Priority to IL165977A priority patent/IL165977A/en
Priority to NO20050636A priority patent/NO331166B1/en
Priority to HK05109671.2A priority patent/HK1077811A1/en
Priority to US11/607,542 priority patent/US20070093506A1/en
Priority to US12/061,334 priority patent/US7569566B2/en
Priority to IL198996A priority patent/IL198996A/en
Priority to US12/489,049 priority patent/US7956053B2/en
Priority to US13/106,582 priority patent/US20110218187A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the invention relates to novel substituted pyrimidinylaminobenzamides, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
  • PKs Protein kinases
  • PKs are enzymes which catalyze the phosphorylation of specific serine, threonine or tyrosine residues in cellular proteins. These post-translational modifications of substrate proteins act as molecular switches regulating cell proliferation, activation and/or differentiation. Aberrant or excessive PK activity has been observed in many disease states including benign and malignant proliferative disorders. In a number of cases, it has been possible to treat diseases, such as proliferative disorders, by making use of PK inhibitors in vitro and in vivo.
  • the Philadelphia Chromosome is a hallmark for chronic myelogenous leukaemia (CML) and carries a hybrid gene that contains N-terminal exons of the bcr gene and the major C- terminal part (exons 2-11) of the c-abl gene.
  • the gene product is a 210 kD protein (p210 Bcr-Abl).
  • the Abl-part of the Bcr-Abl protein contains the abl-tyrosine kinase which is tightly regulated in the wild type c-abl, but constitutively activated in the Bcr-Abl fusion protein. This deregulated tyrosine kinase interacts with multiple cellular signalling pathways leading to transformation and deregulated proliferation of the cells (Lugo et al., Science 247. 1079 [1990]).
  • the compounds of formula I show inhibition of protein kinase activity.
  • the compounds of formula I described below in more detail, especially show inhibition of one or more tyrosine kinases, such as c-Abl, Bcr- Abl, the receptor tyrosine kinases PDGF-R, Flt3, VEGF-R, EGF-R, and c-Kit, as well as combinations of two or more of these; in the case of novel pyrimidinylaminobenzamides according to the invention, the compounds are appropriate for the inhibition of these and/or other protein kinases, especially those mentioned above and/or for the inhibition of mutants of these enzymes, especially of Bcr-Abl, for example the Glu255 -> Valine mutant. In view of these activities, the compounds can be used for the treatment of diseases related to especially aberrant or excessive activity of such types of kinases, especially those mentioned.
  • the invention relates to a compound of formula I,
  • Ri represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, carboxy- lower alkyl, lower alkoxycarbony Mower alkyl, or phenyl-lower alkyl;
  • R 2 represents hydrogen, lower alkyl, optionally substituted by one or more identical or different radicals R 3 , cycloalkyl, benzcycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; and R 3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amino, mono- or disubstituted amino, cycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each
  • R and R 2 together represent alkylene with four, five or six carbon atoms optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, oxo, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms; oxaalkylene with one oxygen and three or four carbon atoms; or azaalkylene with one nitrogen and three or four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N- disubstituted carbamoyl-lower alkyl, cycloalkyl, lower al
  • R 4 represents hydrogen, lower alkyl, or halogen
  • the prefix “lower” denotes a radical having up to and including a maximum of 7, especially up to and including a maximum of 4 carbon atoms, the radicals in question being either linear or branched with single or multiple branching.
  • Any asymmetric carbon atoms may be present in the (R)-, (S)- or (R,S)-configuration, preferably in the (R)- or (S)-configuration.
  • the compounds may thus be present as mixtures of isomers or as pure isomers, preferably as enantiomer-pure diastereomers.
  • the invention relates also to possible tautomers of the compounds of formula I.
  • Lower alkyl is preferably alkyl with from and including 1 up to and including 7, preferably from and including 1 to and including 4, and is linear or branched; preferably, lower alkyl is butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, such as n-propyl or isopropyl, ethyl or methyl.
  • Preferably lower alkyl is methyl, propyl or tert-butyl.
  • Lower acyl is preferably formyl or lower alkylcarbonyl, in particular acetyl.
  • aryl group is an aromatic radical which is bound to the molecule via a bond located at an aromatic ring carbon atom of the radical.
  • aryl is an aromatic radical having 6 to 14 carbon atoms, especially phenyl, naphthyl, tetrahydronaphthyl, fluorenyl or phenanthrenyl, and is unsubstituted or substituted by one or more, preferably up to three, especially one or two substituents, especially selected from amino, mono- or disubstituted amino, halogen, lower alkyl, substituted lower alkyl, lower alkenyl, lower alkynyl, phenyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, benzoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, urei
  • Aryl is more preferably phenyl, naphthyl or tetrahydronaphthyl, which in each case is either unsubstituted or independently substituted by one or two substituents selected from the group comprising halogen, especially fluorine, chlorine, or bromine; hydroxy; hydroxy etherified by lower alkyl, e.g. by methyl, by halogen-lower alkyl, e.g. trifluoromethyl, or by phenyl; lower alkylene dioxy bound to two adjacent C-atoms, e.g. methylenedioxy, lower alkyl, e.g. methyl or propyl; halogen-lower alkyl, e.g.
  • hydroxy-lower alkyl e.g. hydroxymethyl or 2-hydroxy-2-propyl
  • lower alkoxy-lower alkyl e.g. methoxymethyl or 2-methoxyethyl
  • lower alkoxycarbonyl-lower alkyl e.g. methoxy- carbonylmethyl
  • lower alkynyl such as 1-propynyl
  • esterified carboxy especially lower alkoxycarbonyl, e.g. methoxycarbonyl, n-propoxy carbonyl or iso-propoxy carbonyl
  • N-mono- substituted carbamoyl in particular carbamoyl monosubstituted by lower alkyl, e.g.
  • lower alkylamino e.g. methylamino
  • di-lower alkylamino e.g. dimethylamino or diethylamino
  • a cycloalkyl group is preferably cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl, and may be unsubstituted or substituted by one or more, especially one or two, substitutents selected from the group defined above as substitutents for aryl, most preferably by lower alkyl, such as methyl, lower alkoxy, such as methoxy or ethoxy, or hydroxy, and further by oxo or fused to a benzo ring, such as in benzcyclopentyl or benzcyclohexyl.
  • Substituted alkyl is alkyl as last defined, especially lower alkyl, preferably methyl; where one or more, especially up to three, substituents may be present, primarily from the group selected from halogen, especially fluorine, amino, N-lower alkylamino, N,N-di-lower alkylamino, N-lower alkanoylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, and phenyl-lower alkoxycarbonyl. Trifluoromethyl is especially preferred.
  • Mono- or disubstituted amino is especially amino substituted by one or two radicals selected independently of one another from lower alkyl, such as methyl; hydroxy-lower alkyl, such as 2-hydroxyethyl; lower alkoxy lower alkyl, such as methoxy ethyl; phenyl-lower alkyl, such as benzyl or 2-phenylethyI; lower alkanoyl, such as acetyl; benzoyl; substituted benzoyl, wherein the phenyl radical is especially substituted by one or more, preferably one or two, substituents selected from nitro, amino, halogen, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl, and carbamoyl; and phenyl-lower alkoxycarbonyl, wherein the phenyl radical is unsubstituted or especially
  • Disubstituted amino is also lower alkylene-amino, e.g. pyrrolidino, 2-oxopyrrolidino or piperidino; lower oxaalkylene-amino, e.g. morpholino, or lower azaalkylene-amino, e.g. piperazino or N-substituted piperazino, such as N-methylpiperazino or N- methoxycarbonylpiperazino.
  • lower alkylene-amino e.g. pyrrolidino, 2-oxopyrrolidino or piperidino
  • lower oxaalkylene-amino e.g. morpholino
  • lower azaalkylene-amino e.g. piperazino or N-substituted piperazino, such as N-methylpiperazino or N- methoxycarbonylpiperazino.
  • Halogen is especially fluorine, chlorine, bromine, or iodine, especially fluorine, chlorine, or bromine.
  • Etherified hydroxy is especially C 8 -C 2 oalkyloxy, such as n-decyloxy, lower alkoxy (preferred), such as methoxy, ethoxy, isopropyloxy, or tert-butyloxy, phenyl-lower alkoxy, such as benzyloxy, phenyloxy, halogen-lower alkoxy, such as trifluoromethoxy, 2,2,2-trifluoroethoxy or 1 ,1 ,2,2-tetrafluoroethoxy, or lower alkoxy which is substituted by mono- or bicyclic heteroaryl comprising one or two nitrogen atoms, preferably lower alkoxy which is substituted by imidazolyl, such as 1 H-imidazol-1 -yl, pyrrolyl, benzimidazolyl, such as 1-benzimidazolyl, pyridyl, especially 2-, 3- or 4-pyridyl, pyrimidinyl, especially 2-pyr
  • Esterified hydroxy is especially lower alkanoyloxy, benzoyloxy, lower alkoxycarbonyloxy, such as tert-butoxycarbonyloxy, or phenyl-lower alkoxycarbonyloxy, such as benzyloxycarbonyloxy.
  • Esterified carboxy is especially lower alkoxycarbonyl, such as tert-butoxycarbonyl, iso- propoxycarbonyl, methoxycarbonyl or ethoxycarbonyl, phenyl-lower alkoxycarbonyl, or phenyloxycarbonyl.
  • Alkanoyl is primarily alkylcarbonyl, especially lower alkanoyl, e.g. acetyl.
  • N-Mono- or N,N-disubstituted carbamoyl is especially substituted by one or two substituents independently selected from lower alkyl, phenyl-lower alkyl and hydroxy-lower alkyl, or lower alkylene, oxa-lower alkylene or aza-lower alkylene optionally substituted at the terminal nitrogen atom.
  • a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted, refers to a heterocyclic moiety that is unsaturated in the ring binding the heteroaryl radical to the rest of the molecule in formula I and is preferably a ring, where in the binding ring, but optionally also in any annealed ring, at least one carbon atom is replaced by a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur; where the binding ring preferably has 5 to 12, more preferably 5 or 6 ring atoms; and which may be unsubstituted or substituted by one or more, especially one or two, substitutents selected from the group defined above as substitutents for aryl, most preferably by lower alkyl, such as methyl, lower alkoxy, such as methoxy or ethoxy, or hydroxy.
  • the mono- or bicyclic heteroaryl group is selected from 2H-pyrrolyl, pyrrolyl, imidazolyl, benzimidazolyl, pyrazolyl, indazolyl, purinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalyl, quinazolinyl, quinnolinyl, pteridinyl, indolizinyl, 3H-indolyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, furazanyl, benzo[d]pyrazolyl, thienyl and furanyl.
  • the mono- or bicyclic heteroaryl group is selected from the group consisting of pyrrolyl, imidazolyl, such as 1 H-imidazol-1-yl, benzimidazolyl, such as 1- benzimidazolyl, indazolyl, especially 5-indazolyl, pyridyl, especially 2-, 3- or 4-pyridyl, pyrimidinyl, especially 2-pyrimidinyl, pyrazinyl, isoquinolinyl, especially 3-isoquinolinyl, quinolinyl, especially 4- or 8-quinolinyl, indolyl, especially 3-indolyl, thiazolyl, benzo[d]pyrazolyl, thienyl, and furanyl.
  • imidazolyl such as 1 H-imidazol-1-yl
  • benzimidazolyl such as 1- benzimidazolyl
  • indazolyl especially 5-indazolyl
  • the pyridyl radical is substituted by hydroxy in ortho position to the nitrogen atom and hence exists at least partially in the form of the corresponding tautomer which is pyridin-(1 H)2-one.
  • the pyrimidinyl radical is substituted by hydroxy both in position 2 and 4 and hence exists in several tautomeric forms, e.g. as pyrimidine-(1 H, 3H)2,4-dione.
  • Heterocyclyl is especially a five, six or seven-membered heterocyclic system with one or two heteroatoms selected from the group comprising nitrogen, oxygen, and sulfur, which may be unsaturated or wholly or partly saturated, and is unsubstituted or substituted especially by lower alkyl, such as methyl, phenyl-lower alkyl, such as benzyl, oxo, or heteroaryl, such as 2- piperazinyl; heterocyclyl is especially 2- or 3-pyrrolidinyl, 2-oxo-5-pyrrolidinyl, piperidinyl, N- benzyl-4-piperidinyl, N-lower alkyl-4-piperidinyl, N-lower alkyl-piperazinyl, morpholinyl, e.g. 2- or 3-morpholinyl, 2-oxo-1 H-azepin-3-yl, 2-tetrahydrofuranyl, or 2-methyl-1 ,3-dioxolan-2-
  • Salts are especially the pharmaceutically acceptable salts of compounds of formula I.
  • Such salts are formed, for example, as acid addition salts, preferably with organic or inorganic acids, from compounds of formula I with a basic nitrogen atom, especially the pharmaceutically acceptable salts.
  • Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
  • Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane-sulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1 ,2-d
  • salts may also be formed with bases, e.g. metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example N-ethyl-piperidine or N,N'- dimethylpiperazine.
  • bases e.g. metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example N-ethyl-piperidine or N,N'- dimethylpiperazine.
  • a compound of formula I may also form internal salts.
  • salts for isolation or purification purposes it is also possible to use pharmaceutically unacceptable salts, for example picrates or perchlorates.
  • pharmaceutically acceptable salts or free compounds are employed (where applicable in the form of pharmaceutical preparations), and these are therefore preferred.
  • any reference to the free compounds hereinbefore and hereinafter is to be understood as referring also to the corresponding salts, as appropriate and expedient.
  • Test for activity against c-Abl protein tyrosine kinase The test is conducted as a filter binding assay as follows: The His-tagged kinase domain of c-Abl is cloned and expressed in the baculovirus/Sf9 system as described by Bhat ef al., J Biol Chem. 272, 16170-5 (1997). A protein of 37 kD (c-Abl kinase) is purified by a two-step procedure over a Cobalt metal chelate column followed by an anion exchange column with a yield of 1-2 mg/L of Sf9 cells.
  • the purity of the c-Abl kinase is >90% as judged by SDS-PAGE after Coomassie blue staining.
  • the assay contains: c-Abl kinase (50 ng), 20 mM Tris-HCI, pH 7.5, 10 mM MgCI 2 , 10 ⁇ M Na 3 VO 4 , 1 mM DTT and 0.06 Ci/assay [ ⁇ 33 P]-ATP (5//M ATP) using 30 g/mL poly- Ala,Glu,Lys,Tyr-6:2:5:1 (Poly-AEKY, Sigma P1152) in the presence of 1% DMSO, total volume of 30 ⁇ L.
  • Reactions are terminated by adding 10 ⁇ L of 250 mM EDTA, and 30 ⁇ L of the reaction mixture is transferred onto Immobilon-PVDF membrane (Millipore, Bedford, MA, USA) previously soaked for 5 min with methanol, rinsed with water, then soaked for 5 min with 0.5% H 3 PO and mounted on vacuum manifold with disconnected vacuum source. After spotting all samples, vacuum is connected and each well rinsed with 200 ⁇ L 0.5 % H 3 PO 4 . Membranes are removed and washed on a shaker with 0.5% H 3 PO (4 times) and once with ethanol. Membranes are counted after drying at ambient temperature, mounting in Packard TopCount 96-well frame, and addition of 10 ⁇ L ⁇ /vell of Microscint TM (Packard).
  • the murine myeloid progenitor cell line 32Dcl3 transfected with the p210 Bcr-Abl expression vector pGDp210Bcr/Abl (32D-bcr/abl) was obtained from J. Griffin (Dana Faber Cancer Institue, Bosten, MA, USA).
  • the cells express the fusion Bcr-Abl protein with a constitutively active abl kinase and proliferate growth factor independent.
  • the cells are expanded in RPM1 1640 (AMI MED), 10% fetal calf serum, 2 mM glutamine (Gibco)nuancescomplete medium"), and a working stock is prepared by freezing aliquots of 2 x 10 6 cells per vial in freezing medium (95% FCS, 5% DMSO (SIGMA)). After thawing, the cells are used during maximally 10 -12 passages for the experiments.
  • the compound is incubated together with the cells for 90 min at 37°C, 5% CO 2 , followed by centrifugation of the tissue culture plates at 1300 rpm (Beckmann GPR centrifuge) and removal of the supematants by careful aspiration taking care not to remove any of the pelleted cells.
  • the cell pellets are lysed by addition of 150 ⁇ L lysis buffer (50 mM Tris/HCI, pH 7.4, 150 mM sodium chloride, 5 mM EDTA, 1 mM EGTA, 1% NP-40, 2 mM sodium ortho- vanadate, 1 mM PMSF, 50 ⁇ g/mL aprotinin and 80 ⁇ glmL leupeptin) and either used immediatedly for the ELISA or stored frozen in the plates at -20°C until usage.
  • Black ELISA plates (Packard HTRF-96 black plates) are precoated over night at 4°C with 50 ng/well of the rabbit polyclonal anti-abl-SH3 domain Ab 06-466 from Upstate in 50 ⁇ L PBS.
  • the difference between the ELISA-readout (CPS) obtained for with the lysates of the untreated 32D-Bcr/Abl cells and the readout for the assay-background (all components, but without cell lysate) is calculated and taken as 100% reflecting the constitutively phosphorylated Bcr-Abl protein present in these cells.
  • the activity of the compound on the Bcr-Abl kinase activity is expressed as percent reduction of the Bcr-Abl phosphorylation.
  • the values for the IC 50 and IC 90 are determined from the dose response curves by graphical extrapolation.
  • Test for activity against VEGF-receptor tyrosine kinase The test is conducted using Flt-1 VEGF-receptor tyrosine kinase. The detailed procedure is as follows: 30 ⁇ L kinase solution (10 ng of the kinase domain of Flt-1 , Shibuya etal., Oncogene 5, 519-24 [1990]) in 20 mM Tris»HCI pH 7.5, 3 mM manganese dichloride (MnCI 2 ), 3 mM magnesium chloride (MgCI 2 ), 10 ⁇ M sodium vanadate, 0.25 mg/mL polyethylenglycol (PEG) 20000, 1 mM dithiothreitol and 3 ⁇ g/ ⁇ L poly(Glu,Tyr) 4:1 (Sigma, Buchs, Switzerland), 8 ⁇ M [ 33 P]-ATP (0.2 ⁇ Ci) , 1% DMSO, and 0 to 100 ⁇ M of the compound to be tested
  • the reaction is then terminated by the addition of 10 ⁇ L 0.25 M ethylenediaminetetraacetate (EDTA) pH 7.
  • EDTA ethylenediaminetetraacetate
  • LAB SYSTEMS LAB SYSTEMS, USA
  • IC 50 -values are determined by linear regression analysis of the percentages for the inhibition of each compound in at least four concentrations (as a rule 0.01 , 0.1 , 1.0 and 10 ⁇ mol).
  • the IC 50 -values that can be found with compounds of formula I are in the range of 1 to 10'OOO nM, preferably in the range of 1 to 100 nM.
  • transfected CHO cells which permanently express human VEGF receptor (KDR)
  • KDR human VEGF receptor
  • FCS fetal calf serum
  • the compounds to be tested are then diluted in culture medium (without FCS, with 0.1% bovine serum albumin) and added to the cells. (Controls comprise medium without test compounds). After two hours of incubation at 37°C, recombinant VEGF is added; the final VEGF concentration is 20 ng/mL).
  • the cells are washed twice with ice-cold PBS (phosphate-buffered saline) and immediately lysed in 100//L lysis buffer per well.
  • the lysates are then centrifuged to remove the cell nuclei, and the protein concentrations of the supernatants are determined using a commercial protein assay (BIORAD).
  • BIORAD commercial protein assay
  • a sandwich ELISA is carried out to measure the KDR-receptor phosphorylation: a monoclonal antibody to KDR (for example Mab 1495.12.14) is immobilized on black ELISA plates (OptiPlateTM HTRF-96 from Packard). The plates are then washed and the remaining free protein-binding sites are saturated with 1% BSA in PBS. The cell lysates (20 ⁇ g protein per well) are then incubated in these plates overnight at 4°C together with an anti-phosphotyrosine antibody coupled with alkaline phosphatase (PY20:AP from Transduction Laboratories).
  • PY20 alkaline phosphatase
  • the plates are washed again and the binding of the antiphosphotyrosine antibody to the captured phosphorylated receptor is then demonstrated using a luminescent AP substrate (CDP-Star, ready to use, with Emerald II; TROPIX).
  • the luminescence is measured in a Packard Top Count Microplate Scintillation Counter (Top Count).
  • Top Count Packard Top Count Microplate Scintillation Counter
  • the activity of the tested substances is calculated as % inhibition of VEGF-induced KDR-receptor phosphorylation, wherein the concentration of substance that induces half the maximum inhibition is defined as the ED50 (effective dose for 50% inhibition).
  • Compounds of formula I here preferably show ED50 values in the range of 0.25 nM to 1000 nM, preferably 0.25 to 250 nM.
  • a compound of formula I or a N-oxide thereof inhibits to varying degrees also other tyrosine kinases involved in signal transduction which are mediated by trophic factors, for example Bcr-Abl and Abl kinase, Arg, kinases from the Src family, especially c-Src kinase, Lck, and Fyn; also kinases of the EGF family, for example, c-erbB2 kinase (HER-2), c-erbB3 kinase, c-erbB4 kinase; insulin-like growth factor receptor kinase (IGF-1 kinase), especially members of the PDGF-receptor tyrosine kinase family, such as PDGF-receptor kinase, CSF-1 -receptor kinase, Kit-receptor kinase and VEGF-receptor kinase; and also serine
  • HER-2 c-erbB2 tyrosine kinase
  • HER-2 c-erbB2 tyrosine kinase
  • a compound of formula I according to the invention shows therapeutic efficacy especially against disorders dependent on protein kinase, especially proliferative diseases.
  • the compounds of the formula I primarily inhibit the growth of blood vessels and are thus, for example, effective against a number of diseases associated with deregulated angiogenesis, especially diseases caused by ocular neovascularisation, especially retinopathies, such as diabetic retinopathy or age-related macula degeneration, psoriasis, haemangioblastoma, such as haemangioma, mesangial cell proliferative disorders, such as chronic or acute renal diseases, e.g.
  • diabetic nephropathy malignant nephrosclerosis, thrombotic microangiopathy syndromes or transplant rejection, or especially inflammatory renal disease, such as glomerulonephritis, especially mesangioproliferative glomerulonephritis, haemolytic-uraemic syndrome, diabetic nephropathy, hypertensive nephrosclerosis, atheroma, arterial restenosis, autoimmune diseases, diabetes, endometriosis, chronic asthma, and especially neoplastic diseases (solid tumors, but also leukemias and other "liquid tumors", especially those expressing c-kit, KDR, Flt-1 or Flt-3), such as especially breast cancer, cancer of the colon, lung cancer (especially small-cell lung cancer), cancer of the prostate or Kaposi's sarcoma.
  • a compound of formula I (or an N-oxide thereof) inhibits the growth of tumours and is especially suited to preventing the metastatic spread of tumors and the growth of micrometastases.
  • a compound of formula I can be administered alone or in combination with one or more other therapeutic agents, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic agents being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic agents.
  • a compound of formula I can besides or in addition be administered especially for tumor therapy, such as leukaemia therapy, in combination with chemotherapy, radiotherapy, immunotherapy, surgical intervention, or a combination of these. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are therapy to maintain the patient's status after tumor regression, or even chemopreventive therapy, for example in patients at risk.
  • Therapeutic agents for possible combination are especially one or more cytostatic or cytotoxic compounds, for example a chemotherapeutic agent or several selected from the group comprising indarubicin, cytarabine, interferon, hydroxyurea, bisulfan, or an inhibitor of polyamine biosynthesis, an inhibitor of protein kinase, especially of serine/threonine protein kinase, such as protein kinase C, or of tyrosine protein kinase, such as epidermal growth factor receptor tyrosine kinase, a cytokine, a negative growth regulator, such as TGF- ⁇ or IFN- ⁇ , an aromatase inhibitor, a classical cytostatic, and an inhibitor of the interaction of an SH2 domain with a phosphorylated protein.
  • cytostatic or cytotoxic compounds for example a chemotherapeutic agent or several selected from the group comprising indarubicin, cytarabine, interferon, hydroxyurea, bisulfan
  • a compound according to the invention is not only for the (prophylactic and preferably therapeutic) management of humans, but also for the treatment of other warm-blooded animals, for example of commercially useful animals, for example rodents, such as mice, rabbits or rats, or guinea-pigs. Such a compound may also be used as a reference standard in the test systems described above to permit a comparison with other compounds.
  • the invention relates also to the use of a compound of formula I or a N-oxide thereof for the inhibition of tyrosine kinase activity, either in vitro or in vivo.
  • R ⁇ represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, carboxy- lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl;
  • R 2 represents hydrogen, lower alkyl, optionally substituted by one or two identical or different radicals R 3 , cycloalkyl, benzcycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising one, two or three nitrogen atoms or one sulfur atom, which aryl and heteroaryl groups in each case are unsubstituted or mono- or polysubstituted; and R 3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amino, mono- or disubstituted amino, cycloalkyl, heterocyclyl, an aryl group, furanoyl, thienoyl, or a mono- or bicyclic heteroaryl group comprising one, two or three ring nitrogen atoms, zero or one ring oxygen atom and zero or one
  • Ri and R 2 together represent alkylene with four or five carbon atoms, optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms in the alkylene group; oxaalkylene with one oxygen and three or four carbon atoms, or azaalkylene with one nitrogen and three or four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N- disubstituted carbamoyl-lower alkyl, cycloalkyl, lower al
  • R 4 represents hydrogen, lower alkyl, or halogen
  • Ri represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl;
  • R 2 represents hydrogen, lower alkyl, optionally substituted by one or two identical or different radicals R 3 , cyclopentyl, benzcyclopentyl, cylcohexyl, pyrrolidinyl, oxazolinyl, piperidinyl, N- substituted piperidinyl, morpholinyl, azepinyl, oxo-azepinyl, oxazepinyl, phenyl, naphthalinyl, tetrahydronaphthalinyl or a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which phenyl, naphthalinyl and heteroaryl groups in each case are unsubstituted or mono- or polysubstituted, thienyl, or lower alkoxycarbonyl-lower alkylthienyl; and R 3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbon
  • Ri and R 2 together represent alkylene with four or five carbon atoms, optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms in the alkylene group; oxaalkylene with one oxygen and four carbon atoms; or azaalkylene with one nitrogen and four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N-disubstituted carbamoyl- lower alkyl, cycloalkyl, lower alkoxycarbony
  • R 4 represents hydrogen, lower alkyl, or halogen
  • i represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl;
  • R 2 represents hydrogen; lower alkyl, optionally substituted by one radical R 3 , by two phenyl groups, by two lower alkoxycarbonyl groups, by phenyl and lower alkoxycarbonyl, or by hydroxyphenyl and lower alkoxycarbonyl; cyclopentyl; benzcyclopentyl; cylcohexyl; pyrrolidinyl; oxazolinyl; piperidinyl; N-lower alkylpiperidinyl; N-benzylpiperidinyl; N- pyrimidinylpiperidinyl; morpholinyl; azepinyl; oxo-azepinyl; oxazepinyl; phenyl, naphthalinyl, tetrahydronaphthalinyl or a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which phenyl, naphthalinyl and heteroaryl groups
  • R 3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, carbamoyl mono-or disubstituted by lower alkyl, phenyl or lower alkylene, amino, lower alkylamino, di-lower alkylamino, phenylamino, N-lower alkyl-N-phenylamino, pyrrolidino, oxopyrrolidino, piperidino, morpholino, imidazolino, oxoimidazolino, cycloalkyl, heterocyclyl, furyl; phenyl, naphthalinyl, tetrahydronaphthalinyl, or a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which phenyl, naphthalinyl and heteroaryl group is unsubstituted or substituted by one or two substituents selected from the group consisting
  • R, and R 2 together represent alkylene with four or five carbon atoms, optionally mono- or disubstituted by lower alkyl, cycloalkyl, phenyl, hydroxy, lower alkoxy, amino, benzoylamino, piperidino, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms in the alkylene group; oxaalkylene with one oxygen and four carbon atoms; or azaalkylene with one nitrogen and four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy- lower alkyl, carbamoyl-lower alkyl, carbamoyl-lower alkyl N-mono- or N,N-disubstituted by lower alkyl, phenyl, lower alkylene or
  • R 4 represents hydrogen or lower alkyl
  • R-i represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, or benzyl
  • R 2 represents lower alkyl, optionally substituted by one radical R 3 , by two phenyl groups, by two lower alkoycarbonyl groups, by phenyl and lower alkoxycarbonyl, or by hydroxyphenyl and lower alkoxycarbonyl; cyclopentyl; benzcyclopentyl; cylcohexyl; pyrrolidinyl; piperidinyl; N-lower alkylpiperidinyl; N-benzylpiperidinyl; N-pyrimidinylpiperidinyl; morpholinyl; azepinyl; oxoazepinyl; phenyl; naphthalinyl; tetrahydronaphthalinyl; pyridyl; lower alkyl-pyridyl; quinolinyl; thienyl; lower alkoxycarbonylmethylthienyl; or phenyl substituted by one or two substituents selected from the group
  • R 3 represents hydroxy, lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, amino, lower alkylamino, di-lower alkylamino, phenylamino, N- lower alkyl-N-phenylamino, pyrrolidino, oxopyrrolidino, piperidino, morpholino, imidazolino, oxoimidazolino, cyclopropyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, phenyl, naphthalinyl, tetrahydronaphthalinyl, furyl, a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which heteroaryl group is unsubstituted or mono- or disubstituted by lower alkyl, hydroxy and lower alkoxy, or phenyl substituted by
  • ⁇ and R 2 together represent alkylene with four or five carbon atoms, optionally mono- or disubstituted by phenyl, hydroxy, amino, benzoylamino, or piperidino; benzalkylene with four or five carbon atoms in the alkylene group; oxaalkylene with one oxygen and four carbon atoms; or azaalkylene with one nitrogen and four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carbamoyl-lower alkyl, pyrrolidinocarbonyl-lower alkyl, morpholinocarbonyl-lower alkyl, cyclopentyl, lower alkoxycarbonyl, phenyl, methoxyphenyl, trifluoromethylphenyl, pyridinyl; pyrimidinyl, or pyrazinyl;
  • R 4 represents hydrogen or methyl
  • a specially preferred group of compounds comprises compounds of formula I wherein R represents hydrogen, and
  • R 2 represents phenyl substituted by trifluoromethyl, especially 3-trifluoromethylphenyl, and optionally a further substituent selected from the group consisting of hydroxy-lower alkyl, e.g. 1-hydroxy-l-methylethyl, lower alkylamino, e.g. methyl- or ethylamino, hydroxy-lower alkylamino, e.g. 2-hydroxy-1 -propylamino or 2-hydroxy-2-propylamino, di-lower alkylamino, e.g. diethylamino, 1 H-imidazolyl, lower alkyl-1 H-imidazolyl, e.g.
  • R 4 represents methyl; and a N-oxide or a pharmaceutically acceptable salt of such a compound.
  • R 2 represents phenyl which is mono- or disubstituted by imidazol-lower alkoxy, lower alkyl amino, trifluoromethyl, hydroxy lower alkyl amino, bis-(lower alkoxy lower alkyl) amino, lower alkyl piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, phenyl, pyridyl, imidazolyl which is unsubstituted or mono- or disubstituted by lower alkyl or N-lower alkyl carbamoyl;
  • R 4 is lower alkyl; and to the N-oxides and pharmaceutically acceptable salts of such compounds.
  • the invention relates also to 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid and to 3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid; intermediates for the formation of the preferred amides of the invention.
  • the invention relates to the use of a compound of formula I or of a N-oxide or a possible tautomer thereof or of a pharmaceutically acceptable salt of such a compound for the preparation of a pharmaceutical composition for the treatment of a disease which responds to an inhibition of protein kinase activity, wherein the disease is a neoplastic disease.
  • the invention relates to the use of a compound of the formula I or of a N- oxide or a possible tautomer thereof; or of a pharmaceutically acceptable salt of such a compound for the preparation of a pharmaceutical composition for the treatment of leukaemia which responds to an inhibition of the Abl tyrosine kinase activity.
  • the invention provides a method for the treatment of a disease which responds to an inhibition of protein kinase activity, which comprises administering a compound of formula I or a N-oxide or a pharmaceutically acceptable salt thereof, wherein the radicals and symbols have the meanings as defined above, in a quantity effective against said disease, to a warm-blooded animal requiring such treatment.
  • a compound of the invention may be prepared by processes that, though not applied hitherto for the new compounds of the present invention, are known per se, especially a process characterized in that for the synthesis of a compound of the formula I wherein the symbols R 1? R 2 and R 4 are as defined for a compound of the formula I, a 4- R 4 -3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]-benzoic acid of formula II
  • R is as defined for a compound of formula I, or a derivative thereof wherein the carboxy group -COOH is in activated form, is reacted with an amine of the formula III
  • R ⁇ and R 2 are as defined for a compound of the formula I, optionally in the presence of a dehydrating agent and an inert base and/or a suitable catalyst, and optionally in the presence of an inert solvent;
  • an obtainable compound of formula I is converted into another compound of formula I or a N-oxide thereof, a free compound of formula I is converted into a salt, an obtainable salt of a compound of formula I is converted into the free compound or another salt, and/or a mixture of isomeric compounds of formula I is separated into the individual isomers.
  • a derivative of the compound of formula II wherein the carboxy group is in activated form is especially a reactive ester, a reactive anhydride or a reactive cyclic amide.
  • Reactive esters of the acid of formula II are especially esters unsaturated at the linking carbon atom of the esterifying radical, for example esters of the vinyl ester type, such as actual vinyl esters (obtainable, for example, by transesterification of a corresponding ester with vinyl acetate; activated vinyl ester method), carbamoylvinyl esters (obtainable, for example, by treatment of the corresponding acid with an isoxazolium reagent; 1 ,2-oxazolium or Woodward method), or 1 -lower alkoxyvinyl esters (obtainable, for example, by treatment of the corresponding acid with a lower alkoxyacetylene; ethoxyacetylene method), or esters of the amidino type, such as N,N'-disubstituted amidino esters (obtainable, for example, by treatment of the corresponding acid with a suitable N,N'-disubstituted carbodiimide, for example N,N'-dicyclohexyl
  • Anhydrides of the acid of formula II may be symmetric or preferably mixed anhydrides of that acid, for example anhydrides with inorganic acids, such as acid halides, especially acid chlorides (obtainable, for example, by treatment of the corresponding acid with thionyl chloride, phosphorus pentachloride or oxalyl chloride; acid chloride method), azides (obtainable, for example, from a corresponding acid ester via the corresponding hydrazide and treatment thereof with nitrous acid; azide method), anhydrides with carbonic acid semiderivatives, such as corresponding esters, for example carbonic acid lower alkyl semiesters (obtainable, for example, by treatment of the corresponding acid with haloformic, such as chloroformic, acid lower alkyl esters or with a 1 -lower alkoxycarbonyl-2-lower alkoxy- 1 ,2-dihydroquinoline, for example 1 -lower alkoxycarbonyI-2-ethoxy-1 ,2-dihydr
  • Suitable cyclic amides are especially amides with five-membered diazacycles of aromatic character, such as amides with imidazoles, for example imidazole (obtainable, for example, by treatment of the corresponding acid with N.N'-carbonyldiimidazole; imidazolide method), or pyrazoles, for example 3,5-dimethyl-pyrazole (obtainable, for example, by way of the acid hydrazide by treatment with acetylacetone; pyrazolide method).
  • imidazoles for example imidazole (obtainable, for example, by treatment of the corresponding acid with N.N'-carbonyldiimidazole; imidazolide method)
  • pyrazoles for example 3,5-dimethyl-pyrazole (obtainable, for example, by way of the acid hydrazide by treatment with acetylacetone; pyrazolide method).
  • Derivatives of the acid of formula II wherein the carboxy group is in activated form are preferably formed in situ.
  • N,N'-disubstituted amidino esters can be formed in situ by reacting a mixture of the acid of formula II and the amine of formula 111 in the presence of a suitable N,N-disubstituted carbodiimide, for example N,N'-dicyclohexylcarbodiimide.
  • Reactive mixed anhydrides of the acid of formula II with an organic phosphonic acid may be formed in situ by reaction with e.g. propylphosphonic anhydride or diethylcyanophosphonate in the presence of suitable base, preferably a tertiary amine, e.g. triethylamine or dimethylaminopyridine.
  • the reaction can be carried out in a manner known per se, the reaction conditions being dependent especially on whether, and if so how, the carboxy group of the carboxylic acid of formula II has been activated, usually in the presence of a suitable solvent or diluent or of a mixture thereof and, if necessary, in the presence of a condensation agent, which, for example when the carboxy group participating in the reaction is in the form of an anhydride, may also be an acid-binding agent, with cooling or heating, for example in a temperature range from approximately -30 °C to approximately +150 °C, especially approximately from 0 °C to +100 °C, preferably from room temperature (approx.
  • Customary condensation agents are, for example, carbodiimides, for example N,N'-diethyl-, N,N'-dipropyI-, N,N'-dicyclohexyl- or N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide, suitable carbonyl compounds, for example carbonyldiimidazole, or 1 ,2-oxazolium compounds, for example 2-ethyl-5-phenyl-1 ,2-oxazolium 3'-sulfonate and 2-tert-butyl-5- methyl-isoxazolium perchlorate, or a suitable acylamino compound, for example 2-ethoxy-1 - ethoxycarbonyl-1 ,2-dihydroquinoline.
  • carbodiimides for example N,N'-diethyl-, N,N'-dipropyI-, N,N'-dicyclohexyl- or N-e
  • Customary acid-binding condensation agents are, for example, alkali metal carbonates or hydrogen carbonates, for example sodium or potassium carbonate or hydrogen carbonate (customarily together with a sulfate), or organic bases, such as, customarily, pyridine or triethylamine, or sterically hindered tri-lower alkylamines, for example N,N-diisopropyl-N-ethyl-amine.
  • the carboxylic acid of formula II is reacted with an amine of formula III in a suitable solvent, such as e.g. N.N-dimethylformamide, in the presence of propylphosphonic anhydride or diethylcyanophosphanate and triethylamine, between 1 and 48 hours at between 0°C and around 50°C, preferably at room temperature.
  • a suitable solvent such as e.g. N.N-dimethylformamide
  • one or more other functional groups for example carboxy, hydroxy, amino, or mercapto, are or need to be protected in a compound of formula III, because they should not take part in the reaction, these are such groups as are usually used in the synthesis of amides, in particular peptide compounds, and also of cephalosporins and penicillins, as well as nucleic acid derivatives and sugars.
  • the protecting groups may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions, such as acylations, etherifications, esterifications, oxidations, solvolysis, and similar reactions. It is a characteristic of protecting groups that they lend themselves readily, i.e. without undesired secondary reactions, to removal, typically by solvolysis, reduction, photolysis or also by enzyme activity, for example under conditions analogous to physiological conditions, and that they are not present in the end-products.
  • the specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned hereinabove and hereinafter.
  • functional groups of the starting compounds which should not take part in the reaction may be present in unprotected form or may be protected for example by one or more of the protecting groups mentioned hereinabove under "protecting groups".
  • the protecting groups are then wholly or partly removed according to one of the methods described there.
  • Salts of a compound of formula I with a salt-forming group may be prepared in a manner known per se. Acid addition salts of compounds of formula I may thus be obtained by treatment with an acid or with a suitable anion exchange reagent.
  • Salts can usually be converted to free compounds, e.g. by treating with suitable basic agents, for example with alkali metal carbonates, alkali metal hydrogencarbonates, or alkali metal hydroxides, typically potassium carbonate or sodium hydroxide.
  • suitable basic agents for example with alkali metal carbonates, alkali metal hydrogencarbonates, or alkali metal hydroxides, typically potassium carbonate or sodium hydroxide.
  • Stereoisomeric mixtures e.g. mixtures of diastereomers
  • Diastereomeric mixtures for example may be separated into their individual diastereomers by means of fractionated crystallization, chromatography, solvent distribution, and similar procedures. This separation may take place either at the level of a starting compound or in a compound of formula I itself.
  • Enantiomers may be separated through the formation of diastereomeric salts, for example by salt formation with an enantiomer-pure chiral acid, or by means of chromatography, for example by HPLC, using chromatographic substrates with chiral ligands.
  • a compound of the formula I wherein R-i is hydrogen can be converted to the respective compound wherein Ri is lower alkyl by reaction e.g. with a diazo lower alkyl compound, especially diazomethane, in an inert solvent, preferably in the presence of a noble metal catalyst, especially in dispersed form, e.g. copper, or a noble metal salt, e.g. copper(l)- chloride or copper(ll)-sulfate. Also reaction with lower alkylhalogenides is possible, or with other leaving group carrying lower alkanes, e.g.
  • lower alkyl alcohols esterified by a strong organic sulfonic acid such as a lower alkanesulfonic acid (optionally substituted by halogen, such as fluoro), an aromatic sulfonic acid, for example unsubstituted or substituted benzenesulfonic acid, the substituents preferably being selected from lower alkyl, such as methyl, halogen, such as bromo, and/or nitro, e.g. esterified by methanesulfonic acid, or p- toluene sulfonic acid.
  • a strong organic sulfonic acid such as a lower alkanesulfonic acid (optionally substituted by halogen, such as fluoro)
  • an aromatic sulfonic acid for example unsubstituted or substituted benzenesulfonic acid, the substituents preferably being selected from lower alkyl, such as methyl, halogen, such as bromo, and/or nitro
  • the alkylation takes place under usual conditions for alkylation of amides, especially in aqueous solution and/or in the presence of polar solvents, typically alcohols, for example methanol, ethanol, isopropanol, or ethylene glycol, or dipolar aprotic solvents, e.g. tetrahydrofuran, dioxane, or dimethylformamide, where applicable in the presence of acidic or basic catalysts, generally at temperatures from about 0°C to the boiling temperature of the corresponding reaction mixture, preferably between 20°C and reflux temperature, if necessary under increased pressure, e.g. in a sealed tube, and/or under inert gas, typically nitrogen or argon.
  • polar solvents typically alcohols, for example methanol, ethanol, isopropanol, or ethylene glycol
  • dipolar aprotic solvents e.g. tetrahydrofuran, dioxane, or dimethylformamide
  • acidic or basic catalysts generally at temperatures from
  • All process steps described here can be carried out under known reaction conditions, preferably under those specifically mentioned, in the absence of or usually in the presence of solvents or diluents, preferably such as are inert to the reagents used and able to dissolve these, in the absence or presence of catalysts, condensing agents or neutralisiing agents, for example ion exchangers, typically cation exchangers, for example in the H + form, depending on the type of reaction and/or reactants at reduced, normal, or elevated temperature, for example in the range from -100°C to about 190°C, preferably from about -80°C to about 150°C, for example at -80 to -60°C, at room temperature, at - 20 to 40°C or at the boiling point of the solvent used, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under argon or nitrogen.
  • solvents or diluents preferably such as are inert to the reagent
  • Salts may be present in all starting compounds and transients, if these contain salt-forming groups. Salts may also be present during the reaction of such compounds, provided the reaction is not thereby disturbed.
  • isomeric mixtures that occur can be separated into their individual isomers, e.g. diastereomers or enantiomers, or into any mixtures of isomers, e.g. racemates or diastereomeric mixtures.
  • the invention relates also to those forms of the process in which one starts from a compound obtainable at any stage as a transient and carries out the missing steps, or breaks off the process at any stage, or forms a starting material under the reaction conditions, or uses said starting material in the form of a reactive derivative or salt, or produces a compound obtainable by means of the process according to the invention and processes the said compound in situ.
  • a compound of formula I is prepared according to or in analogy to the processes and process steps defined in the Examples.
  • the compounds of formula I are also obtainable in the form of hydrates, or their crystals can include for example the solvent used for crystallization (present as solvates).
  • the present invention relates furthermore to a method for the treatment of a neoplastic disease which responds to an inhibition of a protein kinase activity, which comprises administering a compound of formula I or a N-oxide or a pharmaceutically acceptable salt thereof, wherein the radicals and symbols have the meanings as defined above for formula I, in a quantity effective against said disease, to a warm-blooded animal requiring such treatment.
  • the invention relates to a method for the treatment of leukaemia which responds to an inhibition of the Abl tyrosine kinase activity, which comprises administering a compound of formula I or a N-oxide or a pharmaceutically acceptable salt thereof, wherein the radicals and symbols have the meanings as defined above for formula I, in a quantity effective against said leukaemia, to a warm-blooded animal requiring such treatment.
  • compositions that comprise a compound of formula I or a N-oxide thereof as active ingredient and that can be used especially in the treatment of the diseases mentioned at the beginning.
  • Compositions for enteral administration such as nasal, buccal, rectal or, especially, oral administration, and for parenteral administration, such as intravenous, intramuscular or subcutaneous administration, to warm-blooded animals, especially humans, are especially preferred.
  • the compositions comprise the active ingredient alone or, preferably, together with a pharmaceutically acceptable carrier.
  • the dosage of the active ingredient depends upon the disease to be treated and upon the species, its age, weight, and individual condition, the individual pharmacokinetic data, and the mode of administration.
  • the present invention relates especially to pharmaceutical compositions that comprise a compound of formula I, a tautomer, a N-oxide or a pharmaceutically acceptable salt, or a hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier.
  • the invention relates also to pharmaceutical compositions for use in a method for the prophylactic or especially therapeutic management of the human or animal body, to a process for the preparation thereof (especially in the form of compositions for the treatment of tumors) and to a method of treating tumor diseases, especially those mentioned hereinabove.
  • a pharmaceutical preparation is suitable for administration to a warm-blooded animal, especially humans or commercially useful mammals suffering from a disease responsive to an inhibition of the Abl tyrosine kinase, for example chronic myelo- genous leukaemia (CML), and comprises an effective quantity of a compound of formula I or N-oxides thereof for the inhibition of the Bcr-Abl fusion protein, or a pharmaceutically acceptable salt thereof, if salt-forming groups are present, together with at least one pharmaceutically acceptable carrier.
  • CML chronic myelo- genous leukaemia
  • a pharmaceutical composition for the prophylactic or especially therapeutic management of neoplastic and other proliferative diseases of a warm-blooded animal, especially a human or a commercially useful mammal requiring such treatment, especially suffering from such a disease, comprising as active ingredient in a quantity that is prophylactically or especially therapeutically active against the said diseases a novel compound of formula I or N-oxides thereof, is likewise preferred.
  • the pharmaceutical compositions comprise from approximately 1 % to approximately 95% active ingredient, single-dose administration forms comprising in the preferred embodiment from approximately 20% to approximately 90% active ingredient and forms that are not of single-dose type comprising in the preferred embodiment from approximately 5% to approximately 20% active ingredient.
  • Unit dose forms are, for example, coated and uncoated tablets, ampoules, vials, suppositories, or capsules.
  • Further dosage forms are, for example, ointments, creams, pastes, foams, tinctures, sprays, etc. Examples are capsules containing from about 0.05 g to about 1.0 g active ingredient.
  • compositions of the present invention are prepared in a manner known per se, for example by means of conventional mixing, granulating, coating, dissolving or lyophilizing processes.
  • compositions of the active ingredient Preference is given to the use of solutions of the active ingredient, and also suspensions or dispersions, especially isotonic aqueous solutions, dispersions or suspensions which, for example in the case of lyophilized compositions comprising the active ingredient alone or together with a carrier can be made up before use.
  • the pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes.
  • the said solutions or suspensions may comprise viscosity-increasing agents or solubilizers.
  • Suspensions in oil comprise as the oil component the vegetable, synthetic, or semi-synthetic oils customary for injection purposes.
  • liquid fatty acid esters that contain as the acid component a long-chained fatty acid having from 8 to 22 carbon atoms.
  • the alcohol component of these fatty acid esters has a maximum of 6 carbon atoms and is a monovalent or polyvalent, for example a mono-, di- or trivalent, alcohol, especially glycol and glycerol.
  • compositions for oral administration can be obtained, for example, by combining the active ingredient with one or more solid carriers, if desired granulating a resulting mixture, and processing the mixture or granules, if desired or necessary, by the inclusion of additional excipients, to form tablets or tablet cores.
  • Suitable carriers are especially fillers, such as sugars, cellulose preparations, and/or calcium phosphates, and also binders, such as starches, and/or polyvinylpyrrolidone, and/or, if desired, disintegrators. Additional excipients are especially flow conditioners and lubricants.
  • Tablet cores can be provided with suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations.
  • suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations.
  • compositions for oral administration also include hard capsules consisting of gelatin, and also soft, sealed capsules consisting of gelatin and a plasticizer.
  • the hard capsules may contain the active ingredient in the form of granules, for example in admixture with fillers, binders, and/or glidants, and optionally stabilizers.
  • the active ingredient is preferably dissolved or suspended in suitable liquid excipients, to which stabilizers and detergents may also be added.
  • Pharmaceutical compositions suitable for rectal administration are, for example, suppositories that consist of a combination of the active ingredient and a suppository base.
  • aqueous solutions of an active ingredient in water-soluble form for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers, are especially suitable.
  • the active ingredient optionally together with excipients, can also be in the form of a lyophilizate and can be made into a solution before parenteral administration by the addition of suitable solvents.
  • Solutions such as are used, for example, for parenteral administration can also be employed as infusion solutions.
  • Preferred preservatives are, for example, antioxidants, such as ascorbic acid, or microbicides, such as sorbic acid or benzoic acid.
  • the invention relates likewise to a process or a method for the treatment of one of the pathological conditions mentioned hereinabove, especially a disease which responds to an inhibition of a tyrosine kinase, especially a corresponding neoplastic disease.
  • the compounds of formula I or N-oxides thereof can be administered as such or especially in the form of pharmaceutical compositions, prophylactically or therapeutically, preferably in an amount effective against the said diseases, to a warm-blooded animal, for example a human, requiring such treatment.
  • the daily dose administered is from approximately 0.05 g to approximately 5 g, preferably from approximately 0.25 g to approximately 1.5 g, of a compound of the present invention.
  • the present invention relates especially also to the use of a compound of formula I or N- oxides thereof, or a pharmaceutically acceptable salt thereof, especially a compound of formula I which is said to be preferred, or a pharmaceutically acceptable salt thereof, as such or in the form of a pharmaceutical formulation with at least one pharmaceutically acceptable carrier for the therapeutic and also prophylactic management of one or more of the diseases mentioned hereinabove, preferably a disease which responds to an inhibition of a protein kinase, especially a neoplastic disease, more especially leukaemia which responds to an inhibition of the Abl tyrosine kinase.
  • the preferred dose quantity, composition, and preparation of pharmaceutical formulations (medicines) which are to be used in each case are described above.
  • New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention.
  • such starting materials are used and reaction conditions so selected as to enable the preferred compounds to be obtained.
  • the substituted aminobenzoic acid of formula II for example, can be obtained by reaction of an ester of 3-amino-4-R -benzoic acid, e.g. 3-amino-4-methylbenzoic acid, with cyanamide and condensing the obtainable guanidine with 3-(dimethylamino)-1 -(3-pyridinyl)-2-propen-1 - one, and finally hyrolysing the ester function.
  • Example 1 ⁇ /-(2-Furanylmethyl)-4-methyl-3-r[4-(3-pyridinv ⁇ -2-pyrimidinyl1aminolbenzamide
  • a solution containing -50% of propylphosphonic anhydride in /V, ⁇ /-dimethylformamide (Fluka, Buchs, Switzerland; 674 ⁇ L, ⁇ 1 mmol) is added within 20 minutes to a stirred mixture of 4- methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzoic acid (214.4 mg, 0.7 mmol), furfurylamine (Aldrich, Buchs, Switzerland; 61.8 ⁇ L, 0.7 mmol) and triethylamine (776 ⁇ L, 5.6 mmol) in 2 mL ⁇ /, ⁇ /-dimethylformamide.
  • the starting material is prepared as follows:
  • Example 1 a 3-r(Aminoiminomethyl)amino1-4-methyl-benzoic acid ethyl ester mononitrate Cyanamide (Fluka, Buchs, Switzerland; 77.4 g, 1.842 mol) is added to a solution of 3-amino- 4-methylbenzoic acid ethyl ester (J. Med. Chem. 16, 118-122, 1973; 150 g, 0.837 mol) in 850 mL of ethanol. Hydrochloric acid (Fluka, Buchs, Switzerland; 108 mL of 12M, 1.27 mol) is then added dropwise over 15 min and the reaction mixture is then stirred at 90°C (bath temperature) for 15 hours.
  • Cyanamide (Fluka, Buchs, Switzerland; 77.4 g, 1.842 mol) is added to a solution of 3-amino- 4-methylbenzoic acid ethyl ester (J. Med. Chem. 16, 118-122, 1973; 150
  • Example 1 b 4-Methyl-3-rr4-(3-pyridinyl)-2-pyrimidinv ⁇ amino '
  • Example 1 c 4-Methyl-3-ff4-(3-pyridinyl)-2-pyrimidinyllamino1-benzoic acid
  • Aqueous sodium hydroxide 500 mL of 2M is added dropwise to a stirred suspension of the intermediate Example 1b (132.8 g, 0.397 mol) in ethanol (1200 m L) and water (1200 mL).
  • the reaction mixture is stirred at 45°C for 2.5 h and then treated dropwise with aqueous HCI (1000 mL of 1 M) over 1.5 hours. After addition of water (1000 mL) the precipitate is filtered off, washed with water (4 x 500 mL) and dried at room temperature.
  • Residual water present in the air-dried product is removed by azeotropic distillation with toluene under reduced pressure.
  • the dried toluene suspension is diluted with diethyl ether and filtered.
  • the solid residue is washed with diethyl ether and dried in vacuo at 80°C to give the title compound, m.p. 277-278°C.
  • Example 3 1 -r4-Methyl-3-fr4-(3-pyridinyl)-2-pyrimidinvnaminolbenzov ⁇ -4-(2-pyridinyl)- piperazine
  • a solution containing -50% of propylphosphonic anhydride in /,N-dimethyIformamide (Fluka, Buchs, Switzerland; 674 ⁇ L, -1 mmol) is added within 20 minutes to a stirred mixture of 4- methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzoic acid (214.4 mg, 0.7 mmol), 1-(2- pyridyl)piperazine (Aldrich, Buchs, Switzerland; 114.3 mg, 0.7 mmol) and triethylamine (776 ⁇ L, 5.6 mmol) in 2 mL ⁇ /, ⁇ /-dimethylformamide.
  • Example 4 4-Methvl- V-[2-(2-pvridinvl)ethvll-3-fr4-(3-pvridinv ⁇ -2-pvrimidinvnamino]- benzamide utilising 2-(2-aminoethyi)pyridine (Fluka, Buchs, Switzerland).
  • Example 5 4-Methyl-/V-H -(phenvlmethvl)-4-piperidinvl1-3-rf4-(3-pvridinvl)-2-pvrimidinvl]- amino]benzamide utilising 4-amino-1 -benzylpiperidine (Aldrich, Buchs, Switzerland).
  • Example 6 4-Methvl- ⁇ /-(4-pvridinvlmethvl)-3-[[4-(3-pyridinvl)-2-pvrimidinvl]amino]benzamide utilising 4-(aminomethyl)pyridine (Aldrich, Buchs, Switzerland).
  • Example 7 4-Methyl- ⁇ -[2-(1 -methyl-1 H-pyrrol-2-yl)ethyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]- aminojbenzamide utilising 2-(2-aminoethyl)-1 -methylpyrrol [Chem. Abstr. Reg. Number: 83732-75-6].
  • Example 8 /-r(4-Methoxvphenvl)methvn-4-methyl-3-rr4-(3-pvridinvl)-2-pvrimidinvl1aminol- benzamide utilising 4-methoxybenzylamine (Fluka, Buchs, Switzerland).
  • Example 9 4-Methvl- ⁇ /-(2-methvlpropvl)-3-[f4-(3-pvridinvl)-2-pyrimidinvnaminolbenzamide utilising isobutylamine (Fluka, Buchs, Switzerland).
  • Example 11 4-Methvl-3-[r4-(3-pvridinvl)-2-pvrimidinyllamino1-N-[(tetrahvdro-2-furanv ⁇ - methyl]benzamide utilising tetrahydrofurfurylamine (Fluka, Buchs, Switzerland).
  • Example 14 ⁇ /-[(3S)-Hexahydro-2-oxo-1 H-azepin-3-yl1-4-methvl-3-[r4-(3-pyridinvl)-2- pyrimidinyl]amino]benzamide utilising L(-)-alpha-amino-epsilon-caprolactam [Chem. Abstr. Reg. Number: 21568-87-6].
  • Example 15 ⁇ -f2-(3.4-Dimethoxvphenvl)ethvn-4-methvl-3-rr4-(3-pvridinvl)-2-pyrimidinvn- amino]benzamide utilising 2-(3,4-dimethoxyphenyl)ethylamine (Fluka, Buchs, Switzerland).
  • Example 16 2-f [4-Methvl-3-rr4-(3-pvridinv ⁇ -2-pvrimidinvllamino1benzoyllaminol-4-thiazole- acetic acid ethyl ester utilising ethyl 2-amino-4-thiazo!eacetate (Aldrich, Buchs, Switzerland).
  • Example 17 ⁇ /-[3-(1 H-lmidazol-1 -yl)propyl]-4-methyl-3-[[4-(3-pyridinyl)-2pyrimidinyl]amino]- benzamide utilising 1 -(3-aminopropyl)imidazole (Aldrich, Buchs, Switzerland).
  • Example 19 ⁇ /-(2-methoxvethvl)-4-methvl-3-[f4-(3-pvridinvl)-2-pyrimidinv ⁇ aminolbenzamide utilising 2-methoxyethylamine (Fluka, Buchs, Switzerland).
  • Example 20 4-Methyl- ⁇ /-f3-(2-oxo-1 -pvrrolidinvl)propvn-3-[[4-(3-pvridinvl)-2-pyrimidinvn- amino]benzamide utilising 1-(3-aminopropyl)-2-pyrrolidinone (Aldrich, Buchs, Switzerland).
  • Example 21 ⁇ /.4-Dimethvl-N-(phenvlmethvl)-3-rr4-(3-pyridinvl)-2-pvrimidinynamino1- benzamide utilising N-benzylmethylamine (Fluka, Buchs, Switzerland).
  • Example 22 ⁇ /-f4-(Acetvlamino)phenvll-4-methvl-3- f4-(3-pvridinvl)-2-pvrimidinyl1amino]- benzamide utilising 4-aminoacetanilide (Fluka, Buchs, Switzerland).
  • Example 23 ⁇ /-(4-Methoxv-2-methvlphenv ⁇ -4-methvl-3-[[4-(3-pvridinvl)-2-pvrimidinvnamino]- benzamide utilising 4-methoxy-2-methylaniline (Aldrich, Buchs, Switzerland).
  • Example 24 4-Methvl- ⁇ /-[4-(methvlsulfonvl)benzvn-3-f[4-(3-pvridinvl)-2-pvrimidinvHamino]- benzamide utilising 4-methylsulfonylbenzylamine hydrochloride (Acros, Morris Plains, NJ).
  • Example 25 ⁇ /-fr4-(Dimethvlamino)phenvnmethvn-4-methvl-3-fr4-(3-pvridinvl)-2-pyrimidinvn- amino]benzamide utilising 4-(dimethylamino)benzylamine dihydrochloride (Aldrich, Buchs, Switzerland).
  • Example 26 A/-(2-Amino-2-oxoethvl)-4-methvl-3-[f4-(3-pvridinvl)-2-pyrimidinvnamino1- benzamide utilising glycinamide hydrochloride (Fluka, Buchs, Switzerland).
  • 1 H-NMR 400 MHz, DMSO-d 6 , ⁇ ): 2.29 (s, 3H); 3.78 (d, 2H); 7.02 (s, 1 H); 7.30-7.36 (m, 2H); 7.44 (d, 1H);
  • Example 27 /V-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]glycine methyl ester utilising glycine methylester hydrochloride (Fluka, Buchs, Switzerland).
  • Example 28 ⁇ /-[4-Methvl-3-rf4-(3-pvridinv ⁇ -2-pvrimidinvl1amino]benzovl1beta-alanine methyl ester utilising beta-alanine methylester hydrochloride (Fluka, Buchs, Switzerland).
  • Example 30 A/-(3-Hvdroxvpropvl)-4-methvl-3-[f4-(3-pvridinvl)-2-pyrimidinvnamino1benzamide utilising 3-amino-1-propanol (Aldrich, Buchs, Switzerland).
  • Example 31 ⁇ . ⁇ /-Diethvl-4-methvl-3-fr4-(3-pyridinvl)-2-pvrimidinynaminolbenzamide utilising diethylamine (Fluka, Buchs, Switzerland).
  • Example 33 ⁇ /-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyI]-(D)-alanine 1 ,1- dimethylethyl ester utilising D-alanine t-butylester hydrochloride (Novabiochem (Juro), Lucerne, Switzerland).
  • Example 34 ⁇ H1 -[4-Methvl-3-[r4-(3-pvridinvl)-2-pvrimidinvlaminolbenzov ⁇ -4-piperidinvl]- benzamide utilising N-4-piperidinyl-benzamide (Maybridge Chemical Co. Ltd).
  • Example 36 1 -(4-Methoxvphenvl)-4-f4-methvl-3-rf4-(3-pvridinvl)-2-pvrimidinyllaminol- benzoyl]piperazine utilising 1 -(4-methoxyphenyl)-piperazine (Emka Chemie, Neufahrn, Germany).
  • Example 38 1-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-4-(pyrazinyl)- piperazine utilising 1 -(2-pyrazinyl)-piperazine (Emka Chemie, Neufahrn, Germany).
  • Example 40 1 -Cvclopentvl-4-4-methvl-3-[
  • gxarnpJe_4L 4- ⁇ 4-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-1-piperazinyl ⁇ - acetyl ⁇ morpholine utilising 4-[2-(piperazin-1-yl)-acetyl]-morpholine (Emka Chemie, Neufahrn, Germany).
  • Example 42 1 -[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-4-[2-oxo-2-(1 - pyrrolidinyl)ethyl]piperazine utilising 1-[2-(piperazin-1-yl)-acetyl-pyrrolidine (Emka Chemie, Neufahrn, Germany).
  • Example 43 4-[4-Methvl-3-r[4-(3-pvridinvl)-2-pvrimidinvllaminolbenzoyl -1 -piperazine- carboxylic acid ethyl ester utilising ethyl 1 -piperazinecarboxylate (Aldrich, Buchs, Switzerland).
  • Example 44 2-r4-Methvl-3-[f4-(3-pvridinvl)-2-pvrimidinvllaminolbenzovl]-1 ,2.34-tetrahvdro- isoquinoline utilising 1 ,2,3,4-tetrahydroisoquinoline (Fluka, Buchs, Switzerland).
  • Example 45 ⁇ /. ⁇ /-bis(2-Methoxvethvl)-4-methvl-3-rr4-(3-pvridinvl)-2-pvrimidinvllaminol- benzamide utilising bis(2-methoxyethyl)amine (Aldrich, Buchs, Switzerland).
  • Example 46 1 '-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-1 ,4'-bipiperidine utilising 4-piperidinopiperidine (Aldrich, Buchs, Switzerland).
  • Example 47 ⁇ /-[4-Methvl-3-r[4-(3-pvridinvl)-2-pvrimidinvl1amino1benzovn-N-(phenylmethvl)- glycine ethyl ester utilising N-benzylglycine ethyl ester (Fluka, Buchs, Switzerland).
  • Example 48 ⁇ /-(3-Chlorophenvl)-4-methvl-3-[[4-(3-pyridinvl)-2-pyrimidinvl1amino1benzamide utilising 3-chlor-aniline (Fluka, Buchs, Switzerland).
  • Example 49 ⁇ /-(2.2-Diphenvlethvl)-4-methvl-3-ff4-(3-pvridinvl)-2-pyrimidinvl1aminol- benzamide utilising 2,2-diphenylethylamine (Aldrich, Buchs, Switzerland).
  • Example 50 ⁇ /-(2,3-Dihydro-1 H-inden-1 -yl)-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- benzamide utilising 1 -Aminoindane (Fluka, Buchs, Switzerland).
  • Example 51 ⁇ /-(Diphenylmethyl)-4-methvl-3-
  • Example 52 4-Methvl- ⁇ /-f2-(1 -piperidinvl)ethvll-3-fr4-(3-pvridinvl)-2-pvrimidinvllamino1- benzamide utilising 1 -(2-aminoethyl)piperidine (Aldrich, Buchs, Switzerland).
  • Example 54 4-Methvl-3-rr4-(3-pvridinvl)-2-pvrimidinvnamino]-N-r[4-(trifluoromethvl)phenvn- methyl]benzamide utilising 4-(trifluoromethyl)benzylamine (Aldrich, Buchs, Switzerland).
  • Example 55 4-Methvl-/V-r(5-methvlpvrazinv ⁇ methvl1-3-r[4-(3-pvridinvl)-2-pvrimidinvnamino]- benzamide utilising 2-(aminomethyl)-5-methylpyrazine (TCI-JP, Distrib. Zurich, Switzerland).
  • Example 56 ⁇ /-(2-Ethoxvethvl)-4-methyl-3-[f4-(3-pvridinvl)-2-pyrimidinvl]amino1benzamide utilising 2-ethoxyethylamine (TCI-JP, Distrib. Zurich, Switzerland).
  • Example 58 4-Methvl- ⁇ /-(5-methvl-2-pvridinvl)-3-[[4-(3-pvridinvl)-2-pyrimidinvnamino1- benzamide utilising 2-amino-5-picoIine (Aldrich, Buchs, Switzerland).
  • carnpje 59 1-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-4-phenyl-4- piperidinol utilising 4-hydroxy-4-phenylpiperidine (Aldrich, Buchs, Switzerland).
  • Example 60 V-(3-Benzovlphenvl)-4-methvl-3-
  • Example 61 /V-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-glycine 1 ,1- dimethylethyl ester utilising glycine t-butyl ester hydrochloride (Aldrich, Buchs, Switzerland).
  • Example 63 4-Methvl- ⁇ /-f3-(methvlphenvlamino)propvn-3-r[4-(3-pyridinvl)-2-pyrimidinvl - amino]benzamide utilising N-(3-aminopropyI)-N-methylaniline (TCI-JP, Distrib. Zurich, Switzerland).
  • Example 66 ⁇ /-[2-fbis(1 -Methvlethvl)amino1ethvn-4-methvl-3-rf4-(3-pvridinvl)-2-pyrimidinvll- amino]benzamide utilising 2-diisopropylamino-ethylamine (Fluka, Buchs, Switzerland).
  • Example 68 4-Methyl-3-fr4-(3-pyridinyl)-2-pyrimidinvnamino]-/V-[f3-f(1 -hvdroxy-1 -methyl- ethyl)]-5-(1.1.1 -trifluoromethvDphenvnmethyllbenzamide
  • Diethylcyanophosphonate (Aldrich, Buchs, Switzerland; 0.33 mL, 2.0 mmol) is added to a stirred mixture of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzoic acid (306 mg, 1.0 mmol), 3-[(1-hydroxy-1 -methylethyl)]-5-(1 ,1 ,1-trifluoromethyl)benzeneamine (220 mg, 1.0 mmol) and triethylamine (560 ⁇ L, 4.0 mmol) in 5 mL ⁇ /,/V-dimethylformamide at 10°C.
  • Diethylcyanophosphonate (Aldrich, Buchs, Switzerland; 0.50 mL, 3.0 mmol) is added to a stirred mixture of 3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzoic acid (438 mg, 1.5 mmol), 4- [(4-methyl-1 -piperazinyl)methyl]benzeneamine (308 mg, 1.5 mmol) and triethylamine (840 ⁇ L, 3.0 mmol) in 10 mL ⁇ /,A/-dimethylformamide at 10°C. After stirring for 12 hours at 60°C, the mixture is treated with an aqueous solution of sodium hydrogen carbonate and extracted three times with ethyl acetate.
  • Example 69a 3-f(Aminoiminomethyl)amino1-4-methylbenzoic acid methyl ester mononitrate
  • 3-aminobenzoic acid methyl ester Fluka, Buchs, Switzerland
  • 3-amino-4-methylbenzoic acid ethyl ester afforded the title compound as a crystalline solid, m.p. 170-172°C.
  • Example 69b 3-[f4-(3-Pyridinyl)-2-pyrimidinyllaminolbenzoic acid methyl ester
  • Example 69a 3-[f4-(3-Pyridinyl)-2-pyrimidinyllaminolbenzoic acid methyl ester
  • Example 69a 4-methyl-3-[(aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate, afforded the title compound as a crystalline solid, m.p. 195-200°C.
  • Example 69b Utilizing the procedure described in Example 1 c, but with the intermediate of Example 69b in lieu of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester, afforded the title compound as a crystalline solid, m.p. 285-293°C.
  • Example 70 3-rr4-(3-Pyridinyl)-2-pyrimidinyllamino1- ⁇ /-r(3-(1 -hvdroxy-1 -methylethyl)-5-(1.1.1- trifluoromethvDphenyllbenzamide
  • Example 72 4-Methyl-3-ff4-(3-pyridinyl)-2-pyrimidinvnaminol- ⁇ /-f3-f2-(1 H-imidazol-1 - yl)ethoxy1phenyl]benzamide
  • the aniline is prepared as follows:
  • Example 74 4-Methyl-3-rr4-(3-pyridinv ⁇ -2-pyrimidinvnaminol-/V-r4-(diethylamino)-3- (trifluoromethyl)phenv ⁇ benzamide
  • N,N-diethyl-2-(trifluoromethyl)- 1 ,4-benzenediamine Toshio Niwa, DE 3524519
  • 1 -(2-pyridyl)piperazine afforded the title compound as a crystalline solid, m.p. 128-131 °C.
  • Example 76 4-Methyl-3-IT4-(3-pyridinyl)-2-pyrimidinv ⁇ amino1-/V-r4-fbis(2-methoxy- ethyl)amino]-3-(trifluoromethyl)phenyl1benzamide
  • Example 77 4-Methyl-3-[ 4-(3-pyridinyl)-2-pyrimidinvnaminol- ⁇ /-[4-(4-methyl-1-piperazinyl)-3-
  • Example 78 4-Methyl-3-r[4-(3-pyridinyl)-2-pyrimidinyllaminol- ⁇ /-[4-(1 -piperidinyl)-3-
  • the aniline is prepared as follows:
  • Phenyl boronic acid (Aldrich, Buchs, Switzerland; 2.7 g, 22 mmol), Palladium II acetate (0.225 g, 1 mmol), tri-o-tolylphosphine (0.608 g, 2 mmol) and aqueous potassium carbonate solution (50 mL of 1 M) is added to a stirred solution of 2-bromo-5-nitrobenzotrifuoride (Lancaster Synthesis, GmbH; 5.4 g, 20 mmol) in dimethylformamide (200 mL) and heated at 120°C under an argon atmosphere for 1 h.
  • Example 82 4-Methyl-3-r[4-(3-pyridinyl)-2-pyrimidinvnamino -N-[3-[4-(3-pyridinyl)-3- (trifluoromethvOphenyllmethyllbenzamide
  • Example 69 4-(3-pyridinyl)-3- (trifluoromethyl)-benzenamine in lieu of 3-[(1-hydroxy-1-methylethyl)]-5-(1 ,1 ,1- trifluoromethyl)benzeneamine, afforded the title compound as a crystalline solid, m.p. 276- 280°C.
  • the aniline is prepared as follows:
  • Example 82a 4-(3-Pyridinyl)-3-(trifluoromethyl)benzenamine
  • the orgainic phase is then sequentially washed with water (2 x 80 mL) and saturated aqueous sodium chloride (1 x 80 mL), dried (MgSO ), filtered and the solvent is evaporated off under reduced pressure to yield the crude product which is purified by column chromatography (silica gel, eluent 50% ethyl acetate in hexane) to afford 3-[(4-nitro-3-(trifluoromethyl)phenyl]pyridine.
  • This product is dissolved in ethanol (200 mL) and hydrogenated at atmospheric pressure over Raney nickel (0.23 g) at 22°C. The calculated amount of hydrogen is taken up in 24 hours.
  • Example 83 4-Methyl-3-r 4-(3-pyridinyl)-2-pyrimidinv ⁇ amino1- ⁇ /-r4-(1 H-imidazol-1 -yl)-3-
  • Example 84 4-Methyl-3-fr4-(3-pyridinyl)-2-pyrimidinvnamino1-/v-r4-(2.4-dimethyl-1 H-imidazol- 1-yl)-3-(trifluoromethyl)phenyllbenzamide
  • Example 69 4-(2,4-dimethyl-1 H-imidazol- 1-yl)-3-(trifluoromethyl)-benzenamine in lieu of 3-[(1-hydroxy-1-methylethyl)]-5-(1,1,1- trifluoromethyl)benzeneamine, afforded the title compound as an amorphous solid.
  • the aniline is prepared as follows:
  • Example 84a 4-(2,4-dimethyl-1 H-imidazol-1 -yl)-3-(trif luoromethyl)-benzenamine
  • 2-bromo-5-nitrobenzotrifuoride (Lancaster Synthesis, GmbH; 6.0 g, 22 mmol) and 2,4-dimethylimidazole (10.6, 110 mmol) is heated at 120°C for 36 hours under an argon atmosphere. The mixture is then cooled and the residue is treated with water (150 mL) and extracted with ethyl acetate (3 x 80 mL).
  • Example 85 4-Methyl-3-rf4-(3-pyridinv ⁇ -2-pyrimidinv ⁇ amino]- ⁇ /-[4-(4-methyl-1 H-imidazol-1 - yl)-3-(trifluoromethyl)phenyr
  • the aniline is prepared as follows:
  • Example 85a 4-(4-Methyl-1 H-imidazol-1 -yl)-3-(trif luoromethyl)-benzenamine
  • Example 86 4-Methyl-3-ff4-(3-pyridinyl)-2-pyrimidinyl1amino]-A/-r4-(2-methyl-1 H-imidazol-1 - yl)-3-(trifluoromethyl)phenv ⁇ benzamide
  • the aniline is prepared as follows:
  • Example 86a 4-(2-Methyl-1 H-imidazol-1 -yl)-3-(trifluoromethyl)-benzenamine
  • 2-methyl-1 H-imidazole in lieu of 2,4-dimethylimidazole, afforded the title compound as a colourless crystalline solid, m.p. 117-119°C.
  • Example 87 4-Methyl-3-fr4-(3-pyridinyl)-2-pyrimidinyl]aminol- ⁇ /-[3-(4-morpholinyl)-5- f(methylamino)carbonyl1phenyllbenzamide
  • the aniline is prepared as follows:
  • Example 87a 3-Bromo-5-nitro-benzoic acid, 1 ,1-dimethylethyl ester
  • a solution of n-butyllithium in hexane (12.8 mL of 2.5 M, 32 mmol) is added with stirring to t- butanol (46 mL) at 25°C under an argon atmosphere. After 30 min the mixture is treated dropwise with a solution of 3-bromo-5-nitro-benzoyl chloride (J. Mindl, Collect. Czech. Chem. Commun. (1973), 38, 3496-505; 32 mmol) in dry THF (40 mL) and stirred for a further 17 h.
  • Example 87b 3-(4-Morpholinyl)-5-nitro-benzoic acid, 1 ,1-dimethylethyl ester
  • a stirred mixture of 3-bromo-5-nitro-benzoic acid, 1,1-dimethylethyl ester (example 86a; 3.02 g, 10 mmol) and morpholine (1.22 mL, 14 mmol) in toluene (50 mL) is treated with sodium t- butylate (1.34 g, 14 mmol), tri-t-butylphosphine (3 mL, 1.5 mmol) and tris-(dibenzylidene- acetone)dipalladium[0] (0.45 g, 0.5 mmol) under an argon atmosphere, and then heated at 60°C for 18 h.
  • Example 87c 3-(4-Morpholinyl)-5-nitro-benzoic acid, methyl ester
  • a mixture of 3-(4-morpholinyl)-5-nitro-benzoic acid, 1,1-dimethylethyl ester (Example 87b; 0.77 g, 2.5 mmol), 1 ,8-diazabicyclo[5,4,0]undec-7-ene (o.56 mL, 3.75 mL), and potassium bromide (1.09 g, 12.5 mmol) in methanol (25 mL) is stirred at 90 °C for 250 min.
  • Example 87e 3-Amino-5-(4-Morpholinyl)-N-(methvl)-benzamide
  • a solution of 3-(4-morpholinyl)-5-nitro-N-(methyl)-benzamide (Example 86d; 300 mg, 1.12 mmol) in ethanol (20 mL) is hydrogenated at atmospheric pressure over Raney nickel (0.2 g) at 25°C. The calculated amount of hydrogen is taken up in 19 hours. The mixture is then filtered and the solvent is evaporated off under reduced pressure to yield the crude product which is purified by recrystallisation from ethyl acetate to give the title compound as a beige crystalline solid, m.p. 201-204°C.
  • Example 88 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinv ⁇ amino]- ⁇ /-f3-[(methylamino)carbonyl1-5-
  • the aniline is prepared as follows:
  • the mixture is then cooled, treated with an aqueous solution of sodium hydroxide (100 mL of 0.1 M) and purged with air for 2 hours.
  • the resulting mixture is then diluted with ethylacetate (200 mL) and filtered.
  • the orgainic phase is then sequentially washed with water (2 x 80 mL) and saturated aqueous sodium chloride (1 x 80 mL), dried (MgSO 4 ), filtered and the solvent is evaporated off under reduced pressure to yield the crude product which is purified by column chromatography (silica gel, eluent ethyl acetate) to afford the title compound as a brown oil.
  • Example 90 4-Methyl-3-
  • the aniline is prepared as follows:
  • Example 90a [3-Bromo-5-(trifluoromethyl)phenyl]-carbamic acid, 1,1-dimethylethyl ester
  • Example 90b [3-(4-Morpholinyl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1 ,1-dimethylethyl ester
  • Example 90a Utilizing the procedure described in Example 86b but employing [3-bromo-5-(trifluoromethyl)- phenylj-carbamic acid, 1,1-dimethylethyl ester (Example 90a) in lieu of 3-bromo-5-nitro- benzoic acid, 1,1-dimethylethyl ester, afforded the title compound as a crystalline solid, m.p.
  • [3-(4-morpholinyl)-5-(trifluoromethyI)phenyl]-carbamic acid, 1,1-dimethylethyl ester (Example 90b; 1.7 g, 5 mmol) is treated with a solution of hydrogen chloride in isopropanol (30 mL of 4 M) and heated at 60°C for 5 h. The solvent is evaporated off under reduced pressure and the residue is treated with aqueous sodium hydrogen carbonate solution (80 mL) and extracted with ethyl acetate (3 x 80 mL).
  • the was aniline is prepared as follows:
  • Example 91a 3-(2-Methyl-1 H-imidazol-1 -yl)-5-(trif luoromethyl)-benzonitrile
  • a mixture of 3-fluoro-5-(trifIuoromethyl)-benzonitrile (Lancaster Synthesis GmbH; 17 g, 89 mmol) and 2-methylimidazole (Fluka, Buchs, Switzerland; 22.2 g, 270 mmol) in N,N- dimethylacetamide (80 mL) is stirred at 145°C for 19 h.
  • the solvent is evaporated off under reduced pressure and the residue is dissolved in ethyl acetate (200 mL).
  • Example 91 b 3-(2-Methyl-1 H-imidazol-1 -yl)-5-(trifluoromethyl)-benzoic acid
  • a solution of 3-(2-methyl-1 H-imidazol-1 -yl)-5-(trif luoromethyl)-benzonitrile (Example 91 a; 16.7 g, 66 mmol) in dioxane (300 mL) is added to an aqueous solution of sodium hydroxide (275 mL of 1 M) and the mixture is heated at 95°C for 18 h. The solvent is evaporated off under reduced pressure and the residue is neutralised with hydrochloric acid (1 M) and extracted with butanol (2 x 250 mL).
  • Triethylamine (5.23 mL, 37.5 mmol) is added to a stirred suspension of 3-(2-methyl-1 H- imidazol-1 -yl)-5-(trif Iuoromethyl)-benzoic acid (Example 91 b; 6.8 g, 25 mmol) in t-butanol (200 mL).
  • Diphenylphosphorylazide (7.6 g, 27.5 mmol) is added to the resulting solution and the mixture is heated 80°C for 16 h. The solvent is evaporated off under reduced pressure and the residue is treated with water (100 mL) and extracted with ethyl acetate (2 x 100 mL).
  • Example 91 d 5-(2-Methyl-1 H-imidazol-1 -yl)-3-(trif luoromethyl)-benzenamine
  • Example 90c employing [3-(2-methyl-1 H-imidazol-1 - yl)-5-(trifIuoromethyl)phenyl]-carbamic acid, 1,1-dimethylethyl ester (Example 91c) in lieu of [3-(4-morpholinyl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1 ,1-dimethylethyl ester, afforded the title compound as a yellow crystalline solid, m.p. 130-133°C.
  • Example 92 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyllaminol- ⁇ /-r5-(4-methyl-1 H-imidazol-1 - yl)-3-(trifluoromethyl)phenyr]benzamide
  • the was aniline is prepared as follows:
  • Example 92b 3-(4-Methyl-1 H-imidazol-1 -yl)-5-(trif luoromethyl)-benzoic acid
  • Example 92a 3-(4-methyl-1 H-imidazol-1 - yl)-5-(trifluoromethyl)-benzonitrile
  • Example 92c [3-(4-Methyl-1 H-imidazol-1 -yl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1 ,1- dimethylethyl ester
  • Example 92b Considering the procedure described in Example 91 c, but employing 3-(4-methyl-1 H-imidazol-1 - yl)-5-(trifluoromethyl)-benzoic acid (Example 92b) in lieu of 3-(2-methyl-1 H-imidazol-1 -yl)-5- (trifluoromethyl)-benzoic acid, afforded the title compound as a crystalline solid, m.p. 186- 188°C.
  • Example 92d 5-(2-Methyl-1 H-imidazol-1 -yl)-3-(trif luoromethyl)-benzenamine
  • Example 92c in lieu of [3-(2-methyl-1 H-imidazol-1 -yl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1 ,1-dimethylethyl ester, afforded the title compound as a colourless crystalline solid, m.p. 127-131 °C.
  • Example 93 4-Methyl-3-fr4-(3-pyridinyl)-2-pyrimidinyl]aminol- ⁇ /-[5-(5-methyl-1 H-imidazol-1 - yl)-3-(trifluoromethyl)phenv ⁇ benzamide
  • the aniline is prepared as follows:
  • Example 93b 3-(5-MethyI-1 H-imidazol-1 -yl)-5-(trifluoromethyl)-benzoic acid
  • Example 91b employing 3-(5-methyl-1 H-imidazol-1 - yl)-5-(trifluoromethyl)-benzonitrile (Example 93a) in lieu of 3-(2-methyl-1 H-imidazol-1 -yl)-5- (trifluoromethyl)-benzonitrile, afforded the title compound as a colourless crystalline solid, m.p. 243-245°C.
  • Example 93c [3-(5-Methyl-1 H-imidazol-1 -yl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1,1- dimethylethyl ester
  • Example 93b [3-(5-Methyl-1 H-imidazol-1 -yl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1,1- dimethylethyl ester
  • Example 93d 5-(5-Methyl-1 H-imidazol-1 -yl)-3-(trifluoromethyl)-benzenamine
  • Example 93c in lieu of [3-(2-methyl-1 H-imidazol-1 -yl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1 ,1-dimethylethyl ester, afforded the title compound as a colourless crystalline solid, m.p. 131-133°C.
  • the aniline is prepared as follows:
  • Example 94a [3-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1,1- dimethylethyl ester
  • Example 94b 3-(4-methyl-1 -piperazinyl)-5-(trifluoromethyl)-benzenamine
  • Example 90c employing [3-(4-methyl-1 -piperazinyl)- 5-(trifluoromethyl)phenyl]-carbamic acid, 1,1-dimethylethyl ester (Example 94a) in lieu of [3- (4-morpholinyl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1,1-dimethylethyl ester, afforded the title compound as oil.
  • Example 95 4-Methyl-3-
  • 2-(1-pyrrolidinyI)-5- (trifluoromethyl)-benzenamine (Lancaster Synthesis Ltd.; Yasuhiro Ohtake et al., WO 9965874) in lieu of 1 -(2-pyridyl)piperazine, afforded the title compound as a crystalline solid.
  • Example 96a 3-[(Aminoiminomethyl)amino]-benzoic acid ethyl ester mononitrate
  • 3-amino-benzoic acid ethyl ester Fluka, Buchs, Switzerland
  • 3-amino-4-methylbenzoic acid ethyl ester afforded the title compound as a crystalline solid, m.p. 170-172°C.
  • 5000 soft gelatin capsules each comprising as active ingredient 0.05 g of one of the compounds of formula I mentioned in the preceding Examples, are prepared as follows: 250 g pulverized active ingredient is suspended in 2L Lauroglykol® (propylene glycol laurate, Gattefosse S.A., Saint Priest, France) and ground in a wet pulverizer to produce a particle size of about 1 to 3 ⁇ m. 0.419 g portions of the mixture are then introduced into soft gelatin capsules using a capsule-filling machine.
  • Lauroglykol® propylene glycol laurate, Gattefosse S.A., Saint Priest, France
  • the compound of formula I to be tested is formulated for administration to female OF1 mice from IFACREDO, France, by first dissolving in NMP, and then by diluting with PEG300 to a final concentration of 10 % v/v NMP: 90 % v/v PEG300, producing a clear solution of the compound. The concentrations were adjusted to deliver a constant volume of 10 mL/kg body weight.
  • the compound is prepared immediately before use.
  • the formulated compound is administered perorally by gavage to provide dosages of 50 mg/kg.
  • mice (4 at each time) are anesthetized with 3 % isoflurane in medical oxygen and blood samples are obtained by heart puncture into heparinized tubes (ca. 30 lU/mL). The animals are subsequently killed without recovering from the anesthetic. Plasma is prepared from the blood by centrifugation (10,000 g, 5 min) and either analyzed immediately or stored frozen at - 70 °C.
  • the plasma samples (10 - 250 ⁇ L) are e.g. spiked with 5//L of internal standard, mixed with 200 ⁇ L 0.1 M NaOH and 500 ⁇ L chloroform in a 1.5 mL Eppendorf tube and shaken vigorously for 10 minutes on an Eppendorf mixer. Thereafter, the mixture is centrifuged (3 min at 10'000xg), the organic phase transferred to a second Eppendorf tube and evaporated to dryness in a vacuum centrifuge (Speedvac 5301). The dry residue e.g. is dissolved in 250 ⁇ L of 10 % v/v Acetonitrile in water containing 0.1 % formic acid. The subsequent analysis is carried out e.g.
  • the column is prepared for the next sample e.g. by re-equilibrating for 3 min with 100 % water to the starting conditions.
  • the separation is performed e.g. at a column temperature of 40 °C.
  • the column effluent is introduced e.g.
  • the concentration of unknown samples is calculated from a plot of the peak area ratio of the selected daughter ion of the analyte to the product of its internal standard (ordinate) against the nominal concentration (abscissa). Regression analysis is performed using Quanlynx TM, MasslynxTM software 3.5 (Micromass, Manchester, UK).
  • Enzymatic (c-Abl, KDR, Flt3) in vitro inhibition data are presented as % inhibition at 10 ⁇ M.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to compounds of formula (I) Wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such disease.

Description

Inhibitors of Tyrosine Kinases
The invention relates to novel substituted pyrimidinylaminobenzamides, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
Background of the invention
Protein kinases (PKs) are enzymes which catalyze the phosphorylation of specific serine, threonine or tyrosine residues in cellular proteins. These post-translational modifications of substrate proteins act as molecular switches regulating cell proliferation, activation and/or differentiation. Aberrant or excessive PK activity has been observed in many disease states including benign and malignant proliferative disorders. In a number of cases, it has been possible to treat diseases, such as proliferative disorders, by making use of PK inhibitors in vitro and in vivo.
In view of the large number of protein kinase inhibitors and the multitude of proliferative and other PK-related diseases, there is an ever-existing need to provide novel classes of compounds that are useful as PK inhibitors and thus in the treatment of these PTK related diseases. What is required are new classes of pharmaceutically advantageous PK inhibiting compounds.
The Philadelphia Chromosome is a hallmark for chronic myelogenous leukaemia (CML) and carries a hybrid gene that contains N-terminal exons of the bcr gene and the major C- terminal part (exons 2-11) of the c-abl gene. The gene product is a 210 kD protein (p210 Bcr-Abl). The Abl-part of the Bcr-Abl protein contains the abl-tyrosine kinase which is tightly regulated in the wild type c-abl, but constitutively activated in the Bcr-Abl fusion protein. This deregulated tyrosine kinase interacts with multiple cellular signalling pathways leading to transformation and deregulated proliferation of the cells (Lugo et al., Science 247. 1079 [1990]).
General description of the invention
It has now been found that various compounds of the pyrimidinylaminobenzamide class show inhibition of protein kinase activity. The compounds of formula I, described below in more detail, especially show inhibition of one or more tyrosine kinases, such as c-Abl, Bcr- Abl, the receptor tyrosine kinases PDGF-R, Flt3, VEGF-R, EGF-R, and c-Kit, as well as combinations of two or more of these; in the case of novel pyrimidinylaminobenzamides according to the invention, the compounds are appropriate for the inhibition of these and/or other protein kinases, especially those mentioned above and/or for the inhibition of mutants of these enzymes, especially of Bcr-Abl, for example the Glu255 -> Valine mutant. In view of these activities, the compounds can be used for the treatment of diseases related to especially aberrant or excessive activity of such types of kinases, especially those mentioned.
Detailed description of the invention
The invention relates to a compound of formula I,
Figure imgf000003_0001
wherein
Ri represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, carboxy- lower alkyl, lower alkoxycarbony Mower alkyl, or phenyl-lower alkyl;
R2 represents hydrogen, lower alkyl, optionally substituted by one or more identical or different radicals R3, cycloalkyl, benzcycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; and R3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amino, mono- or disubstituted amino, cycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted;
or wherein R and R2 together represent alkylene with four, five or six carbon atoms optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, oxo, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms; oxaalkylene with one oxygen and three or four carbon atoms; or azaalkylene with one nitrogen and three or four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N- disubstituted carbamoyl-lower alkyl, cycloalkyl, lower alkoxycarbonyl, carboxy, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl;
R4 represents hydrogen, lower alkyl, or halogen;
and a N-oxide or a pharmaceutically acceptable salt of such a compound.
The general terms used hereinbefore and hereinafter preferably have within the context of this disclosure the following meanings, unless otherwise indicated:
The prefix "lower" denotes a radical having up to and including a maximum of 7, especially up to and including a maximum of 4 carbon atoms, the radicals in question being either linear or branched with single or multiple branching.
Where the plural form is used for compounds, salts, and the like, this is taken to mean also a single compound, salt, or the like.
Any asymmetric carbon atoms may be present in the (R)-, (S)- or (R,S)-configuration, preferably in the (R)- or (S)-configuration. The compounds may thus be present as mixtures of isomers or as pure isomers, preferably as enantiomer-pure diastereomers.
The invention relates also to possible tautomers of the compounds of formula I.
Lower alkyl is preferably alkyl with from and including 1 up to and including 7, preferably from and including 1 to and including 4, and is linear or branched; preferably, lower alkyl is butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, such as n-propyl or isopropyl, ethyl or methyl. Preferably lower alkyl is methyl, propyl or tert-butyl.
Lower acyl is preferably formyl or lower alkylcarbonyl, in particular acetyl.
An aryl group is an aromatic radical which is bound to the molecule via a bond located at an aromatic ring carbon atom of the radical. In a preferred embodiment, aryl is an aromatic radical having 6 to 14 carbon atoms, especially phenyl, naphthyl, tetrahydronaphthyl, fluorenyl or phenanthrenyl, and is unsubstituted or substituted by one or more, preferably up to three, especially one or two substituents, especially selected from amino, mono- or disubstituted amino, halogen, lower alkyl, substituted lower alkyl, lower alkenyl, lower alkynyl, phenyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, benzoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, ureido, mercapto, sulfo, lower alkylthio, phenylthio, phenyl-lower alkylthio, lower alkylphenylthio, lower alkylsulfinyl, phenylsulfinyl, phenyl-lower alkylsulfinyl, lower alkylphenylsulfinyl, lower alkylsulfonyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, lower alkylphenylsulfonyl, halogen-lower alkylmercapto, halogen-lower alkylsulfonyl, such as especially trifluoromethanesulfonyl, dihydroxybora (-B(OH)2), heterocyclyl, a mono- or bicyclic heteroaryl group and lower alkylene dioxy bound at adjacent C-atoms of the ring, such as methylene dioxy. Aryl is more preferably phenyl, naphthyl or tetrahydronaphthyl, which in each case is either unsubstituted or independently substituted by one or two substituents selected from the group comprising halogen, especially fluorine, chlorine, or bromine; hydroxy; hydroxy etherified by lower alkyl, e.g. by methyl, by halogen-lower alkyl, e.g. trifluoromethyl, or by phenyl; lower alkylene dioxy bound to two adjacent C-atoms, e.g. methylenedioxy, lower alkyl, e.g. methyl or propyl; halogen-lower alkyl, e.g. trifluoromethyl; hydroxy-lower alkyl, e.g. hydroxymethyl or 2-hydroxy-2-propyl; lower alkoxy-lower alkyl; e.g. methoxymethyl or 2-methoxyethyl; lower alkoxycarbonyl-lower alkyl, e.g. methoxy- carbonylmethyl; lower alkynyl, such as 1-propynyl; esterified carboxy, especially lower alkoxycarbonyl, e.g. methoxycarbonyl, n-propoxy carbonyl or iso-propoxy carbonyl; N-mono- substituted carbamoyl, in particular carbamoyl monosubstituted by lower alkyl, e.g. methyl, n- propyl or iso-propyl; amino; lower alkylamino, e.g. methylamino; di-lower alkylamino, e.g. dimethylamino or diethylamino; lower alkylene-annino, e.g. pyrrolidino or piperidino; lower oxaalkylene-amino, e.g. morpholino, lower azaalkylene-amino, e.g. piperazino, acylamino, e.g. acetylamino or benzoylamino; lower alkylsulfonyl, e.g. methylsulfonyl; sulfamoyl; or phenylsulfonyl.
A cycloalkyl group is preferably cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl, and may be unsubstituted or substituted by one or more, especially one or two, substitutents selected from the group defined above as substitutents for aryl, most preferably by lower alkyl, such as methyl, lower alkoxy, such as methoxy or ethoxy, or hydroxy, and further by oxo or fused to a benzo ring, such as in benzcyclopentyl or benzcyclohexyl.
Substituted alkyl is alkyl as last defined, especially lower alkyl, preferably methyl; where one or more, especially up to three, substituents may be present, primarily from the group selected from halogen, especially fluorine, amino, N-lower alkylamino, N,N-di-lower alkylamino, N-lower alkanoylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, and phenyl-lower alkoxycarbonyl. Trifluoromethyl is especially preferred.
Mono- or disubstituted amino is especially amino substituted by one or two radicals selected independently of one another from lower alkyl, such as methyl; hydroxy-lower alkyl, such as 2-hydroxyethyl; lower alkoxy lower alkyl, such as methoxy ethyl; phenyl-lower alkyl, such as benzyl or 2-phenylethyI; lower alkanoyl, such as acetyl; benzoyl; substituted benzoyl, wherein the phenyl radical is especially substituted by one or more, preferably one or two, substituents selected from nitro, amino, halogen, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl, and carbamoyl; and phenyl-lower alkoxycarbonyl, wherein the phenyl radical is unsubstituted or especially substituted by one or more, preferably one or two, substituents selected from nitro, amino, halogen, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl, and carbamoyl; and is preferably N-lower alkylamino, such as N-methylamino, hydroxy-lower alkylamino, such as 2-hydroxyethylamino or 2- hydroxypropyl, lower alkoxy lower alkyl, such as methoxy ethyl, phenyl-lower alkylamino, such as benzylamino, N,N-di-lower alkylamino, N-phenyl-lower alkyl-N-lower alkylamino, N,N-di-lower alkylphenylamino, lower alkanoylamino, such as acetylamino, or a substituent selected from the group comprising benzoylamino and phenyl-lower alkoxycarbonylamino, wherein the phenyl radical in each case is unsubstituted or especially substituted by nitro or amino, or also by halogen, amino, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl, carbamoyl or aminocarbonylamino. Disubstituted amino is also lower alkylene-amino, e.g. pyrrolidino, 2-oxopyrrolidino or piperidino; lower oxaalkylene-amino, e.g. morpholino, or lower azaalkylene-amino, e.g. piperazino or N-substituted piperazino, such as N-methylpiperazino or N- methoxycarbonylpiperazino.
Halogen is especially fluorine, chlorine, bromine, or iodine, especially fluorine, chlorine, or bromine.
Etherified hydroxy is especially C8-C2oalkyloxy, such as n-decyloxy, lower alkoxy (preferred), such as methoxy, ethoxy, isopropyloxy, or tert-butyloxy, phenyl-lower alkoxy, such as benzyloxy, phenyloxy, halogen-lower alkoxy, such as trifluoromethoxy, 2,2,2-trifluoroethoxy or 1 ,1 ,2,2-tetrafluoroethoxy, or lower alkoxy which is substituted by mono- or bicyclic heteroaryl comprising one or two nitrogen atoms, preferably lower alkoxy which is substituted by imidazolyl, such as 1 H-imidazol-1 -yl, pyrrolyl, benzimidazolyl, such as 1-benzimidazolyl, pyridyl, especially 2-, 3- or 4-pyridyl, pyrimidinyl, especially 2-pyrimidinyl, pyrazinyl, isoquinolinyi, especially 3-isoquinolinyl, quinolinyl, indolyl or thiazolyl.
Esterified hydroxy is especially lower alkanoyloxy, benzoyloxy, lower alkoxycarbonyloxy, such as tert-butoxycarbonyloxy, or phenyl-lower alkoxycarbonyloxy, such as benzyloxycarbonyloxy.
Esterified carboxy is especially lower alkoxycarbonyl, such as tert-butoxycarbonyl, iso- propoxycarbonyl, methoxycarbonyl or ethoxycarbonyl, phenyl-lower alkoxycarbonyl, or phenyloxycarbonyl.
Alkanoyl is primarily alkylcarbonyl, especially lower alkanoyl, e.g. acetyl.
N-Mono- or N,N-disubstituted carbamoyl is especially substituted by one or two substituents independently selected from lower alkyl, phenyl-lower alkyl and hydroxy-lower alkyl, or lower alkylene, oxa-lower alkylene or aza-lower alkylene optionally substituted at the terminal nitrogen atom.
A mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted, refers to a heterocyclic moiety that is unsaturated in the ring binding the heteroaryl radical to the rest of the molecule in formula I and is preferably a ring, where in the binding ring, but optionally also in any annealed ring, at least one carbon atom is replaced by a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur; where the binding ring preferably has 5 to 12, more preferably 5 or 6 ring atoms; and which may be unsubstituted or substituted by one or more, especially one or two, substitutents selected from the group defined above as substitutents for aryl, most preferably by lower alkyl, such as methyl, lower alkoxy, such as methoxy or ethoxy, or hydroxy. Preferably the mono- or bicyclic heteroaryl group is selected from 2H-pyrrolyl, pyrrolyl, imidazolyl, benzimidazolyl, pyrazolyl, indazolyl, purinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalyl, quinazolinyl, quinnolinyl, pteridinyl, indolizinyl, 3H-indolyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, furazanyl, benzo[d]pyrazolyl, thienyl and furanyl. More preferably the mono- or bicyclic heteroaryl group is selected from the group consisting of pyrrolyl, imidazolyl, such as 1 H-imidazol-1-yl, benzimidazolyl, such as 1- benzimidazolyl, indazolyl, especially 5-indazolyl, pyridyl, especially 2-, 3- or 4-pyridyl, pyrimidinyl, especially 2-pyrimidinyl, pyrazinyl, isoquinolinyl, especially 3-isoquinolinyl, quinolinyl, especially 4- or 8-quinolinyl, indolyl, especially 3-indolyl, thiazolyl, benzo[d]pyrazolyl, thienyl, and furanyl. In one preferred embodiment of the invention the pyridyl radical is substituted by hydroxy in ortho position to the nitrogen atom and hence exists at least partially in the form of the corresponding tautomer which is pyridin-(1 H)2-one. In another preferred embodiment, the pyrimidinyl radical is substituted by hydroxy both in position 2 and 4 and hence exists in several tautomeric forms, e.g. as pyrimidine-(1 H, 3H)2,4-dione.
Heterocyclyl is especially a five, six or seven-membered heterocyclic system with one or two heteroatoms selected from the group comprising nitrogen, oxygen, and sulfur, which may be unsaturated or wholly or partly saturated, and is unsubstituted or substituted especially by lower alkyl, such as methyl, phenyl-lower alkyl, such as benzyl, oxo, or heteroaryl, such as 2- piperazinyl; heterocyclyl is especially 2- or 3-pyrrolidinyl, 2-oxo-5-pyrrolidinyl, piperidinyl, N- benzyl-4-piperidinyl, N-lower alkyl-4-piperidinyl, N-lower alkyl-piperazinyl, morpholinyl, e.g. 2- or 3-morpholinyl, 2-oxo-1 H-azepin-3-yl, 2-tetrahydrofuranyl, or 2-methyl-1 ,3-dioxolan-2-yl.
Salts are especially the pharmaceutically acceptable salts of compounds of formula I. Such salts are formed, for example, as acid addition salts, preferably with organic or inorganic acids, from compounds of formula I with a basic nitrogen atom, especially the pharmaceutically acceptable salts. Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid. Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane-sulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1 ,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesuIfonic acid, 1 ,5- naphthalene-disulfonic acid, 2-, 3- or 4-methylbenzenesulfonic acid, methylsulfuric acid, ethylsulfuric acid, dodecylsulfuric acid, N-cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N- propyl-sulfamic acid, or other organic protonic acids, such as ascorbic acid.
In the presence of negatively charged radicals, such as carboxy or sulfo, salts may also be formed with bases, e.g. metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example N-ethyl-piperidine or N,N'- dimethylpiperazine.
When a basic group and an acid group are present in the same molecule, a compound of formula I may also form internal salts.
For isolation or purification purposes it is also possible to use pharmaceutically unacceptable salts, for example picrates or perchlorates. For therapeutic use, only pharmaceutically acceptable salts or free compounds are employed (where applicable in the form of pharmaceutical preparations), and these are therefore preferred.
In view of the close relationship between the novel compounds in free form and those in the form of their salts, including those salts that can be used as intermediates, for example in the purification or identification of the novel compounds, any reference to the free compounds hereinbefore and hereinafter is to be understood as referring also to the corresponding salts, as appropriate and expedient.
The compounds of formula I and N-oxides thereof have valuable pharmacological properties, as described hereinbefore and hereinafter.
The efficacy of the compounds of the invention as inhibitors of c-Abl, Bcr-Abl, and VEGF- receptor tyrosine kinase activity can be demonstrated as follows:
Test for activity against c-Abl protein tyrosine kinase. The test is conducted as a filter binding assay as follows: The His-tagged kinase domain of c-Abl is cloned and expressed in the baculovirus/Sf9 system as described by Bhat ef al., J Biol Chem. 272, 16170-5 (1997). A protein of 37 kD (c-Abl kinase) is purified by a two-step procedure over a Cobalt metal chelate column followed by an anion exchange column with a yield of 1-2 mg/L of Sf9 cells. The purity of the c-Abl kinase is >90% as judged by SDS-PAGE after Coomassie blue staining. The assay contains: c-Abl kinase (50 ng), 20 mM Tris-HCI, pH 7.5, 10 mM MgCI2, 10 μM Na3VO4, 1 mM DTT and 0.06 Ci/assay [γ33 P]-ATP (5//M ATP) using 30 g/mL poly- Ala,Glu,Lys,Tyr-6:2:5:1 (Poly-AEKY, Sigma P1152) in the presence of 1% DMSO, total volume of 30 μL. Reactions are terminated by adding 10 μL of 250 mM EDTA, and 30 μL of the reaction mixture is transferred onto Immobilon-PVDF membrane (Millipore, Bedford, MA, USA) previously soaked for 5 min with methanol, rinsed with water, then soaked for 5 min with 0.5% H3PO and mounted on vacuum manifold with disconnected vacuum source. After spotting all samples, vacuum is connected and each well rinsed with 200 μL 0.5 % H3PO4. Membranes are removed and washed on a shaker with 0.5% H3PO (4 times) and once with ethanol. Membranes are counted after drying at ambient temperature, mounting in Packard TopCount 96-well frame, and addition of 10 μLΛ/vell of Microscint TM (Packard).
Test for activity against Bcr-Abl. The murine myeloid progenitor cell line 32Dcl3 transfected with the p210 Bcr-Abl expression vector pGDp210Bcr/Abl (32D-bcr/abl) was obtained from J. Griffin (Dana Faber Cancer Institue, Bosten, MA, USA). The cells express the fusion Bcr-Abl protein with a constitutively active abl kinase and proliferate growth factor independent. The cells are expanded in RPM1 1640 (AMI MED), 10% fetal calf serum, 2 mM glutamine (Gibco) („complete medium"), and a working stock is prepared by freezing aliquots of 2 x 106 cells per vial in freezing medium (95% FCS, 5% DMSO (SIGMA)). After thawing, the cells are used during maximally 10 -12 passages for the experiments.
For cellular assays, compounds are dissolved in DMSO and diluted with complete medium to yield a starting concentration of 10 μM followed by preparation of serial 3-fold dilutions in complete medium. 200O00 32D-Bcr/Abl cells in 50 μL complete medium are seeded per well in 96 well round bottom tissue culture plates. 50 μL per well of serial 3-fold dilutions of the test compound are added to the cells in triplicates. Untreated cells are used as control. The compound is incubated together with the cells for 90 min at 37°C, 5% CO2, followed by centrifugation of the tissue culture plates at 1300 rpm (Beckmann GPR centrifuge) and removal of the supematants by careful aspiration taking care not to remove any of the pelleted cells. The cell pellets are lysed by addition of 150 μL lysis buffer (50 mM Tris/HCI, pH 7.4, 150 mM sodium chloride, 5 mM EDTA, 1 mM EGTA, 1% NP-40, 2 mM sodium ortho- vanadate, 1 mM PMSF, 50 μg/mL aprotinin and 80 μglmL leupeptin) and either used immediatedly for the ELISA or stored frozen in the plates at -20°C until usage. Black ELISA plates (Packard HTRF-96 black plates) are precoated over night at 4°C with 50 ng/well of the rabbit polyclonal anti-abl-SH3 domain Ab 06-466 from Upstate in 50 μL PBS. After washing 3 times with 200 / L/well PBS containing 0.05% Tween20 (PBST) and 0.5% TopBlock (Juro), residual protein binding sites are blocked with 200 /L/well PBST, 3% TopBIock for 4 h at room temperature followed by incubation with 50 μL lysates of untreated or compound-treated cells (20 μg total protein per well) for 3-4 h at 4°C. After 3 washings, 50 //L/well anti-phosphotyrosine Ab PY20(AP) labeled with alkaline phosphatase (Zymed) diluted to 0.2 μglmL in blocking buffer is added and incubated over night (4°C). For all incubation steps the plates are covered with plate sealers (Costar). Finally, the plates are washed another three times with washing buffer and once with deionized water before addition of 90 //L/well of the AP-substrate CDPStar RTU with Emerald II. The plates, now sealed with Packard TopSeal™-A plate sealers, are incubated for 45 min at room temperature in the dark and luminescence is quantified by measuring counts per second (CPS) with a Packard Top Count Microplate Scintillation Counter (Top Count). The difference between the ELISA-readout (CPS) obtained for with the lysates of the untreated 32D-Bcr/Abl cells and the readout for the assay-background (all components, but without cell lysate) is calculated and taken as 100% reflecting the constitutively phosphorylated Bcr-Abl protein present in these cells. The activity of the compound on the Bcr-Abl kinase activity is expressed as percent reduction of the Bcr-Abl phosphorylation. The values for the IC50 and IC90 are determined from the dose response curves by graphical extrapolation.
Test for activity against VEGF-receptor tyrosine kinase. The test is conducted using Flt-1 VEGF-receptor tyrosine kinase. The detailed procedure is as follows: 30 μL kinase solution (10 ng of the kinase domain of Flt-1 , Shibuya etal., Oncogene 5, 519-24 [1990]) in 20 mM Tris»HCI pH 7.5, 3 mM manganese dichloride (MnCI2), 3 mM magnesium chloride (MgCI2), 10 μM sodium vanadate, 0.25 mg/mL polyethylenglycol (PEG) 20000, 1 mM dithiothreitol and 3 μg/μL poly(Glu,Tyr) 4:1 (Sigma, Buchs, Switzerland), 8 μM [33P]-ATP (0.2 μCi) , 1% DMSO, and 0 to 100 μM of the compound to be tested are incubated together for 10 minutes at room temperature. The reaction is then terminated by the addition of 10 μL 0.25 M ethylenediaminetetraacetate (EDTA) pH 7. Using a multichannel dispenser (LAB SYSTEMS, USA), an aliquot of 20 μL is applied to a PVDF (= polyvinyl difluoride) Immobiion P membrane (Millipore, Bedford, USA), through a Gibco-BRL microtiter filter manifold and connected to a vacuum. Following complete elimination of the liquid, the membrane is washed 4 times successively in a bath containing 0.5% phosphoric acid (H3PO4) and once with ethanol, incubated for 10 minutes each time while shaking, then mounted in a Hewlett Packard TopCount Manifold and the radioactivity measured after the addition of 10 μL Microscint® (3-scintillation counter liquid). IC50-values are determined by linear regression analysis of the percentages for the inhibition of each compound in at least four concentrations (as a rule 0.01 , 0.1 , 1.0 and 10 μmol). The IC50-values that can be found with compounds of formula I are in the range of 1 to 10'OOO nM, preferably in the range of 1 to 100 nM.
The inhibition of VEGF-induced KDR-receptor autophosphorylation can be confirmed with a further in vitro experiment in cells: transfected CHO cells, which permanently express human VEGF receptor (KDR), are seeded in complete culture medium with 10% fetal calf serum (FCS) in 6-weli cell-culture plates and incubated at 37°C under 5% CO2 until they show about 80% confluency. The compounds to be tested are then diluted in culture medium (without FCS, with 0.1% bovine serum albumin) and added to the cells. (Controls comprise medium without test compounds). After two hours of incubation at 37°C, recombinant VEGF is added; the final VEGF concentration is 20 ng/mL). After a further five minute incubation at 37°C, the cells are washed twice with ice-cold PBS (phosphate-buffered saline) and immediately lysed in 100//L lysis buffer per well. The lysates are then centrifuged to remove the cell nuclei, and the protein concentrations of the supernatants are determined using a commercial protein assay (BIORAD). The lysates can then either be immediately used or, if necessary, stored at -20°C.
A sandwich ELISA is carried out to measure the KDR-receptor phosphorylation: a monoclonal antibody to KDR (for example Mab 1495.12.14) is immobilized on black ELISA plates (OptiPlate™ HTRF-96 from Packard). The plates are then washed and the remaining free protein-binding sites are saturated with 1% BSA in PBS. The cell lysates (20 μg protein per well) are then incubated in these plates overnight at 4°C together with an anti-phosphotyrosine antibody coupled with alkaline phosphatase (PY20:AP from Transduction Laboratories). The plates are washed again and the binding of the antiphosphotyrosine antibody to the captured phosphorylated receptor is then demonstrated using a luminescent AP substrate (CDP-Star, ready to use, with Emerald II; TROPIX). The luminescence is measured in a Packard Top Count Microplate Scintillation Counter (Top Count). The difference between the signal of the positive control (stimulated with VEGF) and that of the negative control (not stimulated with VEGF) corresponds to VEGF-induced KDR-receptor phosphorylation (= 100 %). The activity of the tested substances is calculated as % inhibition of VEGF-induced KDR-receptor phosphorylation, wherein the concentration of substance that induces half the maximum inhibition is defined as the ED50 (effective dose for 50% inhibition). Compounds of formula I here preferably show ED50 values in the range of 0.25 nM to 1000 nM, preferably 0.25 to 250 nM.
A compound of formula I or a N-oxide thereof inhibits to varying degrees also other tyrosine kinases involved in signal transduction which are mediated by trophic factors, for example Bcr-Abl and Abl kinase, Arg, kinases from the Src family, especially c-Src kinase, Lck, and Fyn; also kinases of the EGF family, for example, c-erbB2 kinase (HER-2), c-erbB3 kinase, c-erbB4 kinase; insulin-like growth factor receptor kinase (IGF-1 kinase), especially members of the PDGF-receptor tyrosine kinase family, such as PDGF-receptor kinase, CSF-1 -receptor kinase, Kit-receptor kinase and VEGF-receptor kinase; and also serine/threonine kinases, all of which play a role in growth regulation and transformation in mammalian cells, including human cells.
The inhibition of c-erbB2 tyrosine kinase (HER-2) can be measured, for example, in the same way as the inhibition of EGF-R protein kinase, using known procedures. On the basis of these studies, a compound of formula I according to the invention shows therapeutic efficacy especially against disorders dependent on protein kinase, especially proliferative diseases.
On the basis of their efficacy as inhibitors of VEGF-receptor tyrosine kinase activity, the compounds of the formula I primarily inhibit the growth of blood vessels and are thus, for example, effective against a number of diseases associated with deregulated angiogenesis, especially diseases caused by ocular neovascularisation, especially retinopathies, such as diabetic retinopathy or age-related macula degeneration, psoriasis, haemangioblastoma, such as haemangioma, mesangial cell proliferative disorders, such as chronic or acute renal diseases, e.g. diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes or transplant rejection, or especially inflammatory renal disease, such as glomerulonephritis, especially mesangioproliferative glomerulonephritis, haemolytic-uraemic syndrome, diabetic nephropathy, hypertensive nephrosclerosis, atheroma, arterial restenosis, autoimmune diseases, diabetes, endometriosis, chronic asthma, and especially neoplastic diseases (solid tumors, but also leukemias and other "liquid tumors", especially those expressing c-kit, KDR, Flt-1 or Flt-3), such as especially breast cancer, cancer of the colon, lung cancer (especially small-cell lung cancer), cancer of the prostate or Kaposi's sarcoma. A compound of formula I (or an N-oxide thereof) inhibits the growth of tumours and is especially suited to preventing the metastatic spread of tumors and the growth of micrometastases.
A compound of formula I can be administered alone or in combination with one or more other therapeutic agents, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic agents being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic agents. A compound of formula I can besides or in addition be administered especially for tumor therapy, such as leukaemia therapy, in combination with chemotherapy, radiotherapy, immunotherapy, surgical intervention, or a combination of these. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are therapy to maintain the patient's status after tumor regression, or even chemopreventive therapy, for example in patients at risk. Therapeutic agents for possible combination are especially one or more cytostatic or cytotoxic compounds, for example a chemotherapeutic agent or several selected from the group comprising indarubicin, cytarabine, interferon, hydroxyurea, bisulfan, or an inhibitor of polyamine biosynthesis, an inhibitor of protein kinase, especially of serine/threonine protein kinase, such as protein kinase C, or of tyrosine protein kinase, such as epidermal growth factor receptor tyrosine kinase, a cytokine, a negative growth regulator, such as TGF-β or IFN-β, an aromatase inhibitor, a classical cytostatic, and an inhibitor of the interaction of an SH2 domain with a phosphorylated protein.
A compound according to the invention is not only for the (prophylactic and preferably therapeutic) management of humans, but also for the treatment of other warm-blooded animals, for example of commercially useful animals, for example rodents, such as mice, rabbits or rats, or guinea-pigs. Such a compound may also be used as a reference standard in the test systems described above to permit a comparison with other compounds.
In general, the invention relates also to the use of a compound of formula I or a N-oxide thereof for the inhibition of tyrosine kinase activity, either in vitro or in vivo.
With the groups of preferred compounds of formula I and N-oxides thereof mentioned hereinafter, definitions of substituents from the general definitions mentioned hereinbefore may reasonably be used, for example, to replace more general definitions with more specific definitions or especially with definitions characterized as being preferred.
In particular, the invention relates to compounds of formula I, wherein
R^ represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, carboxy- lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl;
R2 represents hydrogen, lower alkyl, optionally substituted by one or two identical or different radicals R3, cycloalkyl, benzcycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising one, two or three nitrogen atoms or one sulfur atom, which aryl and heteroaryl groups in each case are unsubstituted or mono- or polysubstituted; and R3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amino, mono- or disubstituted amino, cycloalkyl, heterocyclyl, an aryl group, furanoyl, thienoyl, or a mono- or bicyclic heteroaryl group comprising one, two or three ring nitrogen atoms, zero or one ring oxygen atom and zero or one ring sulphur atom, which aryl and heteroaryl groups in each case are unsubstituted or mono- or polysubstituted;
or wherein Ri and R2 together represent alkylene with four or five carbon atoms, optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms in the alkylene group; oxaalkylene with one oxygen and three or four carbon atoms, or azaalkylene with one nitrogen and three or four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N- disubstituted carbamoyl-lower alkyl, cycloalkyl, lower alkoxycarbonyl, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl;
R4 represents hydrogen, lower alkyl, or halogen;
and a N-oxide or a pharmaceutically acceptable salt of such a compound.
More particular, the invention relates to compounds of formula I, wherein
Ri represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl;
R2 represents hydrogen, lower alkyl, optionally substituted by one or two identical or different radicals R3, cyclopentyl, benzcyclopentyl, cylcohexyl, pyrrolidinyl, oxazolinyl, piperidinyl, N- substituted piperidinyl, morpholinyl, azepinyl, oxo-azepinyl, oxazepinyl, phenyl, naphthalinyl, tetrahydronaphthalinyl or a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which phenyl, naphthalinyl and heteroaryl groups in each case are unsubstituted or mono- or polysubstituted, thienyl, or lower alkoxycarbonyl-lower alkylthienyl; and R3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amino, lower alkylamino, di-lower alkylamino, phenylamino, N-lower aikyl-N-phenylamino, pyrrolidino, oxopyrrolidino, piperidino, morpholino, imidazolino, oxoimidazolino, cycloalkyl, heterocyclyl, furyl, phenyl, naphthalinyl, tetrahydronaphthalinyl, or a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which phenyl, naphthalinyl and heteroaryl group are unsubstituted or mono- or polysubstituted;
or wherein Ri and R2 together represent alkylene with four or five carbon atoms, optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms in the alkylene group; oxaalkylene with one oxygen and four carbon atoms; or azaalkylene with one nitrogen and four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N-disubstituted carbamoyl- lower alkyl, cycloalkyl, lower alkoxycarbonyl, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl;
R4 represents hydrogen, lower alkyl, or halogen;
and a N-oxide or a pharmaceutically acceptable salt of such a compound.
More particular, the invention relates to compounds of formula I, wherein
i represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl;
R2 represents hydrogen; lower alkyl, optionally substituted by one radical R3, by two phenyl groups, by two lower alkoxycarbonyl groups, by phenyl and lower alkoxycarbonyl, or by hydroxyphenyl and lower alkoxycarbonyl; cyclopentyl; benzcyclopentyl; cylcohexyl; pyrrolidinyl; oxazolinyl; piperidinyl; N-lower alkylpiperidinyl; N-benzylpiperidinyl; N- pyrimidinylpiperidinyl; morpholinyl; azepinyl; oxo-azepinyl; oxazepinyl; phenyl, naphthalinyl, tetrahydronaphthalinyl or a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which phenyl, naphthalinyl and heteroaryl groups in each case are unsubstituted or substituted by one or two substituents selected from the group consisting of lower alkyl, trifluoro-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, amino-lower alkyl, lower alkylamino-lower alkyl, di-lower alkylamino-lower alkyl, N-cyclohexyl-N-lower alkylamino- lower alkyl, lower alkoxycarbonylpiperidino-lower alkyl, N-lower alkylpiperazino-lower alkyl, lower alkoxycarbonyl-lower alkyl, hydroxy, lower alkoxy, trifluoro-lower alkoxy, 1 H-imidazolyl- lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, lower alkyl carbamoyl, amino, lower alkanoylamino, benzoylamino, amino mono- or disubstituted by lower alkyl, by hydroxy-lower alkyl or by lower alkoxy-lower alkyl, 1 H- imidazolyl, mono- or di-lower alkyl-1 H-imidazolyl, pyrrolidino, piperidino, piperazino, N-lower alkylpiperazino, morpholino, sulfamoyl, lower alkylsulfonyl, phenylsulfonyl, lower alkylsulfinyl, phenylsulfinyl, lower alkylthio, phenylthio, phenyl, pyridyl, halogenyl, or benzoyl; thienyl; or lower alkoxycarbonyl-lower alkylthienyl; and
R3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, carbamoyl mono-or disubstituted by lower alkyl, phenyl or lower alkylene, amino, lower alkylamino, di-lower alkylamino, phenylamino, N-lower alkyl-N-phenylamino, pyrrolidino, oxopyrrolidino, piperidino, morpholino, imidazolino, oxoimidazolino, cycloalkyl, heterocyclyl, furyl; phenyl, naphthalinyl, tetrahydronaphthalinyl, or a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which phenyl, naphthalinyl and heteroaryl group is unsubstituted or substituted by one or two substituents selected from the group consisting of lower alkyl, trifluoro-lower alkyl, lower alkoxycarbonyl-lower alkyl, hydroxy, lower alkoxy, trifluoro-lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, amino, lower alkanoylamino, benzoylamino, amino mono- or disubstituted by lower alkyl, by hydroxy-lower alkyl or by loweralkoxy-lower alkyl, pyrrolidino, piperidino, morpholino, piperazino, N-lower alkylpiperazino, N-lower alkoxycarbonylpiperazino, phenyl, pyridyl, 1 H-imidazolyl, lower alkyl-1 H-imidazolyl, sulfamoyl, lower alkylsulfonyl, phenylsulfonyl, lower alkylsulfinyl, phenylsulfinyl, lower alkylthio, phenylthio, halogenyl, or benzoyl;
or wherein R, and R2 together represent alkylene with four or five carbon atoms, optionally mono- or disubstituted by lower alkyl, cycloalkyl, phenyl, hydroxy, lower alkoxy, amino, benzoylamino, piperidino, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms in the alkylene group; oxaalkylene with one oxygen and four carbon atoms; or azaalkylene with one nitrogen and four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy- lower alkyl, carbamoyl-lower alkyl, carbamoyl-lower alkyl N-mono- or N,N-disubstituted by lower alkyl, phenyl, lower alkylene or oxa-lower alkylene, cycloalkyl, lower alkoxycarbonyl, phenyl, methoxyphenyl, trifluoromethylphenyl, trifluoromethoxyphenyl, pyridinyl, pyrimidinyl, or pyrazinyl;
R4 represents hydrogen or lower alkyl;
and a N-oxide or a pharmaceutically acceptable salt of such a compound.
In a preferred group of compounds of formula I,
R-i represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, or benzyl;
R2 represents lower alkyl, optionally substituted by one radical R3 , by two phenyl groups, by two lower alkoycarbonyl groups, by phenyl and lower alkoxycarbonyl, or by hydroxyphenyl and lower alkoxycarbonyl; cyclopentyl; benzcyclopentyl; cylcohexyl; pyrrolidinyl; piperidinyl; N-lower alkylpiperidinyl; N-benzylpiperidinyl; N-pyrimidinylpiperidinyl; morpholinyl; azepinyl; oxoazepinyl; phenyl; naphthalinyl; tetrahydronaphthalinyl; pyridyl; lower alkyl-pyridyl; quinolinyl; thienyl; lower alkoxycarbonylmethylthienyl; or phenyl substituted by one or two substituents selected from the group consisting of lower alkyl, trifluoro-lower alkyl, hydroxy- lower alkyl, amino-lower alkyl, lower alkylamino-lower alkyl, di-lower alkylamino-lower alkyl, N-cyclohexyl-N-lower alkylamino-lower alkyl, lower alkoxycarbonylpiperidino-lower alkyl, N- lower alkylpiperazino-lower alkyl, lower alkoxycarbonyl-lower alkyl, hydroxy, lower alkoxy, trifluoro-lower alkoxy, 1 H-imidazolyl-lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, amino, lower alkanoylamino, benzoylamino, amino mono- or disubstituted by lower alkyl, by hydroxy-lower alkyl or by loweralkoxy-lower alkyl, 1 H-imidazolyl, lower alkyl-1 H-imidazolyl, pyrrolidino, piperidino, piperazino, N-lower alkylpiperazino, morpholino, sulfamoyl, lower alkylsulfonyl, phenyl, pyridyl, halogenyl, or benzoyl;
and R3 represents hydroxy, lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, amino, lower alkylamino, di-lower alkylamino, phenylamino, N- lower alkyl-N-phenylamino, pyrrolidino, oxopyrrolidino, piperidino, morpholino, imidazolino, oxoimidazolino, cyclopropyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, phenyl, naphthalinyl, tetrahydronaphthalinyl, furyl, a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which heteroaryl group is unsubstituted or mono- or disubstituted by lower alkyl, hydroxy and lower alkoxy, or phenyl substituted by one or two substituents selected from the group consisting of lower alkyl, trifluoro-lower alkyl, lower alkoxycarbonyl-lower alkyl, hydroxy, lower alkoxy, trifluoro-lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, amino, lower alkanoylamino, benzoylamino, amino mono- or disubstituted by lower alkyl, by hydroxy-lower alkyl or by loweralkoxy-lower alkyl, pyrrolidino, piperidino, morpholino, piperazino, N-lower alkylpiperazino, N-lower alkoxycarbonylpiperazino, phenyl, pyridyl, 1 H-imidazolyl, lower alkyl-1 H-imidazolyl, sulfamoyl, lower alkylsulfonyl, halogenyl, or benzoyl;
or wherein ^ and R2 together represent alkylene with four or five carbon atoms, optionally mono- or disubstituted by phenyl, hydroxy, amino, benzoylamino, or piperidino; benzalkylene with four or five carbon atoms in the alkylene group; oxaalkylene with one oxygen and four carbon atoms; or azaalkylene with one nitrogen and four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carbamoyl-lower alkyl, pyrrolidinocarbonyl-lower alkyl, morpholinocarbonyl-lower alkyl, cyclopentyl, lower alkoxycarbonyl, phenyl, methoxyphenyl, trifluoromethylphenyl, pyridinyl; pyrimidinyl, or pyrazinyl;
R4 represents hydrogen or methyl;
and a N-oxide or a pharmaceutically acceptable salt of such a compound.
A specially preferred group of compounds comprises compounds of formula I wherein R represents hydrogen, and
R2 represents phenyl substituted by trifluoromethyl, especially 3-trifluoromethylphenyl, and optionally a further substituent selected from the group consisting of hydroxy-lower alkyl, e.g. 1-hydroxy-l-methylethyl, lower alkylamino, e.g. methyl- or ethylamino, hydroxy-lower alkylamino, e.g. 2-hydroxy-1 -propylamino or 2-hydroxy-2-propylamino, di-lower alkylamino, e.g. diethylamino, 1 H-imidazolyl, lower alkyl-1 H-imidazolyl, e.g. 2- or 4-methyl-1 H-imidazolyl, carbamoyl, lower alkylcarbamoyl, e.g. methylcarbamoyl, pyrrolidino, piperidino, piperazino, lower alkylpiperazino, e.g. 4-methylpiperazino, morpholino, lower alkoxy, e.g. methoxy, fluoro-lower alkoxy, e.g. trifluoromethoxy or 2,2,2-trifluoroethoxy, phenyl, pyridyl, e.g. 2-, 3- or
4-pyridyl, and halogenyl, e.g.chloro or fluoro;
R4 represents methyl; and a N-oxide or a pharmaceutically acceptable salt of such a compound.
One preferred embodiment of the invention relates to compounds of formula I wherein
Ri is hydrogen,
R2 represents phenyl which is mono- or disubstituted by imidazol-lower alkoxy, lower alkyl amino, trifluoromethyl, hydroxy lower alkyl amino, bis-(lower alkoxy lower alkyl) amino, lower alkyl piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, phenyl, pyridyl, imidazolyl which is unsubstituted or mono- or disubstituted by lower alkyl or N-lower alkyl carbamoyl;
R4 is lower alkyl; and to the N-oxides and pharmaceutically acceptable salts of such compounds.
Particularly preferred are the compounds of the Examples.
Other compounds which are particularly preferred are:
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzanilide,
4-Methyl-Λ/-(3-pyridinyl)-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide,
Λ/-(4-Chlorophenyl)-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide,
2(R)- and 2(S)-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoylamino]propanoic acid,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(8-quinolinyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(3-[trifluoromethoxy]phenyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(2-pyrrolidinoethyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(3-pyrrolidinophenyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(1-[2-pyrimidinyl]-4-piperidinyl)benzamide,
Λ/-(4-Di-[2-methoxyethyl]amino-3-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Λ/-(4-[1 H-lmidazolyl]-3-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(2-pyrrolidino-5- trifluoromethylphenyl)benzamide,
Λ/-(3,4-difluorophenyl)-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide, 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-/V-(3-trifluoromethylbenzyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-/V-(3-trifluoromethylphenyl)benzamide,
Λ/-(3-Chloro-5-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Λ/-(4-Dimethylaminobutyl)-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide,
4-Methyl-Λ/-[4-(4-methyl-1-piperazinyl)-3-trifluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(2,2,2-trifIuoroethoxy)-3- trifluoromethylphenyljbenzamide,
4-Methyl-Λ/-[4-(2-methyl-1H-imidazolyl)-3-thfluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-Λ/-(4-phenyl-3-trifluoromethylphenyl)-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-Λ/-[4-(4-methyl-1 H-imidazolyl)-3-trifluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Methyl 2(R)- and 2(S)-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoylamio]-3-[4- hydroxyphenyl]propanoate,
Λ/-[2-(Λ/-Cyclohexyl-Λ/-methylaminomethyl)phenyl]-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Λ/-[3-[2-(1 H-lmidazolyl)ethoxy]phenyl]-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-Λ/-[3-morpholino-5-trifluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(4-pyrrolidino-3- trifluoromethylphenyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(4-piperidino-3- trifluoromethylphenyl)benzamide,
4-Methyl-Λ/-[4-morpholino-3-trifluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide, iV-(4-Ethylamino-3-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-(3-trifluoromethoxyphenyl)benzamide,
Λ/-[4-(2-Hydroxypropylamino)-3-trifluoromethylphenyl]-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide, Λ/-(4-Diethylamino-3-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidiny!]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[3-(3-pyridinyl)-5- trifluorophenyljbenzamide,
Λ/-[3-[3-(1 H-lmidazolyl)propoxy]phenyl]-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(3-pyridinyl)-3- trifluorophenyl]benzamide,
4-Methyl-Λ/-[3-(4-methyl-1-piperazinyl)-5-trifluorophenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-Λ/-[3-methylcarbamoyl-5-trifluorophenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-Λ/-[3-methylcarbamoyl-5-morpholino]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide.
Further compounds which are particularly preferred are:
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[3-[3-(1H-imidazol-1-yl)propoxy]- phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[3-[2-(1 H-imidazol-1- yl)ethoxy]phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(ethylamino)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(diethylamino)-3-
(trifluoromethyl)phenyl]benzamide,
(±)-4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-[(2-hydroxypropyl)amino]-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyI]amino]-Λ/-[4-[bis(2-methoxyethyl)amino]-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(4-methyl-1-piperazinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(1-piperidinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(1 -pyrrolidinyl)-3-
(trifluoromethyl)phenyl]benzamide, 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4 (4-morphoiinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4 phenyl-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[3 4-(3-pyridinyl)-3-
(trifluoromethyl)phenyl]methyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4- 1H-imidazol-1-yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4- 2,4-dimethyl-1 H-imidazol-1 -yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4- 4-methyl-1 H-imidazol-1 -yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4- 2-methyI-1 H-imidazol-1 -yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[3- 4-morpholinyl)-5-
[(methylamino)carbonyl]phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[3- (methylamino)carbonyl]-5-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[5- 3-pyridinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[5- 4-morpholinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[5- 2-methyl-1 H-imidazol-1 -yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[5- 4-methyl-1 H-imidazol-1 -yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[5- 5-methyl-1 H-imidazol-1 -yl)-3-
(trifIuoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-/v'-[3-ι 4-methyl-1 -piperazinyl)-5-
(trifluoromethyl)phenyl]benzamide, and
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[2-ι 1 -pyrrolidinyl)-5-
(trifluoromethyl)phenyl]benzamide. The invention relates also to 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid and to 3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid; intermediates for the formation of the preferred amides of the invention.
Especially, the invention relates to the use of a compound of formula I or of a N-oxide or a possible tautomer thereof or of a pharmaceutically acceptable salt of such a compound for the preparation of a pharmaceutical composition for the treatment of a disease which responds to an inhibition of protein kinase activity, wherein the disease is a neoplastic disease.
More particularly, the invention relates to the use of a compound of the formula I or of a N- oxide or a possible tautomer thereof; or of a pharmaceutically acceptable salt of such a compound for the preparation of a pharmaceutical composition for the treatment of leukaemia which responds to an inhibition of the Abl tyrosine kinase activity.
Furthermore, the invention provides a method for the treatment of a disease which responds to an inhibition of protein kinase activity, which comprises administering a compound of formula I or a N-oxide or a pharmaceutically acceptable salt thereof, wherein the radicals and symbols have the meanings as defined above, in a quantity effective against said disease, to a warm-blooded animal requiring such treatment.
A compound of the invention may be prepared by processes that, though not applied hitherto for the new compounds of the present invention, are known per se, especially a process characterized in that for the synthesis of a compound of the formula I wherein the symbols R1? R2 and R4 are as defined for a compound of the formula I, a 4- R4-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]-benzoic acid of formula II
Figure imgf000025_0001
wherein R is as defined for a compound of formula I, or a derivative thereof wherein the carboxy group -COOH is in activated form, is reacted with an amine of the formula III
Rn-NH-R2 (III)
wherein R^ and R2 are as defined for a compound of the formula I, optionally in the presence of a dehydrating agent and an inert base and/or a suitable catalyst, and optionally in the presence of an inert solvent;
where the above starting compounds II and III may also be present with functional groups in protected form if necessary and/or in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible;
any protecting groups in a protected derivative of a compound of the formula I are removed;
and, if so desired, an obtainable compound of formula I is converted into another compound of formula I or a N-oxide thereof, a free compound of formula I is converted into a salt, an obtainable salt of a compound of formula I is converted into the free compound or another salt, and/or a mixture of isomeric compounds of formula I is separated into the individual isomers.
Detailed description of the process:
A derivative of the compound of formula II wherein the carboxy group is in activated form is especially a reactive ester, a reactive anhydride or a reactive cyclic amide.
Reactive esters of the acid of formula II are especially esters unsaturated at the linking carbon atom of the esterifying radical, for example esters of the vinyl ester type, such as actual vinyl esters (obtainable, for example, by transesterification of a corresponding ester with vinyl acetate; activated vinyl ester method), carbamoylvinyl esters (obtainable, for example, by treatment of the corresponding acid with an isoxazolium reagent; 1 ,2-oxazolium or Woodward method), or 1 -lower alkoxyvinyl esters (obtainable, for example, by treatment of the corresponding acid with a lower alkoxyacetylene; ethoxyacetylene method), or esters of the amidino type, such as N,N'-disubstituted amidino esters (obtainable, for example, by treatment of the corresponding acid with a suitable N,N'-disubstituted carbodiimide, for example N,N'-dicyclohexylcarbodiimide; carbodiimide method), or N,N-disubstituted amidino esters (obtainable, for example, by treatment of the corresponding acid with an N,N- disubstituted cyanamide; cyanamide method), suitable aryl esters, especially phenyl esters suitably substituted by electron-attracting substituents (obtainable, for example, by treatment of the corresponding acid with a suitably substituted phenol, for example 4-nitrophenol, 4- methylsulfonyl-phenol, 2,4,5-trichlorophenol, 2,3,4,5,6-pentachloro-phenol or 4- phenyidiazophenol, in the presence of a condensation agent, such as N,N'-dicyclohexyl- carbodiimide; activated aryl esters method), cyanomethyl esters (obtainable, for example, by treatment of the corresponding acid with chloroacetonitrile in the presence of a base; cyanomethyl esters method), thio esters, especially unsubstituted or substituted, for example nitro-substituted, phenylthio esters (obtainable, for example, by treatment of the corresponding acid with unsubstituted or substituted, for example nitro-substituted, thiophenols, inter alia by the anhydride or carbodiimide method; activated thiol esters method), amino or amido esters (obtainable, for example, by treatment of the corresponding acid with an N-hydroxy-amino or N-hydroxy-amido compound, for example N-hydroxy- succinimide, N-hydroxy-piperidine, N-hydroxy-phthalimide or 1 -hydroxy-benzotriazole, for example by the anhydride or carbodiimide method; activated N-hydroxy esters method), or silyl esters (which are obtainable, for example, by treatment of the corresponding acid with a silylating agent, for example hexamethyl disilazane, and react readily with hydroxy groups but not with amino groups).
Anhydrides of the acid of formula II may be symmetric or preferably mixed anhydrides of that acid, for example anhydrides with inorganic acids, such as acid halides, especially acid chlorides (obtainable, for example, by treatment of the corresponding acid with thionyl chloride, phosphorus pentachloride or oxalyl chloride; acid chloride method), azides (obtainable, for example, from a corresponding acid ester via the corresponding hydrazide and treatment thereof with nitrous acid; azide method), anhydrides with carbonic acid semiderivatives, such as corresponding esters, for example carbonic acid lower alkyl semiesters (obtainable, for example, by treatment of the corresponding acid with haloformic, such as chloroformic, acid lower alkyl esters or with a 1 -lower alkoxycarbonyl-2-lower alkoxy- 1 ,2-dihydroquinoline, for example 1 -lower alkoxycarbonyI-2-ethoxy-1 ,2-dihydroquinoline; mixed O-alkylcarbonic acid anhydrides method), or anhydrides with dihalogenated, especially dichlorinated, phosphoric acid (obtainable, for example, by treatment of the corresponding acid with phosphorus oxychloride; phosphorus oxychloride method), or anhydrides with organic acids, such as mixed anhydrides with organic carboxylic acids (obtainable, for example, by treatment of the corresponding acid with an unsubstituted or substituted lower alkane- or phenylalkane-carboxylic acid halide, for example phenylacetic acid chloride, pivalic acid chloride or trifluoroacetic acid chloride; mixed carboxylic acid anhydrides method), with organic sulfonic acids (obtainable, for example, by treatment of a salt, such as an alkali metal salt, of the corresponding acid, with a suitable organic sulfonic acid halide, such as lower alkane- or aryl-, for example methane- or p-toluene-sulfonic acid chloride; mixed sulfonic acid anhydrides method), or with organic phosphonic acids (obtainable, for example, by treatment of the corresponding acid with a suitable organic phosphonic anhydride or phosphonic cyanide; mixed phosphonic acid anhydrides methhod), and symmetric anhydrides (obtainable, for example, by condensation of the corresponding acid in the presence of a carbodiimide or of 1-diethylaminopropyne; symmetric anhydrides method).
Suitable cyclic amides are especially amides with five-membered diazacycles of aromatic character, such as amides with imidazoles, for example imidazole (obtainable, for example, by treatment of the corresponding acid with N.N'-carbonyldiimidazole; imidazolide method), or pyrazoles, for example 3,5-dimethyl-pyrazole (obtainable, for example, by way of the acid hydrazide by treatment with acetylacetone; pyrazolide method).
Derivatives of the acid of formula II wherein the carboxy group is in activated form are preferably formed in situ. For example, N,N'-disubstituted amidino esters can be formed in situ by reacting a mixture of the acid of formula II and the amine of formula 111 in the presence of a suitable N,N-disubstituted carbodiimide, for example N,N'-dicyclohexylcarbodiimide. Reactive mixed anhydrides of the acid of formula II with an organic phosphonic acid may be formed in situ by reaction with e.g. propylphosphonic anhydride or diethylcyanophosphonate in the presence of suitable base, preferably a tertiary amine, e.g. triethylamine or dimethylaminopyridine.
The reaction can be carried out in a manner known per se, the reaction conditions being dependent especially on whether, and if so how, the carboxy group of the carboxylic acid of formula II has been activated, usually in the presence of a suitable solvent or diluent or of a mixture thereof and, if necessary, in the presence of a condensation agent, which, for example when the carboxy group participating in the reaction is in the form of an anhydride, may also be an acid-binding agent, with cooling or heating, for example in a temperature range from approximately -30 °C to approximately +150 °C, especially approximately from 0 °C to +100 °C, preferably from room temperature (approx. +20 °C) to +70 °C, in an open or closed reaction vessel and/or in the atmosphere of an inert gas, for example nitrogen. Customary condensation agents are, for example, carbodiimides, for example N,N'-diethyl-, N,N'-dipropyI-, N,N'-dicyclohexyl- or N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide, suitable carbonyl compounds, for example carbonyldiimidazole, or 1 ,2-oxazolium compounds, for example 2-ethyl-5-phenyl-1 ,2-oxazolium 3'-sulfonate and 2-tert-butyl-5- methyl-isoxazolium perchlorate, or a suitable acylamino compound, for example 2-ethoxy-1 - ethoxycarbonyl-1 ,2-dihydroquinoline. Customary acid-binding condensation agents are, for example, alkali metal carbonates or hydrogen carbonates, for example sodium or potassium carbonate or hydrogen carbonate (customarily together with a sulfate), or organic bases, such as, customarily, pyridine or triethylamine, or sterically hindered tri-lower alkylamines, for example N,N-diisopropyl-N-ethyl-amine.
In a preferred variant, the carboxylic acid of formula II is reacted with an amine of formula III in a suitable solvent, such as e.g. N.N-dimethylformamide, in the presence of propylphosphonic anhydride or diethylcyanophosphanate and triethylamine, between 1 and 48 hours at between 0°C and around 50°C, preferably at room temperature.
Protecting groups
If one or more other functional groups, for example carboxy, hydroxy, amino, or mercapto, are or need to be protected in a compound of formula III, because they should not take part in the reaction, these are such groups as are usually used in the synthesis of amides, in particular peptide compounds, and also of cephalosporins and penicillins, as well as nucleic acid derivatives and sugars.
The protecting groups may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions, such as acylations, etherifications, esterifications, oxidations, solvolysis, and similar reactions. It is a characteristic of protecting groups that they lend themselves readily, i.e. without undesired secondary reactions, to removal, typically by solvolysis, reduction, photolysis or also by enzyme activity, for example under conditions analogous to physiological conditions, and that they are not present in the end-products.The specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned hereinabove and hereinafter.
The protection of such functional groups by such protecting groups, the protecting groups themselves, and their removal reactions are described for example in standard reference books for peptide synthesis as cited hereinbefore, and in special books on protective groups such as J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973, in "Methoden der organischen Chemie" (Methods of organic chemistry), Houben-Weyl, 4th edition, Volume 15/1, Georg Thieme Verlag, Stuttgart 1974, and in T. W. Greene, "Protective Groups in Organic Synthesis", Wiley, New York.
Additional process steps
In the additional process steps, carried out as desired, functional groups of the starting compounds which should not take part in the reaction may be present in unprotected form or may be protected for example by one or more of the protecting groups mentioned hereinabove under "protecting groups". The protecting groups are then wholly or partly removed according to one of the methods described there.
Salts of a compound of formula I with a salt-forming group may be prepared in a manner known per se. Acid addition salts of compounds of formula I may thus be obtained by treatment with an acid or with a suitable anion exchange reagent.
Salts can usually be converted to free compounds, e.g. by treating with suitable basic agents, for example with alkali metal carbonates, alkali metal hydrogencarbonates, or alkali metal hydroxides, typically potassium carbonate or sodium hydroxide.
Stereoisomeric mixtures, e.g. mixtures of diastereomers, can be separated into their corresponding isomers in a manner known per se by means of suitable separation methods. Diastereomeric mixtures for example may be separated into their individual diastereomers by means of fractionated crystallization, chromatography, solvent distribution, and similar procedures. This separation may take place either at the level of a starting compound or in a compound of formula I itself. Enantiomers may be separated through the formation of diastereomeric salts, for example by salt formation with an enantiomer-pure chiral acid, or by means of chromatography, for example by HPLC, using chromatographic substrates with chiral ligands.
A compound of the formula I wherein R-i is hydrogen can be converted to the respective compound wherein Ri is lower alkyl by reaction e.g. with a diazo lower alkyl compound, especially diazomethane, in an inert solvent, preferably in the presence of a noble metal catalyst, especially in dispersed form, e.g. copper, or a noble metal salt, e.g. copper(l)- chloride or copper(ll)-sulfate. Also reaction with lower alkylhalogenides is possible, or with other leaving group carrying lower alkanes, e.g. lower alkyl alcohols esterified by a strong organic sulfonic acid, such as a lower alkanesulfonic acid (optionally substituted by halogen, such as fluoro), an aromatic sulfonic acid, for example unsubstituted or substituted benzenesulfonic acid, the substituents preferably being selected from lower alkyl, such as methyl, halogen, such as bromo, and/or nitro, e.g. esterified by methanesulfonic acid, or p- toluene sulfonic acid. The alkylation takes place under usual conditions for alkylation of amides, especially in aqueous solution and/or in the presence of polar solvents, typically alcohols, for example methanol, ethanol, isopropanol, or ethylene glycol, or dipolar aprotic solvents, e.g. tetrahydrofuran, dioxane, or dimethylformamide, where applicable in the presence of acidic or basic catalysts, generally at temperatures from about 0°C to the boiling temperature of the corresponding reaction mixture, preferably between 20°C and reflux temperature, if necessary under increased pressure, e.g. in a sealed tube, and/or under inert gas, typically nitrogen or argon.
It should be emphasized that reactions analogous to the conversions mentioned in this chapter may also take place at the level of appropriate intermediates.
General process conditions
All process steps described here can be carried out under known reaction conditions, preferably under those specifically mentioned, in the absence of or usually in the presence of solvents or diluents, preferably such as are inert to the reagents used and able to dissolve these, in the absence or presence of catalysts, condensing agents or neutralisiing agents, for example ion exchangers, typically cation exchangers, for example in the H+ form, depending on the type of reaction and/or reactants at reduced, normal, or elevated temperature, for example in the range from -100°C to about 190°C, preferably from about -80°C to about 150°C, for example at -80 to -60°C, at room temperature, at - 20 to 40°C or at the boiling point of the solvent used, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under argon or nitrogen.
Salts may be present in all starting compounds and transients, if these contain salt-forming groups. Salts may also be present during the reaction of such compounds, provided the reaction is not thereby disturbed.
At all reaction stages, isomeric mixtures that occur can be separated into their individual isomers, e.g. diastereomers or enantiomers, or into any mixtures of isomers, e.g. racemates or diastereomeric mixtures.
The invention relates also to those forms of the process in which one starts from a compound obtainable at any stage as a transient and carries out the missing steps, or breaks off the process at any stage, or forms a starting material under the reaction conditions, or uses said starting material in the form of a reactive derivative or salt, or produces a compound obtainable by means of the process according to the invention and processes the said compound in situ. In the preferred embodiment, one starts from those starting materials which lead to the compounds described hereinabove as preferred, particularly as especially preferred, primarily preferred, and/or preferred above all.
In the preferred embodiment, a compound of formula I is prepared according to or in analogy to the processes and process steps defined in the Examples.
The compounds of formula I, including their salts, are also obtainable in the form of hydrates, or their crystals can include for example the solvent used for crystallization (present as solvates).
Pharmaceutical preparations, methods, and uses
The present invention relates furthermore to a method for the treatment of a neoplastic disease which responds to an inhibition of a protein kinase activity, which comprises administering a compound of formula I or a N-oxide or a pharmaceutically acceptable salt thereof, wherein the radicals and symbols have the meanings as defined above for formula I, in a quantity effective against said disease, to a warm-blooded animal requiring such treatment.
In particular the invention relates to a method for the treatment of leukaemia which responds to an inhibition of the Abl tyrosine kinase activity, which comprises administering a compound of formula I or a N-oxide or a pharmaceutically acceptable salt thereof, wherein the radicals and symbols have the meanings as defined above for formula I, in a quantity effective against said leukaemia, to a warm-blooded animal requiring such treatment.
The present invention relates also to pharmaceutical compositions that comprise a compound of formula I or a N-oxide thereof as active ingredient and that can be used especially in the treatment of the diseases mentioned at the beginning. Compositions for enteral administration, such as nasal, buccal, rectal or, especially, oral administration, and for parenteral administration, such as intravenous, intramuscular or subcutaneous administration, to warm-blooded animals, especially humans, are especially preferred. The compositions comprise the active ingredient alone or, preferably, together with a pharmaceutically acceptable carrier. The dosage of the active ingredient depends upon the disease to be treated and upon the species, its age, weight, and individual condition, the individual pharmacokinetic data, and the mode of administration.
The present invention relates especially to pharmaceutical compositions that comprise a compound of formula I, a tautomer, a N-oxide or a pharmaceutically acceptable salt, or a hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier.
The invention relates also to pharmaceutical compositions for use in a method for the prophylactic or especially therapeutic management of the human or animal body, to a process for the preparation thereof (especially in the form of compositions for the treatment of tumors) and to a method of treating tumor diseases, especially those mentioned hereinabove.
The invention relates also to processes and to the use of compounds of formula I or N-oxides thereof for the preparation of pharmaceutical preparations which comprise compounds of formula I or N-oxides thereof as active component (active ingredient). ln the preferred embodiment, a pharmaceutical preparation is suitable for administration to a warm-blooded animal, especially humans or commercially useful mammals suffering from a disease responsive to an inhibition of the Abl tyrosine kinase, for example chronic myelo- genous leukaemia (CML), and comprises an effective quantity of a compound of formula I or N-oxides thereof for the inhibition of the Bcr-Abl fusion protein, or a pharmaceutically acceptable salt thereof, if salt-forming groups are present, together with at least one pharmaceutically acceptable carrier.
A pharmaceutical composition for the prophylactic or especially therapeutic management of neoplastic and other proliferative diseases of a warm-blooded animal, especially a human or a commercially useful mammal requiring such treatment, especially suffering from such a disease, comprising as active ingredient in a quantity that is prophylactically or especially therapeutically active against the said diseases a novel compound of formula I or N-oxides thereof, is likewise preferred.
The pharmaceutical compositions comprise from approximately 1 % to approximately 95% active ingredient, single-dose administration forms comprising in the preferred embodiment from approximately 20% to approximately 90% active ingredient and forms that are not of single-dose type comprising in the preferred embodiment from approximately 5% to approximately 20% active ingredient. Unit dose forms are, for example, coated and uncoated tablets, ampoules, vials, suppositories, or capsules. Further dosage forms are, for example, ointments, creams, pastes, foams, tinctures, sprays, etc. Examples are capsules containing from about 0.05 g to about 1.0 g active ingredient.
The pharmaceutical compositions of the present invention are prepared in a manner known per se, for example by means of conventional mixing, granulating, coating, dissolving or lyophilizing processes.
Preference is given to the use of solutions of the active ingredient, and also suspensions or dispersions, especially isotonic aqueous solutions, dispersions or suspensions which, for example in the case of lyophilized compositions comprising the active ingredient alone or together with a carrier can be made up before use. The pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes. The said solutions or suspensions may comprise viscosity-increasing agents or solubilizers.
Suspensions in oil comprise as the oil component the vegetable, synthetic, or semi-synthetic oils customary for injection purposes. In respect of such, special mention may be made of liquid fatty acid esters that contain as the acid component a long-chained fatty acid having from 8 to 22 carbon atoms. The alcohol component of these fatty acid esters has a maximum of 6 carbon atoms and is a monovalent or polyvalent, for example a mono-, di- or trivalent, alcohol, especially glycol and glycerol.
Pharmaceutical compositions for oral administration can be obtained, for example, by combining the active ingredient with one or more solid carriers, if desired granulating a resulting mixture, and processing the mixture or granules, if desired or necessary, by the inclusion of additional excipients, to form tablets or tablet cores.
Suitable carriers are especially fillers, such as sugars, cellulose preparations, and/or calcium phosphates, and also binders, such as starches, and/or polyvinylpyrrolidone, and/or, if desired, disintegrators. Additional excipients are especially flow conditioners and lubricants.
Tablet cores can be provided with suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations.
Pharmaceutical compositions for oral administration also include hard capsules consisting of gelatin, and also soft, sealed capsules consisting of gelatin and a plasticizer. The hard capsules may contain the active ingredient in the form of granules, for example in admixture with fillers, binders, and/or glidants, and optionally stabilizers. In soft capsules, the active ingredient is preferably dissolved or suspended in suitable liquid excipients, to which stabilizers and detergents may also be added. Pharmaceutical compositions suitable for rectal administration are, for example, suppositories that consist of a combination of the active ingredient and a suppository base.
For parenteral administration, aqueous solutions of an active ingredient in water-soluble form, for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers, are especially suitable. The active ingredient, optionally together with excipients, can also be in the form of a lyophilizate and can be made into a solution before parenteral administration by the addition of suitable solvents.
Solutions such as are used, for example, for parenteral administration can also be employed as infusion solutions.
Preferred preservatives are, for example, antioxidants, such as ascorbic acid, or microbicides, such as sorbic acid or benzoic acid.
The invention relates likewise to a process or a method for the treatment of one of the pathological conditions mentioned hereinabove, especially a disease which responds to an inhibition of a tyrosine kinase, especially a corresponding neoplastic disease. The compounds of formula I or N-oxides thereof can be administered as such or especially in the form of pharmaceutical compositions, prophylactically or therapeutically, preferably in an amount effective against the said diseases, to a warm-blooded animal, for example a human, requiring such treatment. In the case of an individual having a bodyweight of about 70 kg the daily dose administered is from approximately 0.05 g to approximately 5 g, preferably from approximately 0.25 g to approximately 1.5 g, of a compound of the present invention.
The present invention relates especially also to the use of a compound of formula I or N- oxides thereof, or a pharmaceutically acceptable salt thereof, especially a compound of formula I which is said to be preferred, or a pharmaceutically acceptable salt thereof, as such or in the form of a pharmaceutical formulation with at least one pharmaceutically acceptable carrier for the therapeutic and also prophylactic management of one or more of the diseases mentioned hereinabove, preferably a disease which responds to an inhibition of a protein kinase, especially a neoplastic disease, more especially leukaemia which responds to an inhibition of the Abl tyrosine kinase. The preferred dose quantity, composition, and preparation of pharmaceutical formulations (medicines) which are to be used in each case are described above.
Starting materials
New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention. In the preferred embodiment, such starting materials are used and reaction conditions so selected as to enable the preferred compounds to be obtained.
The substituted aminobenzoic acid of formula II, for example, can be obtained by reaction of an ester of 3-amino-4-R -benzoic acid, e.g. 3-amino-4-methylbenzoic acid, with cyanamide and condensing the obtainable guanidine with 3-(dimethylamino)-1 -(3-pyridinyl)-2-propen-1 - one, and finally hyrolysing the ester function.
Starting materials of the formula III are known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art.
The following Examples serve to illustrate the invention without limiting the invention in its scope.
Abbreviations
DMSO dimethylsulfoxide
HPLC/MS-MS high-pressure liquid chromatography/ tandem mass spectrometry min minutes m.p. melting point
NMP N-methyl-pyrrolidone
NMR nuclear magnetic resonance
PEG polyethylen glycol
THF tetrahydrofuran Examples
Example 1 : Λ/-(2-Furanylmethyl)-4-methyl-3-r[4-(3-pyridinvπ-2-pyrimidinyl1aminolbenzamide A solution containing -50% of propylphosphonic anhydride in /V,Λ/-dimethylformamide (Fluka, Buchs, Switzerland; 674 μL, ~1 mmol) is added within 20 minutes to a stirred mixture of 4- methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzoic acid (214.4 mg, 0.7 mmol), furfurylamine (Aldrich, Buchs, Switzerland; 61.8 μL, 0.7 mmol) and triethylamine (776 μL, 5.6 mmol) in 2 mL Λ/,Λ/-dimethylformamide. After stirring for 24 hours at room temperature, the mixture is treated with a half-saturated aqueous solution of sodium hydrogen carbonate and extracted three times with ethyl acetate. The solvent is evaporated off under reduced pressure and the residue dried in vacuo. The crude product is crystallised from dichloromethane to give the title compound as a crystalline solid.
1H-NMR (400 MHz, DMSO-d6, δ): 2.28 (s, 3H); 4.43 (d, 2H); 6.23 (m, 1 H); 6.33-6.37 (m, 1H); 7.30 (d,1 H); 7.42 (d, 1 H); 7.49 (ddd, 1 H); 7.53 (m, 1 H); 7.59 (dd, 1 H); 8.11 (d, 1 H); 8.38 (m, 1H); 8.49 (d, 1 H); 8.66 (dd, 1 H); 8.87 (t, 1 H); 9.05 (s, 1 H); 9.22 (m, 1 H).
The starting material is prepared as follows:
Example 1 a: 3-r(Aminoiminomethyl)amino1-4-methyl-benzoic acid ethyl ester mononitrate Cyanamide (Fluka, Buchs, Switzerland; 77.4 g, 1.842 mol) is added to a solution of 3-amino- 4-methylbenzoic acid ethyl ester (J. Med. Chem. 16, 118-122, 1973; 150 g, 0.837 mol) in 850 mL of ethanol. Hydrochloric acid (Fluka, Buchs, Switzerland; 108 mL of 12M, 1.27 mol) is then added dropwise over 15 min and the reaction mixture is then stirred at 90°C (bath temperature) for 15 hours. The solvent is evaporated off under reduced pressure to give a residue which is treated with water (1000 mL) and stirred with cooling at 5-10°C. A solution of ammonium nitrate (Merck, Darmstadt, Germany; 134.8 g, 1.68 mol) in water (400 mL) is added dropwise over 30 min. followed by ice-water (1200 mL). After stirring for an additional 30 min. the product is filtered off, washed with ice-water (3 x 1000 mL) and air-dried. The residue is washed with diethyl ether (2 x 2000 m L) and dried in vacuo at 50° to give the title compound as a crystalline solid, m.p.195-197°C.
Example 1 b: 4-Methyl-3-rr4-(3-pyridinyl)-2-pyrimidinvπamino'|-benzoic acid ethyl ester
A stirred mixture of the intermediate Example 1a (164 g, 0.577 mol), 3-(dimethylamino)-1 -(3- pyridinyl)-2-propen-1-one (113.8 g, 0.646 mol) and powdered NaOH (99%; Merck, Darmstadt, Germany; 26.6 g, 0.658 mol) in ethanol (2200 mL) is heated under reflux for 68 h. The reaction solvent is evaporated off under reduced pressure and the residue partitioned between ethyl acetate and water. The organic layer is separated and the aqueous phase extracted twice with ethyl acetate. The combined organic extracts are washed with water and brine, dried (Na2SO4) and the solvent is evaporated off under reduced pressure to give a residue, which is crystallised from diethyl ether to give the title compound as a crystalline solid, m.p. 95-96°C.
Example 1 c: 4-Methyl-3-ff4-(3-pyridinyl)-2-pyrimidinyllamino1-benzoic acid Aqueous sodium hydroxide (500 mL of 2M) is added dropwise to a stirred suspension of the intermediate Example 1b (132.8 g, 0.397 mol) in ethanol (1200 m L) and water (1200 mL). The reaction mixture is stirred at 45°C for 2.5 h and then treated dropwise with aqueous HCI (1000 mL of 1 M) over 1.5 hours. After addition of water (1000 mL) the precipitate is filtered off, washed with water (4 x 500 mL) and dried at room temperature. Residual water present in the air-dried product is removed by azeotropic distillation with toluene under reduced pressure. The dried toluene suspension is diluted with diethyl ether and filtered. The solid residue is washed with diethyl ether and dried in vacuo at 80°C to give the title compound, m.p. 277-278°C.
Example 2: Λ/-r4-Methyl-3-r[4-(3-pyridinyl)-2-pyrimidinvnaminolbenzovn-4-[(4-methyl-1 - piperazinvDmethyllbenzeneamine
A solution containing -50% of propylphosphonic anhydride in Λ/,Λ/-dimethylformamide (Fluka, Buchs, Switzerland; 875 μL, -1.5 mmol) is added within 20 minutes to a stirred mixture of 4- methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzoic acid (306 mg, 1.0 mmol), 4-[(4-methyl- 1-piperazinyl)methyl]benzeneamine (Chem. Abstr. Reg. Number: 70261-82-4; 205 mg, 1.0 mmol) and triethylamine (830 μL, 6.0 mmol) in 8 mL /V,Λ/-dimethyIformamide. After stirring for 24 hours at room temperature, the mixture is treated with a saturated aqueous ammonium chloride and extracted three times with ethyl acetate. The solvent is evaporated off under reduced pressure and the residue dried in vacuo. The crude product is crystallised from ethanol-ethyl acetate to give the title compound as a crystalline solid, m.p. 153-155°C.
Example 3: 1 -r4-Methyl-3-fr4-(3-pyridinyl)-2-pyrimidinvnaminolbenzovπ-4-(2-pyridinyl)- piperazine A solution containing -50% of propylphosphonic anhydride in /,N-dimethyIformamide (Fluka, Buchs, Switzerland; 674 μL, -1 mmol) is added within 20 minutes to a stirred mixture of 4- methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzoic acid (214.4 mg, 0.7 mmol), 1-(2- pyridyl)piperazine (Aldrich, Buchs, Switzerland; 114.3 mg, 0.7 mmol) and triethylamine (776 μL, 5.6 mmol) in 2 mL Λ/,Λ/-dimethylformamide. After stirring for 24 hours at room temperature, the mixture is treated with a half -saturated aqueous solution of sodium hydrogen carbonate and extracted three times with ethyl acetate. The solvent is evaporated off under reduced pressure and the residue dried in vacuo. The crude product is purified by column chromatography on silica gel, eluent 5-10% methanol in dichloromethane, to give the title compound as a solid. 1 H-NMR (400 MHz, DMSO-d6, δ): 2.31 (s, 3H); 3.35-3.74 (m, 8H); 6.65 (ddd, 1H); 6.79 (d, 1H); 7.13 (dd, 1H); 7.32 (d, 1H); 7.44 (d, 1H); 7.49-7.56 (m, 2H); 7.69 (m, 1H); 8.11 (m, 1H); 8.40 (m, 1H); 8.52 (d, 1H); 8.66 (dd, 1 H); 9.06 (s, 1H); 9.24 (m, 1H).
The following compounds are prepared analogously by utilising the appropriate amine (supplier in parenthesis):
Example 4: 4-Methvl- V-[2-(2-pvridinvl)ethvll-3-fr4-(3-pvridinvπ-2-pvrimidinvnamino]- benzamide utilising 2-(2-aminoethyi)pyridine (Fluka, Buchs, Switzerland). 1H-NMR (400 MHz, DMSO-d6, δ): 2.27 (s, 3H); 2.97 (t, 2H); 3.58 (m, 2H); 7.18 (ddd, 1 H); 7.25 (m, 1 H); 7.29 (d,1 H); 7.42 (d, 1 H); 7.47-7.56 (m, 2H); 7.65 (m, 1 H); 8.06 (d, 1 H); 8.39 (m, 1 H); 8.44-8.51 (m, 3H); 8.66 (dd, 1 H); 9.04 (s, 1 H); 9.22 (m, 1 H).
Example 5: 4-Methyl-/V-H -(phenvlmethvl)-4-piperidinvl1-3-rf4-(3-pvridinvl)-2-pvrimidinvl]- amino]benzamide utilising 4-amino-1 -benzylpiperidine (Aldrich, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-de, δ): 1.47-1.63 (m, 2H); 1.69-1.80 (m, 2H); 1.92-2.05 (m, 2H); 2.27 (s, 3H); 2.73-2.83 (m, 2H); 3.43 (s, 2H); 3.68-3.83 (m, 1 H); 7.18-7.33 (m ,6H); 7.42 (d, 1 H); 7.49 (ddd, 1 H); 7.55 (dd, 1 H); 8.10 (m, 1 H); 8.14 (d, 1 H); 8.37 (m, 1H); 8.49 (d, 1 H); 8.65 (dd, 1 H); 9.04 (s, 1 H); 9.21 (m, 1 H).
Example 6: 4-Methvl-Λ/-(4-pvridinvlmethvl)-3-[[4-(3-pyridinvl)-2-pvrimidinvl]amino]benzamide utilising 4-(aminomethyl)pyridine (Aldrich, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 2.30 (s, 3H); 4.46 (d, 2H); 7.26 (m, 2H); 7.33 (d, 1H); 7.43 (d, 1H); 7.47 (ddd, 1H);7.62 (dd, 1H); 8.16 (d, 1H); 8.38 (m, 1H); 8.45 (m, 2H); 8.50 (d, 1H); 8.66 (dd, 1H); 9.03 (t, 1H); 9.08 (s, 1H); 9.23 (m, 1H). Example 7: 4-Methyl-Λ-[2-(1 -methyl-1 H-pyrrol-2-yl)ethyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]- aminojbenzamide utilising 2-(2-aminoethyl)-1 -methylpyrrol [Chem. Abstr. Reg. Number: 83732-75-6]. 1 H-NMR (400 MHz, DMSO-d6, δ): 2.28 (s, 3H); 2.75 (t, 2H); 3.42 (m, 2H); 3.51 (s, 3H); 5.76-5.85 (m, 2H); 6.57 (m,1H); 7.30 (d,1H); 7.43 (d, 1H); 7.46-7.58 (m, 2H); 8.10 (br. 1H); 8.40 (m, 1 H); 8.48-8.55 (m, 2H); 8.64-8.69 (m, 1H); 9.05 (s, 1H); 9.23 (m, 1 H).
Example 8: /-r(4-Methoxvphenvl)methvn-4-methyl-3-rr4-(3-pvridinvl)-2-pvrimidinvl1aminol- benzamide utilising 4-methoxybenzylamine (Fluka, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-de, δ): 2.28 (s, 3H); 3.69 (s, 3H); 4.37 (d, 2H); 6.80-6.87 (m, 2H); 7.17-7.23 (m, 2H); 7.31 (d,1 H); 7.42 (d, 1H); 7.47 (ddd, 1H); 7.59 (dd, 1 H); 8.11 (d, 1H); 8.38 (m, 1H); 8.49 (d, 1H); 8.66 (dd, 1H); 8.87 (t, 1H); 9.05 (s, 1H); 9.23 (m, 1H).
Example 9: 4-Methvl-Λ/-(2-methvlpropvl)-3-[f4-(3-pvridinvl)-2-pyrimidinvnaminolbenzamide utilising isobutylamine (Fluka, Buchs, Switzerland). 1 H-NMR (400 MHz, DMSO-d6, δ): 0.85 (d, 6H); 1.81 (m, 1 H); 2.27 (s, 3H); 3.04 (m, 2H); 7.29 (d,1H); 7.42 (d, 1 H); 7.48 (dd, 1 H); 7.55 (dd, 1H); 8.07 (d, 1 H); 8.31-8.41 (m, 2H); 8.49 (d, 1 H); 8.65 (dd, 1H); 9.05 (s, 1 H); 9.22 (m, 1 H).
BarnpJe_ P_ 4-Methyl-Λ/-(2-morpholinoethyl)-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- benzamide utilising 4-(2-aminoethyl)morpholine (Fluka, Buchs, Switzerland).1H-NMR (400 MHz, DMSO-de, δ): 2.28 (s, 3H); 2.33-2.46 (m, 6H); 3.30-3.40 (m, 2H); 3.53 (m, 4H); 7.30 (d,1H); 7.42 (d, 1 H); 7.46-7.57 (m, 2H); 8.06 (d, 1 H); 8.30 (m, 1 H); 8.38 (m, 1H); 8.49 (d, 1H); 8.66 (dd, 1 H); 9.05 (s, 1 H); 9.22 (m, 1H).
Example 11 : 4-Methvl-3-[r4-(3-pvridinvl)-2-pvrimidinyllamino1-N-[(tetrahvdro-2-furanvπ- methyl]benzamide utilising tetrahydrofurfurylamine (Fluka, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 1.49-1.63 (m, 1H); 1.70-1.93 (m, 3H); 2.27 (s, 3H); 3.27 (m, 2H); 3.58 (m, 1H); 3.72 (m, 1H); 3.94 (m, 1 H); 7.29 (d,1H); 7.42 (d, 1H); 7.49 (ddd, 1H); 7.56 (dd, 1H); 8.08 (d, 1H); 8.35-8.45 (m, 2H); 8.49 (d, 1H); 8.66 (dd, 1H); 9.04 (s, 1H); 9.21 (m, 1H).
<arnpJeJ2ι Λ/-[2-(2,4-Dihydroxy-5-pyrimidinyl)ethyl]-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide utilising 5-(2-aminoethyl)-2,4(1 H,3H)-pyrimidinedione [Chem. Abstr. Reg. Number: 221170-25-8].1 H-NMR (400 MHz, DMSO-d6, δ): 2.27 (s, 3H); 2.40 (t, 2H); 3.34 (m, 2H); 7.15 (m,1H); 7.29 (d,1H); 7.42 (d, 1H); 7.47-7.55 (m, 2H); 8.07 (d, 1H); 8.35-8.42 (m, 2H); 8.49 (d, 1 H); 8.66 (dd, 1H); 9.04 (s, 1H); 9.22 (m, 1H); 10.59 (s, 1H); 11.01 (s, 1H).
&campJe_13ι Λ/-CycIohexyl-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide utilising cyclohexylamine (Fluka, Buchs, Switzerland). H-NMR (400 MHz, DMSO-d6, δ): 1.00- 1.16 (m, 1H); 1.18-1.36 (m, 4H); 1.52-1.85 (m, 5H); 2.27 (s, 3H); 3.66-3.82 (m, 1 H); 7.28 (d, 1 H); 7.41 (d, 1 H); 7.48 (m, 1 H); 7.55 (dd, 1H); 8.06-8.12 (m, 2H); 8.37 (m, 1 H); 8.49 (d, 1 H); 8.66 (dd, 1H); 9.04 (s, 1 H); 9.21 (m, 1 H).
Example 14: Λ/-[(3S)-Hexahydro-2-oxo-1 H-azepin-3-yl1-4-methvl-3-[r4-(3-pyridinvl)-2- pyrimidinyl]amino]benzamide utilising L(-)-alpha-amino-epsilon-caprolactam [Chem. Abstr. Reg. Number: 21568-87-6].1 H-NMR (400 MHz, DMSO-d6, δ): 1.11-1.31 (m, 1H); 1.37-1.82 (m, 3H); 1.83-1.96 (m, 2H); 2.28 (s, 3H); 3.00-3.13 (m, 1H); 3.15-3.30 (m, 1H); 4.58 (m, 1H); 7.32 (d,1H); 7.43 (d, 1 H); 7.51 (ddd, 1H); 7.55 (dd, 1 H); 7.84 (m, 1H); 8.08 (d, 1H); 8.13 (d, 1 H); 8.40 (m, 1 H); 8.50 (d, 1H); 8.66 (dd, 1H); 9.06 (s, 1H); 9.22 (m, 1H).
Example 15: Λ-f2-(3.4-Dimethoxvphenvl)ethvn-4-methvl-3-rr4-(3-pvridinvl)-2-pyrimidinvn- amino]benzamide utilising 2-(3,4-dimethoxyphenyl)ethylamine (Fluka, Buchs, Switzerland). 1 H-NMR (400 MHz, DMSO-d6, δ): 2.27 (s, 3H); 2.75 (t, 2H); 3.43 (m, 2H); 3.67 (s, 6H); 6.70 (dd, 1 H); 6.77-6.83 (m, 2H); 7.30 (d,1 H); 7.42 (d, 1 H); 7.46-7.57 (m, 2H); 8.07 (d, 1 H); 8.36- 8.46 (m, 2H); 8.49 (d, 1 H); 8.66 (dd, 1 H); 9.05 (s, 1 H); 9.22 (m, 1 H).
Example 16: 2-f [4-Methvl-3-rr4-(3-pvridinvπ-2-pvrimidinvllamino1benzoyllaminol-4-thiazole- acetic acid ethyl ester utilising ethyl 2-amino-4-thiazo!eacetate (Aldrich, Buchs, Switzerland). 1 H-NMR (400 MHz, DMSO-d6, δ): 1.16 (t, 3H); 2.32 (s, 3H); 3.70 (s, 2H); 4.06 (q, 2H); 7.01 (s, 1 H); 7.36 (d,1H); 7.42-7.54 (m, 2H); 7.82 (d, 1H); 8.34-8.47 (m, 2H); 8.52 (d, 1 H); 8.66 (m, 1H); 9.08 (s, 1 H); 9.24 (m, 1H); 12.57 (br., 1H).
Example 17: Λ/-[3-(1 H-lmidazol-1 -yl)propyl]-4-methyl-3-[[4-(3-pyridinyl)-2pyrimidinyl]amino]- benzamide utilising 1 -(3-aminopropyl)imidazole (Aldrich, Buchs, Switzerland).1H-NMR (400 MHz, DMSO-de, δ): 1.96 (qui, 2H); 2.30 (s, 3H); 3.24 (m, 2H); 4.01 (t, 2H); 6.91 (s,1 H); 7.22 (m, 1 H); 7.34 (d,1 H); 7.45 (d, 1 H); 7.51 (ddd, 1H); 7.59 (dd, 1 H); 7.70 (s, 1 H); 8.14 (d, 1 H); 8.42 (m, 1 H); 8.47 (t, 1 H); 8.52 (d, 1 H); 8.68 (dd, 1H); 9.10 (s, 1H); 9.25 (m, 1 H). & ampJe_18. Λ/-(CycIopropylmethyl)-4-methyl-3-[[4-(3-pyridinyI)-2-pyrimidinyl]amino]- benzamide utilising cyclopropanemethylamine (Fluka, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-de, δ): 0.17-0.22 (m, 2H); 0.36-0.42 (m, 2H); 0.96-1.06 (m, 1H); 2.28 (s, 3H); 3.11 (m, 2H); 7.31 (d,1 H); 7.43 (d, 1 H); 7.50 (ddd, 1 H); 7.58 (dd, 1 H); 8.10 (d, 1 H); 8.40 (m, 1H); 8.47 (t, 1 H); 8.50 (d, 1 H); 8.67 (dd, 1 H); 9.07 (s, 1 H); 9.23 (m, 1 H).
Example 19: Λ/-(2-methoxvethvl)-4-methvl-3-[f4-(3-pvridinvl)-2-pyrimidinvπaminolbenzamide utilising 2-methoxyethylamine (Fluka, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 2.28 (s, 3H); 3.23 (s, 3H); 3.36-3.46 (m, 4H); 7.31 (d,1 H); 7.43 (d, 1 H); 7.51 (ddd, 1 H); 7.57 (dd, 1 H); 8.10 (d, 1H); 8.38-8.47 (m, 2H); 8.50 (d, 1 H); 8.68 (dd, 1 H); 9.07 (s, 1 H); 9.23 (m, 1H).
Example 20: 4-Methyl-Λ/-f3-(2-oxo-1 -pvrrolidinvl)propvn-3-[[4-(3-pvridinvl)-2-pyrimidinvn- amino]benzamide utilising 1-(3-aminopropyl)-2-pyrrolidinone (Aldrich, Buchs, Switzerland). 1H-NMR (400 MHz, DMSO-d6, δ): 1.67 (m, 2H); 1.89 (m, 2H); 2.18 (t, 2H); 2.28 (s, 3H); 3.19 (m, 4H); 3.32 (m, 2H); 7.30 (d, 1H); 7.42 (d, 1 H); 7.49 (ddd, 1H); 7.54 (dd, 1H); 8.09 (d, 1H); 8.31-8.42 (m, 2H); 8.49 (d, 1H); 8.66 (dd, 1H); 9.04 (s, 1H); 9.22 (m, 1H).
Example 21 : Λ/.4-Dimethvl-N-(phenvlmethvl)-3-rr4-(3-pyridinvl)-2-pvrimidinynamino1- benzamide utilising N-benzylmethylamine (Fluka, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 2.28 (s, 3H); 2.86 (s, 3H); 4.51-4.68 (m, 2H); 7.08-7.35 (m,7H); 7.43 (d, 1H); 7.48 (m, 1H); 7.71 (s, 1H); 8.35-8.54 (m, 2H); 8.67 (m, 1H); 8.97-9.09 (m, 1H); 9.24 (m, 1H).
Example 22: Λ/-f4-(Acetvlamino)phenvll-4-methvl-3- f4-(3-pvridinvl)-2-pvrimidinyl1amino]- benzamide utilising 4-aminoacetanilide (Fluka, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 2.01 (s, 3H); 2.32 (s, 3H); 7.38 (d,1H); 7.45 (d, 1H); 7.47-7.54 (m, 3H); 7.63- 7.71 (m, 3H); 8.22 (m, 1H); 8.43 (m, 1H); 8.52 (d, 1H); 8.67 (dd, 1H); 9.13 (s, 1H); 9.25 (m, 1 H); 9.90 (s, 1 H); 10.11 (s, 1 H).
Example 23: Λ/-(4-Methoxv-2-methvlphenvπ-4-methvl-3-[[4-(3-pvridinvl)-2-pvrimidinvnamino]- benzamide utilising 4-methoxy-2-methylaniline (Aldrich, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-de, δ): 2.16 (s, 3H); 2.32 (s, 3H); 3.73 (s, 3H); 6.75 (dd, 1H); 6.82 (m, 1H); 7.16 (d, 1H); 7.37 (d,1 H); 7.45 (d, 1H); 7.49 (ddd, 1 H); 7.69 (dd, 1H); 8.25 (d, 1H); 8.41 (m, 1 H);
8.52 (d, 1 H); 8.67 (dd, 1H); 9.12 (s, 1H); 9.25 (m, 1 H); 9.69 (s, 1 H).
Example 24: 4-Methvl-Λ/-[4-(methvlsulfonvl)benzvn-3-f[4-(3-pvridinvl)-2-pvrimidinvHamino]- benzamide utilising 4-methylsulfonylbenzylamine hydrochloride (Acros, Morris Plains, NJ). 1 H-NMR (400 MHz, DMSO-d6, δ): 2.30 (s, 3H); 3.16 (s, 3H); 4.54 (d, 2H); 7.34 (d,1H); 7.44 (d, 1H); 7.49 (ddd, 1H); 7.55 (m, 2H); 7.63 (dd, 1H); 7.86 (m, 2H); 8.16 (d, 1H); 8.40 (m, 1H); 8.51 (d, 1H); 8.67 (dd, 1H); 9.10 (m, 2H); 9.24 (m, 1H).
Example 25: Λ/-fr4-(Dimethvlamino)phenvnmethvn-4-methvl-3-fr4-(3-pvridinvl)-2-pyrimidinvn- amino]benzamide utilising 4-(dimethylamino)benzylamine dihydrochloride (Aldrich, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 2.28 (s, 3H); 2.82 (s, 6H); 4.32 (d, 2H); 6.64 (m, 2H); 7.11 (m, 2H); 7.31 (d, 1 H); 7.43 (d, 1 H); 7.48 (ddd, 1 H); 7.59 (dd, 1 H); 8.12 (d, 1 H); 8.39 (m, 1H); 8.50 (d, 1H); 8.68 (dd, 1H); 8.81 (t, 1H); 9.07 (s, 1H); 9.24 (m, 1 H).
Example 26: A/-(2-Amino-2-oxoethvl)-4-methvl-3-[f4-(3-pvridinvl)-2-pyrimidinvnamino1- benzamide utilising glycinamide hydrochloride (Fluka, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 2.29 (s, 3H); 3.78 (d, 2H); 7.02 (s, 1 H); 7.30-7.36 (m, 2H); 7.44 (d, 1H);
7.53 (ddd, 1H); 7.61 (dd, 1 H); 8.11 (m, 1 H); 8.41 (m, 1 H); 8.50 (d, 1 H); 8.57 (t, 1 H); 8.67 (dd, 1 H); 9.08 (s, 1 H); 9.24 (m, 1 H).
Example 27: /V-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]glycine methyl ester utilising glycine methylester hydrochloride (Fluka, Buchs, Switzerland).1H-NMR (400 MHz, DMSO-de, δ): 2.29 (s, 3H); 3.63 (s, 3H); 3.98 (d, 2H); 7.34 (d,1H); 7.44 (d, 1H); 7.52 (ddd, 1H); 7.59 (dd, 1H); 8.11 (d, 1H); 8.41 (m, 1H); 8.50 (d, 1H); 8.67 (dd, 1 H); 8.87 (t, 1H); 9.09 (s, 1 H); 9.23 (m, 1 H).
Example 28: Λ/-[4-Methvl-3-rf4-(3-pvridinvπ-2-pvrimidinvl1amino]benzovl1beta-alanine methyl ester utilising beta-alanine methylester hydrochloride (Fluka, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-de, δ): 2.27 (s, 3H); 2.57 (t, 2H); 3.46 (m, 2H); 3.57 (s, 3H); 7.31 (d, 1 H); 7.43 (d, 1H); 7.50-7.55 (m, 2H); 8.07 (d, 1 H); 8.40 (m, 1H); 8.47 (t, 1H); 8.50 (d, 1H); 8.67 (dd, 1 H); 9.07 (s, 1 H); 9.23 (m, 1 H). Example^Λ/-[[4-(AminosulfonyI)phenyl]methyl]-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]- aminojbenzamide utilising p-(aminomethyl)benzenesulfonamide hydrochloride (Sigma, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 2.29 (s, 3H); 4.51 (d, 2H); 7.30 (s, 2H); 7.34 (d, 1H); 7.43-7.50 (m, 4H); 7.62 (dd, 1H); 7.75 (m, 2H); 8.16 (d, 1H); 8.40 (m, 1H); 8.51 (d, 1H); 8.68 (dd, 1H); 9.06 (t, 1H); 9.09 (s, 1H); 9.24 (m, 1H).
Example 30: A/-(3-Hvdroxvpropvl)-4-methvl-3-[f4-(3-pvridinvl)-2-pyrimidinvnamino1benzamide utilising 3-amino-1-propanol (Aldrich, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 1.65 (qui, 2H); 2.28 (s, 3H); 3.29 (m, 2H); 3.42 (m, 2H); 4.50 (m, 1H); 7.30 (d, 1H); 7.43 (d, 1H); 7.51 (ddd, 1H); 7.56 (dd, 1H); 8.09 (d, 1H); 8.36-8.43 (m, 2H); 8.50 (d, 1H); 8.67 (dd, 1H);9.07(s, 1H);9.23(m, 1H).
Example 31 : Λ.Λ/-Diethvl-4-methvl-3-fr4-(3-pyridinvl)-2-pvrimidinynaminolbenzamide utilising diethylamine (Fluka, Buchs, Switzerland).1H-NMR (400 MHz, DMSO-d6> δ): 1.04 (m, 6H); 2.28 (s, 3H); 3.31 (m, 4H); 7.02 (dd, 1H); 7.27 (d, 1H); 7.44 (d, 1H); 7.51 (ddd, 1H); 7.61 (m, 1H); 8.39 (m, 1H); 8.51 (d, 1H); 8.68 (dd, 1H); 9.01 (s, 1H); 9.23 (m, 1H).
c Dβ!§_32l/V-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-(L)-phenylalanine 1 ,1-dimethylethyl ester utilising L-phenylalanine t-butylester hydrochloride (Novabiochem (Juro), Lucerne, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 1.32 (s, 9H); 2.28 (s, 3H); 3.07 (m, 2H); 4.53 (m, 1H); 7.13-7.29 (m, 5H); 7.32 (d, 1H); 7.44 (d, 1H); 7.50 (ddd, 1H); 7.55 (dd, 1H); 8.05 (m, 1H); 8.39 (m, 1H); 8.49 (d, 1H); 8.63 (d, 1H); 8.67 (dd, 1H); 9.08 (s, 1H); 9.23 (m,1H).
Example 33: Λ/-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyI]-(D)-alanine 1 ,1- dimethylethyl ester utilising D-alanine t-butylester hydrochloride (Novabiochem (Juro), Lucerne, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 1.34 (d, 3H); 1.38 (s, 9H); 2.28 (s, 3H); 4.32 (m, 1H); 7.33 (d, 1H); 7.43 (d, 1H); 7.51 (ddd, 1H); 7.61 (dd, 1H); 8.14 (m, 1H); 8.40 (m, 1H); 8.50 (m, 1H); 8.58 (d, 1H); 8.67 (dd, 1H); 9.08 (s, 1H); 9.23 (m, 1H).
Example 34: ΛH1 -[4-Methvl-3-[r4-(3-pvridinvl)-2-pvrimidinvlaminolbenzovπ-4-piperidinvl]- benzamide utilising N-4-piperidinyl-benzamide (Maybridge Chemical Co. Ltd).1 H-NMR (400 MHz, DMSO-de, δ): 1.49 (m, 2H); 1.68-1.94 (m, 2H); 2.30 (s, 3H); 2.92 (m, 1H); 3.16 (m, 1H); 3.79 (m, 1H); 4.05 (m, 1H); 4.42 (m, 1H); 7.08 (dd, 1H); 7.31 (d, 1H); 7.41-7.54 (m, 5H); 7.63 (m, 1H); 7.79-7.84 (m, 2H); 8.28 (d, 1H); 8.40 (m, 1H); 8.51 (d, 1H); 8.66 (dd, 1H); 9.06 (s, 1H);9.24(m, 1H).
B<amr!e_35ι4-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-morpholine utilising morpholine (Fluka, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 2.29 (s, 3H); 3.47 (m, 8H); 7.10 (dd, 1H); 7.30 (d, 1H); 7.44 (m, 1H); 7.52 (ddd, 1H); 7.65 (m, 1H); 8.40 (m, 1H); 8.51 (d, 1H); 8.69 (dd, 1H); 9.05 (s, 1H); 9.23 (m, 1H).
Example 36: 1 -(4-Methoxvphenvl)-4-f4-methvl-3-rf4-(3-pvridinvl)-2-pvrimidinyllaminol- benzoyl]piperazine utilising 1 -(4-methoxyphenyl)-piperazine (Emka Chemie, Neufahrn, Germany).1 H-NMR (400 MHz, DMSO-d6, δ): 2.30 (s, 3H); 2.87-3.08 (m, 4H); 3.50-3.75 (m, 4H); 3.67 (s, 3H); 6.78-6.88 (m, 4H); 7.12 (dd, 1H); 7.31 (d, 1H); 7.44 (m, 1H); 7.51 (ddd, 1H); 7.67 (m, 1H); 8.38 (m, 1H); 8.52 (m, 1H); 8.67 (dd, 1H); 9.06 (s, 1H); 9.23 (m, 1H).
cBmJe_37ι1-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-4-(4-pyridinyl)- piperazine utilising 1 -(4-pyridyl)-piperazine (Emka Chemie, Neufahrn, Germany).1 H-NMR (400 MHz, DMSO-de, δ): 2.31 (s, 3H); 3.30 (m, 4H); 3.59 (m, 4H); 6.77 (m, 2H); 7.14 (dd, 1H); 7.32 (d, 1H); 7.45 (d, 1H); 7.52 (ddd, 1H); 7.70 (m, 1H); 8.16 (m, 2H); 8.41 (m, 1H); 8.53 (d, 1H); 8.67 (dd, 1H); 9.07 (s, 1H); 9.24 (m, 1H).
Example 38: 1-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-4-(pyrazinyl)- piperazine utilising 1 -(2-pyrazinyl)-piperazine (Emka Chemie, Neufahrn, Germany).1H-NMR (400 MHz, DMSO-d6, δ):2.31 (s, 3H); 3.57 (m, 8H); 7.14 (dd, 1H); 7.32 (d, 1H); 7.45 (d, 1H); 7.51 (ddd, 1H); 7.72 (m, 1H); 7.85 (d, 1H); 8.08 (d, 1H); 8.29 (d, 1H); 8.40 (m, 1H); 8.53 (d, 1H); 8.65 (dd, 1H); 9.06 (s, 1H); 9.24 (m, 1H).
cBmpJe39ι1-[4-MethyI-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-4-(phenylmethyl)- piperazine utilising 1 -benzyl-piperazine (Aldrich, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-de, δ): 2.21-2.42 (m, 4H); 2.28 (s, 3H); 3.34-3.63 (m, 6H); 7.07 (dd, 1H); 7.21-7.34 (m, 6H); 7.43-7.50 (m, 2H); 7.63 (m, 1H); 8.38 (m, 1H); 8.50 (d, 1H); 8.65 (dd, 1H); 9.03 (s, 1H); 9.22 (m,1H).
Example 40: 1 -Cvclopentvl-4-4-methvl-3-[|"4-(3-pvridinyl)-2-pvrimidinvl]amino]benzovl]- piperazine utilising 1 -cyclopentyl-piperazine (Emka Chemie, Neufahrn, Germany).1 H-NMR (400 MHz, DMSO-de, δ): 1.20-1.31 (m, 2H); 1.39-1.62 (m, 4H); 1.65-1.75 (m, 2H); 2.18-2.47 (m, 8H); 3.27-3.62 (m, 4H); 7.08 (dd, 1 H); 7.29 (d, 1 H); 7.44 (d, 1 H); 7.51 (ddd, 1 H); 7.62 (m, 1H); 8.38 (m, 1 H); 8.51 (d, 1 H); 8.68 (dd, 1 H); 9.04 (s, 1 H); 9.22 (m, 1 H).
gxarnpJe_4L: 4-{{4-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-1-piperazinyl}- acetyl}morpholine utilising 4-[2-(piperazin-1-yl)-acetyl]-morpholine (Emka Chemie, Neufahrn, Germany).1 H-NMR (400 MHz, DMSO-d6, δ): 2.29 (s, 3H); 2.31 -2.49 (m, 4H); 3.16 (s, 2H); 3.37-3.60 (m, 12H); 7.07 (dd, 1 H); 7.29 (d,1 H); 7.45 (d, 1H); 7.52 (ddd, 1 H); 7.65 (m, 1 H); 8.39 (m, 1 H); 8.51 (d, 1 H); 8.68 (dd, 1 H); 9.04 (s, 1 H); 9.23 (m, 1 H).
Example 42: 1 -[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-4-[2-oxo-2-(1 - pyrrolidinyl)ethyl]piperazine utilising 1-[2-(piperazin-1-yl)-acetyl-pyrrolidine (Emka Chemie, Neufahrn, Germany). H-NMR (400 MHz, DMSO-d6, δ): 1.73 (m, 2H); 1.83 (m, 2H); 2.29 (s, 3H); 2.43 (m, 4H); 3.09 (s, 2H); 3.25 (m, 2H); 3.34-3.63 (m, 6H); 7.07 (dd, 1 H); 7.29 (d, 1 H); 7.45 (d, 1 H); 7.52 (ddd, 1H); 7.64 (m, 1 H); 8.39 (m, 1H); 8.51 (d, 1H); 8.68 (dd, 1H); 9.04 (s, 1 H); 9.22 (m, 1 H).
Example 43: 4-[4-Methvl-3-r[4-(3-pvridinvl)-2-pvrimidinvllaminolbenzoyl -1 -piperazine- carboxylic acid ethyl ester utilising ethyl 1 -piperazinecarboxylate (Aldrich, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 1.16 (t, 3H); 2.29 (s, 3H); 3.19-3.63 (m, 8H); 4.02 (q, 2H); 7.10 (dd, 1 H); 7.30 (d, 1 H); 7.45 (d, 1 H); 7.52 (ddd, 1H); 7.66 (m, 1H); 8.40 (m, 1 H); 8.51 (d, 1 H); 8.68 (dd, 1 H); 9.06 (s, 1 H); 9.23 (m, 1 H).
Example 44: 2-r4-Methvl-3-[f4-(3-pvridinvl)-2-pvrimidinvllaminolbenzovl]-1 ,2.34-tetrahvdro- isoquinoline utilising 1 ,2,3,4-tetrahydroisoquinoline (Fluka, Buchs, Switzerland).1H-NMR (400 MHz, DMSO-de, δ): 2.31 (s, 3H); 2.79 (m, 2H); 3.57-3.90 (m, 2H); 4.58-4.79 (m, 2H); 7.08- 7.23 (m, 5H); 7.32 (d, 1 H); 7.42-7.50 (m, 2H); 7.70 (m, 1 H); 8.39 (m, 1 H); 8.51 (d, 1 H); 8.67 (dd, 1 H); 9.05 (s, 1 H); 9.24 (m, 1 H).
Example 45: Λ/.Λ/-bis(2-Methoxvethvl)-4-methvl-3-rr4-(3-pvridinvl)-2-pvrimidinvllaminol- benzamide utilising bis(2-methoxyethyl)amine (Aldrich, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 2.28 (s, 3H); 3.09 (br.s, 3H); 3.23 (br.s, 3H); 3.47 (m, 8H); 7.04 (dd, 1 H); 7.27 (d, 1 H); 7.44 (d, 1 H); 7.51 (ddd, 1 H); 7.62 (m, 1 H); 8.39 (m, 1 H); 8.51 (d, 1 H); 8.68 (dd, 1 H); 9.01 (s, 1 H); 9.23 (m, 1 H). Example 46: 1 '-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-1 ,4'-bipiperidine utilising 4-piperidinopiperidine (Aldrich, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 1.21 -1.50 (m, 8H); 1.51 -1.83 (m, 2H); 2.29 (s, 3H); 2.39 (m, 4H); 2.68 (m, 1 H); 2.95 (m, 1H); 3.71 (m, 1H); 4.42 (m, 1H); 7.07 (dd, 1H); 7.28 (d, 1H); 7.45 (d, 1H); 7.52 (ddd, 1H); 7.63 (m, 1 H); 8.40 (m, 1 H); 8.51 (d, 1 H); 8.67 (dd, 1 H); 9.03 (s, 1 H); 9.23 (m, 1 H).
Example 47: Λ/-[4-Methvl-3-r[4-(3-pvridinvl)-2-pvrimidinvl1amino1benzovn-N-(phenylmethvl)- glycine ethyl ester utilising N-benzylglycine ethyl ester (Fluka, Buchs, Switzerland).1 H-NMR (300 MHz, DMSO-de, δ): 0.97-1.20 (m, 3H); 2.27 (s, 3H); 3.90-4.12 (m, 4H); 4.58-4.68 (m, 2H); 7.07 (m, 1H); 7.15-7.34 (m, 6H); 7.38-7.53 (m, 2H); 7.65-7.74 (m, 1H); 8.35-8.51 (m, 2H); 8.66 (dd, 1 H); 8.96-9.04 (m, 1 H); 9.22 (m, 1H).
Example 48: Λ/-(3-Chlorophenvl)-4-methvl-3-[[4-(3-pyridinvl)-2-pyrimidinvl1amino1benzamide utilising 3-chlor-aniline (Fluka, Buchs, Switzerland).1H-NMR (400 MHz, DMSO-d6, δ): 2.33 (s, 3H); 7.14 (m, 1 H); 7.36 (m, 1 H); 7.41 (d, 1H); 7.46 (d, 1 H); 7.49 (ddd, 1 H); 7.68-7.73 (m, 2H); 7.95 (m, 1H); 8.25 (m, 1H); 8.43 (m, 1H); 8.53 (d, 1H); 8.66 (dd, 1H); 9.15 (s, 1H); 9.26 (m, 1H); 10.33 (s, 1H).
Example 49: Λ/-(2.2-Diphenvlethvl)-4-methvl-3-ff4-(3-pvridinvl)-2-pyrimidinvl1aminol- benzamide utilising 2,2-diphenylethylamine (Aldrich, Buchs, Switzerland).1H-NMR (400 MHz, DMSO-de, δ): 2.24 (s, 3H); 3.87 (m, 2H); 4.41 (m, 1H); 7.12-7.17 (m, 2H); 7.23-7.31 (m, 9H); 7.41-7.44 (m, 2H); 7.51 (ddd, 1H); 7.97 (m, 1H); 8.37-8.44 (m, 2H); 8.48 (d, 1 H); 8.68 (dd, 1 H); 9.05 (s, 1H); 9.23 (m, 1H).
Example 50: Λ/-(2,3-Dihydro-1 H-inden-1 -yl)-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- benzamide utilising 1 -Aminoindane (Fluka, Buchs, Switzerland).1H-NMR (400 MHz, DMSO- de, δ): 1.90-2.01 (m, 1 H); 2.29 (s, 3H); 2.43 (m, 1H); 2.77-2.86 (m, 1 H); 2.91-2.98 (m, 1 H); 5,56 (m, 1H); 7.08-7.25 (m, 4H); 7.31 (d, 1H); 7.43 (d, 1 H); 7.50 (ddd, 1H); 7.64 (dd, 1H); 8.20 (m, 1H); 8.40 (m, 1H); 8.50 (d, 1 H); 8.68-8.72 (m, 2H); 9.08 (s, 1H); 9.24 (m, 1H).
Example 51 : Λ/-(Diphenylmethyl)-4-methvl-3- |'4-(3-pvridinvl)-2-pvrimidinvl'|amino1benzamide utilising alpha-aminodiphenylmethane (Fluka, Buchs, Switzerland) 1 H-NMR (400 MHz, DMSO-d6) δ): 2.29 (s, 3H); 6.41 (d, 1 H); 7.20-7.36 (m, 11 H); 7.43 (d, 1 H); 7.46 (ddd, 1 H); 7.67 (dd, 1H); 8.18 (m, 1H); 8.38 (m, 1H); 8.50 (d, 1H); 8.68 (dd, 1H); 9.10 (s, 1H); 9.20 (d, 1H);9.24(m, 1H).
Example 52: 4-Methvl-Λ/-f2-(1 -piperidinvl)ethvll-3-fr4-(3-pvridinvl)-2-pvrimidinvllamino1- benzamide utilising 1 -(2-aminoethyl)piperidine (Aldrich, Buchs, Switzerland).1H-NMR (400 MHz, DMSO-d6, δ): 1.30-1.38 (m, 2H); 1.41-1.48 (m, 4H); 2.28 (s, 3H); 2.31-2.41 (m, 6H); 3.33 (m, 2H); 7.31 (d, 1H); 7.44 (d, 1H); 7.51 (ddd, 1H); 7.55 (dd, 1H); 8.08 (m, 1H); 8.28 (t, 1H); 8.40 (m, 1H); 8.51 (d, 1H); 8.67 (dd, 1H); 9.07 (s, 1H); 9.24 (m, 1H).
&<anτpJe_53ι4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-(5,6,7,8-tetrahydro-1- naphthalenyl)benzamide utilising 5,6,7,8-tetrahydro-1-naphthylamine (Aldrich, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 1.63-1.71 (m, 4H); 2.32 (s, 3H); 2.60 (m, 2H); 2.74 (m, 2H); 6.96 dd, 1H); 7.07-7.14 (m, 2H); 7.37 (d, 1H); 7.45 (d, 1H); 7.49 (ddd, 1H); 7.69 (dd, 1H); 8.25 (m, 1H); 8.41 (m, 1H); 8.52 (d, 1H); 8.67 (dd, 1H); 9.12 (s, 1H); 9.25 (m, 1H);
9.65 (br.s).
Example 54: 4-Methvl-3-rr4-(3-pvridinvl)-2-pvrimidinvnamino]-N-r[4-(trifluoromethvl)phenvn- methyl]benzamide utilising 4-(trifluoromethyl)benzylamine (Aldrich, Buchs, Switzerland).1H- NMR (400 MHz, DMSO-d6, δ): 2.30 (s, 3H); 4.53 (d, 2H); 7.34 (d,1H); 7.44 (d, 1H); 7.46-7.53 (m, 3H); 7.62 (dd, 1H); 7.66 (m, 2H); 8.16 (m, 1H); 8.40 (m, 1H); 8.51 (d, 1H); 8.67 (dd, 1H); 9.08 (t, 1H); 9.10 (s, 1H); 9.24 (m, 1H).
Example 55: 4-Methvl-/V-r(5-methvlpvrazinvπmethvl1-3-r[4-(3-pvridinvl)-2-pvrimidinvnamino]- benzamide utilising 2-(aminomethyl)-5-methylpyrazine (TCI-JP, Distrib. Zurich, Switzerland). 1H-NMR (400 MHz, DMSO-d6, δ): 2.29 (s, 3H); 2.45 (s, 3H); 4.54 (d, 2H); 7.33 (d, 1H); 7.44 (d, 1H); 7.49 (ddd, 1H); 7.62 (dd, 1H); 8.14 (m, 1H); 8.40 (m, 1H); 8.45 (m, 2H); 8.50 (d, 1H);
8.66 (dd, 1H); 9.07 (t, 1H); 9.09 (s, 1H); 9.23 (m, 1H).
Example 56: Λ/-(2-Ethoxvethvl)-4-methyl-3-[f4-(3-pvridinvl)-2-pyrimidinvl]amino1benzamide utilising 2-ethoxyethylamine (TCI-JP, Distrib. Zurich, Switzerland).1 H-NMR (400 MHz, DMSO-de, δ):1.07 (t, 3H); 2.28 (s, 3H); 3.30-3.49 (m, 6H); 7.31 (d, 1H); 7.43 (d, 1H); 7.51 (ddd, 1H); 7.57 (dd, 1H); 8.09 (m, 1H); 8.38-8.45 (m, 2H); 8.50 (d, 1H); 8.67 (dd, 1H); 9.07 (s, 1H);9.24(m, 1H). Exani Je 57: 4-Methyl-Λ/-[2-(2-oxo-1-imidazolidinyl)ethyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]- amino]benzamide utilising 1 -(2-aminoethyl)imidazolidin-2-one [Chem. Abstr. Reg. Number: 6281-42-1].1H-NMR (400 MHz, DMSO-d6, δ): 2.27 (s, 3H); 3.13-3.22 (m, 4H); 3.30-3.40 (m, 4H); 6.27 (br.s, 1 H); 7.30 (d, 1 H); 7.43 (d, 1 H); 7.49-7.56 (m, 2H); 8.08 (d, 1 H); 8.40 (m, 1 H); 8.45 (t, 1 H); 8.50 (d, 1 H); 8.67 (dd, 1 H); 9.06 (s, 1 H); 9.23 (m, 1 H).
Example 58: 4-Methvl-Λ/-(5-methvl-2-pvridinvl)-3-[[4-(3-pvridinvl)-2-pyrimidinvnamino1- benzamide utilising 2-amino-5-picoIine (Aldrich, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 2.26 (s, 3H); 2.32 (s, 3H); 7.35 (d, 1H); 7.45 (d, 1 H); 7.49 (ddd, 1 H); 7.64 (dd, 1 H); 7.77 (dd, 1H); 8.07 (d, 1 H); 8.18 (m, 1 H); 8.31 (d, 1 H); 8.43 (m, 1 H); 8.52 (d, 1 H); 8.66 (dd, 1 H); 9.08 (s, 1 H); 9.25 (m, 1 H); 10.58 (s, 1 H).
carnpje 59: 1-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-4-phenyl-4- piperidinol utilising 4-hydroxy-4-phenylpiperidine (Aldrich, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-de, δ): 1.45-1.73 (m, 2H); 1.88 (m, 2H); 2.28 (s, 3H); 3.15 (m, 1 H); 3.47 (m, 1 H); 3.64 (m, 1 H); 4.39 (m, 1 H); 5.14 (s, 1 H); 7.14 (dd, 1 H); 7.19 (m, 1 H); 7.26-7.31 (m, 3H); 7.43 (d, 1H); 7.45-7.51 (m, 3H); 7.69 (d, 1H); 8.40 (m, 1H); 8.48 (d, 1H); 8.67 (dd, 1H); 9.03 (s, 1H); 9.24 (m, 1H).
Example 60: V-(3-Benzovlphenvl)-4-methvl-3-|i[4-(3-pvridinvl)-2-pvrimidinvnaminolbenzamide utilising 3-aminobenzophenone (Aldrich, Buchs, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 2.32 (s, 3H); 7.39 (d, 1H); 7.43-7.58 (m, 6H); 7.67 (m, 1H); 7.70-7.77 (m, 3H); 8.13 (m, 1H); 8.20 (m, 1H); 8.27 (m, 1H); 8.42 (m, 1H); 8.52 (d, 1H); 8.66 (dd, 1H); 9.14 (s, 1 H); 9.25 (m, 1 H); 10.41 (s, 1 H).
Example 61 : /V-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]-glycine 1 ,1- dimethylethyl ester utilising glycine t-butyl ester hydrochloride (Aldrich, Buchs, Switzerland). 1H-NMR (400 MHz, DMSO-d6, δ): 1.40 (s, 9H); 2.29 (s, 3H); 3.86 (d, 2H); 7.33 (d, 1H); 7.43 (d, 1 H); 7.51 (ddd, 1 H); 7.58 (dd, 1H); 8.10 (d, 1 H); 8.40 (m, 1 H); 8.50 (d, 1 H); 8.67 (dd, 1 H); 8.75 (t, 1 H); 9.08 (s, 1 H); 9.23 (m, 1 H).
Bcajτιrj!e 62ι 4-[[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]amino]benzene- acetic acid ethyl ester utilising ethyl 4-aminophenylacetate (Maybridge Chemical Co. Ltd.). 1H-NMR (400 MHz, DMSO-d6, δ): 1.16 (t, 3H); 2.32 (s, 3H); 3.60 (s, 2H); 4.06 (q, 2H); 7.21 (m, 2H); 7.38 (d, 1 H); 7.45 (d, 1H); 7.48 (ddd, 1 H); 7.70 (m, 3H); 8.23 (m, 1H); 8.41 (m, 1 H); 8.52 (d, 1 H); 8.66 (dd, 1 H); 9.13 (s, 1 H); 9.25 (m, 1 H); 10.16 (s, 1 H).
Example 63: 4-Methvl-Λ/-f3-(methvlphenvlamino)propvn-3-r[4-(3-pyridinvl)-2-pyrimidinvl - amino]benzamide utilising N-(3-aminopropyI)-N-methylaniline (TCI-JP, Distrib. Zurich, Switzerland).1 H-NMR (400 MHz, DMSO-d6, δ): 1.73 (qui, 2H); 2.28 (s, 3H); 2.84 (s, 3H); 3.24-3.37 (m, 4H); 6.55 (m, 1 H); 6.65 (m, 2H); 7.10 (m, 2H); 7.31 (d, 1H); 7.43 (d, 1H); 7.47 (ddd, 1H); 7.55 (dd, 1H); 8.10 (d, 1 H); 8.37-8.44 (m, 2H); 8.50 (d, 1H); 8.65 (dd, 1H); 9.06 (s, 1H); 9.23 (m, 1H).
&<anτpJe 64ι 1-[[3-[[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]amino]phenyl]- methyl]-4-piperidinecarboxylic acid ethyl ester utilising ethyl 1 -(3-aminobenzyl)piperidine-4- carboxylate (Maybridge Chemical Co. Ltd.).1H-NMR (400 MHz, DMSO-d6, δ): 1.14 (t, 3H); 1.49-1.61 (m, 2H); 1.72-1.80 (m, 2H); 1.92-2.02 (m, 2H); 2.27 (m, 1 H); 2.32 (s, 3H); 2.74 (m, 2H); 3.40 (s, 2H); 4.03 (q, 2H); 6.98 (d, 1 H); 7.25 (m, 1 H); 7.38 (d, 1 H); 7.43-7.51 (m, 2H); 7.66-7.73 (m, 3H); 8.25 (s, 1 H); 8.42 (m, 1 H); 8.52 (d, 1 H); 8.65 (dd, 1 H); 9.12 (s, 1 H); 9.25 (m, 1 H); 10.14 (s, 1 H).
canτpJe_65ι [[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoyl]amino]propanedioic acid diethyl ester utilising diethyl aminomalonate hydrochloride (Aldrich, Buchs, Switzerland). 1H-NMR (400 MHz, DMSO-d6, δ): 1.19 (t, 6H); 2.30 (s, 3H); 4.10-4.22 (m, 4H); 5.27 (d, 1 H); 7.35 (d, 1 H); 7.44 (d, 1 H); 7.51 (ddd, 1 H); 7.63 (dd, 1 H); 8.15 (m, 1 H); 8.40 (m, 1 H); 8.50 (d, 1 H); 8.67 (dd, 1 H); 9.11 (s, 1 H); 9.21-9.25 (m, 2H).
Example 66: Λ/-[2-fbis(1 -Methvlethvl)amino1ethvn-4-methvl-3-rf4-(3-pvridinvl)-2-pyrimidinvll- amino]benzamide utilising 2-diisopropylamino-ethylamine (Fluka, Buchs, Switzerland).1H- NMR (400 MHz, DMSO-d6, δ): 0.95 (m, 12H); 2.28 (s, 3H); 2.49 (m, 2H); 2.94 (m, 2H); 3.17 (m, 2H); 7.30 (d, 1 H); 7.43 (d, 1H); 7.50 (ddd, 1H); 7.54 (dd, 1 H); 8.09 (br.s, 1H); 8.27 (m, 1H); 8.40 (m, 1H); 8.50 (d, 1H); 8.67 (dd, 1 H); 9.06 (s, 1H); 9.23 (m, 1H).
Example 67: Λ/-f3-(Diethylamino)phenvπ-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinvnamino1- benzamide
A solution containing -50% of propylphosphonic anhydride in Λ/,Λ/-dimethylformamide (Fluka,
Buchs, Switzerland; 674 μL, -1.05 mmol) is added within 20 minutes to a stirred mixture of 4- methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzoic acid (214.4 mg, 0.7 mmol), N,N- diethyl-1 ,3-benzenediamine (115 mg, 0.7 mmol) and triethylamine (776 μL, 5.6 mmol) in 2 mL Λ/,Λ/-dimethylformamide. After stirring for 24 hours at room temperature, the mixture is treated with a half-saturated aqueous solution of sodium hydrogen carbonate and extracted three times with ethyl acetate. The solvent is evaporated off under reduced pressure and the residue dried in vacuo. The crude product is purified by chromatography on silica gel, eluent 2% methanol in dichloromethane and crystallised from acetone to give the title compound as a crystalline solid. 1H-NMR (400 MHz, DMSO-d6, δ): 1.07 (t, 6H); 2.31 (s, 3H); 3.29 (m, 4H); 6.38 (m, 1 H); 7.06 (m, 2H); 7.11 (m, 1 H); 7.36 (d, 1 H); 7.43-7.50 (m, 2H); 7.67 (m, 1 H); 8.21 (m, 1 H); 8.43 (m, 1H); 8.51 (d, 1 H); 8.66 (dd, 1H); 9.12 (s, 1H); 9.24 (m, 1H); 9.90 (s, 1H).
Example 68: 4-Methyl-3-fr4-(3-pyridinyl)-2-pyrimidinvnamino]-/V-[f3-f(1 -hvdroxy-1 -methyl- ethyl)]-5-(1.1.1 -trifluoromethvDphenvnmethyllbenzamide
Diethylcyanophosphonate (Aldrich, Buchs, Switzerland; 0.33 mL, 2.0 mmol) is added to a stirred mixture of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzoic acid (306 mg, 1.0 mmol), 3-[(1-hydroxy-1 -methylethyl)]-5-(1 ,1 ,1-trifluoromethyl)benzeneamine (220 mg, 1.0 mmol) and triethylamine (560 μL, 4.0 mmol) in 5 mL Λ/,/V-dimethylformamide at 10°C. After stirring for 3 hours at 60°C, the mixture is treated with saturated aqueous solution of sodium hydrogen carbonate and extracted three times with ethyl acetate. The combined extracts are dried (MgSO4), filtered and the solvent is evaporated off under reduced pressure to afford a crude product which is recrystallised from ethylacetate to give the title compound as a crystalline solid, m.p. 253-258°C.
Example 69: 3-rf4-(3-Pyridinyl)-2-p imidinvπamino1-/V-[(4-methyl-1 -piperazinvDmethylj- benzamide
Diethylcyanophosphonate (Aldrich, Buchs, Switzerland; 0.50 mL, 3.0 mmol) is added to a stirred mixture of 3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzoic acid (438 mg, 1.5 mmol), 4- [(4-methyl-1 -piperazinyl)methyl]benzeneamine (308 mg, 1.5 mmol) and triethylamine (840 μL, 3.0 mmol) in 10 mL Λ/,A/-dimethylformamide at 10°C. After stirring for 12 hours at 60°C, the mixture is treated with an aqueous solution of sodium hydrogen carbonate and extracted three times with ethyl acetate. The combined extracts are washed with water, and the solvent is evaporated off under reduced pressure to give a residue. The residue is resuspended in water and filtered to afford the crude product which is recrystallised from tetrahydrofuran- ethyl acetate to give Λ/-[3-[[4-(3-Pyridinyl)-2-pyrimidinyl]amino]-Λ/-[(4-methyl-1-piperazinyl)- methyljbenzamide as a crystalline solid, m.p. 220-224°C.
Example 69a: 3-f(Aminoiminomethyl)amino1-4-methylbenzoic acid methyl ester mononitrate Utilising the procedure described in Example 1 a, but with 3-aminobenzoic acid methyl ester (Fluka, Buchs, Switzerland) in lieu of 3-amino-4-methylbenzoic acid ethyl ester, afforded the title compound as a crystalline solid, m.p. 170-172°C.
Example 69b: 3-[f4-(3-Pyridinyl)-2-pyrimidinyllaminolbenzoic acid methyl ester Utilising the procedure described in Example 1 b, but with the intermediate of Example 69a in lieu of 4-methyl-3-[(aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate, afforded the title compound as a crystalline solid, m.p. 195-200°C.
Example 69c: 3-f[4-(3-PyridinvO-2-pyrimidinvπaminolbenzoic acid
Utilising the procedure described in Example 1 c, but with the intermediate of Example 69b in lieu of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester, afforded the title compound as a crystalline solid, m.p. 285-293°C.
Example 70: 3-rr4-(3-Pyridinyl)-2-pyrimidinyllamino1-Λ/-r(3-(1 -hvdroxy-1 -methylethyl)-5-(1.1.1- trifluoromethvDphenyllbenzamide
Utilising the procedure described in Example 69, but with 3-(1-hydroxy-1-methylethyl)-5-
(1 ,1 ,1-trifluoromethyl)benzeneamine in lieu of 4-[(4-methyl-1-piperazinyl)methyl]benzene- amine, afforded 3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[(3-(1 -hydroxy-1 -methylethyl)-5-
(1,1 ,1-trifluoromethyl)phenyI]benzamide as a crystalline solid, m.p. 213-215°C.
Example 71 : 4-Methyl-3-fr4-(3-pyridinyl)-2-pyrimidinyl]amino1-Λ/- 3-[3-(1 H-imidazol-1 - vDpropoxyl-phenyllbenzamide
Utilising the procedure described in Example 3, but employing 3-[3-(1 H-imidazol-1 - yl)propoxy]-benzenamine (Takao Nishi et al., JP 10182459) in lieu of 1 -(2-pyridyl)piperazine, afforded the title compound as a solid. 1 H-NMR (400 MHz, DMSO-d6, δ): 2.12-2.21 (m, 2H); 2.33 (s, 3H); 3.87 (t, 2H); 4.13 (t, 2H); 6.66 (dd, 1H); 6.87 (s, 1H); 7.15-7.26 (m, 2H); 7.32- 7.42 (m, 2H); 7.44-7.52 (m, 3H); 7.61 (s, 1 H); 7.70 (d, 1H); 8.24 (s, 1H); 8.43 (d, 1H); 8.53 (d, 1H); 8.67 (d, 1H); 9.13 (s, 1 H); 9.26 (br. s, 1 H); 10.13 (s, 1 H). Example 72: 4-Methyl-3-ff4-(3-pyridinyl)-2-pyrimidinvnaminol-Λ/-f3-f2-(1 H-imidazol-1 - yl)ethoxy1phenyl]benzamide
Utilising the procedure described in Example 3, but employing 3-[2-(1 H-imidazol-1 -yl)ethoxy]- benzenamine (Rolf Paul et al., Journal of Medicinal Chemistry (1993), 36(19), 2716-25) in lieu of 1-(2-pyridyl)piperazine, afforded the title compound as a crystalline solid. 1 H-NMR (400 MHz, DMSO-d6, δ): 2.34 (s, 3H); 4.22 (t, 2H); 4.37 (t, 2H); 6.68 (dd, 1H); 6.90 (s, 1H); 7.21-7.27 (m, 2H); 7.36-7.43 (m, 2H); 7.46-7.53 (m, 3H); 7.67-7.74 (m, 2H); 8.25 (br. s, 1 H); 8.44 (dt, 1 H); 8.54 (d, 1 H); 8.68 (dd, 1 H); 9.15 (s, 1 H); 9.27 (br. d, 1 H); 10.15 (s, 1 H).
Example 73: 4-Methyl-3-[ 4-(3-pyridinvπ-2-pyrimidinvπamino]-Λ/-[4-(ethylamino)-3-
(trifluoromethyl)phenvπbenzamide
Utilising the procedure described in Example 69, but employing N-ethyl-2-(trifluoromethyl)-
1 ,4-benzenediamine in lieu of 3-[(1-hydroxy-1-methylethyl)]-5-(1,1 ,1-trifluoromethyl)- benzeneamine, afforded the title compound as a crystalline solid, m.p. 178-180°C.
The aniline is prepared as follows:
Example 73a: N-ethyl-2-(trifluoromethyl)-1 ,4-benzenediamine
A mixture of 2-bromo-5-nitrobenzotrifuoride (Lancaster Synthesis, GmbH; 5.4 g, 20 mmol) and a solution of ethylamine in ethanol (50 mL of 2M, 100 mmol) is heated at 80°C for 18 hours in a steel pressure vessel. The mixture is then cooled and the solvent is evaopated off under reduced pressure to yield the crude product which is purified by column chromatography (silica gel, eluent 20% ethyl acetate in hexane) to afford N-ethyl-4-nitro-6-(trifluoromethyl)- benzenamine as yellow oil. This product is dissolved in ethanol (180 mL) and hydrogenated at atmospheric pressure over Raney nickel (0.5 g) at 45°C. The calculated amount of hydrogen is taken up in 50 hours. The mixture is then filtered and the solvent is evaporated off under reduced pressure to yield the crude product which is purified by chromatography (silica gel; eluent 50% ethyl acetate in hexane) and recrystallised from ether - hexane to give the title compound as a beige crystalline solid. 1H-NMR (400 MHz, DMSO-d6): 1.11 (t, 3H), 3.05 (m, 2H), 4.18 (br t, 1 H), 4.66 (br.s, 2H), 6.58 - 6.64 (m, 1 H) and 6.68 - 6.75 (m, 2H).
Example 74: 4-Methyl-3-rr4-(3-pyridinvπ-2-pyrimidinvnaminol-/V-r4-(diethylamino)-3- (trifluoromethyl)phenvπbenzamide Utilising the procedure described in Example 3, but employing N,N-diethyl-2-(trifluoromethyl)- 1 ,4-benzenediamine (Toshio Niwa, DE 3524519) in lieu of 1 -(2-pyridyl)piperazine, afforded the title compound as a crystalline solid, m.p. 128-131 °C.
Example 75: (±)-4-Methyl-3-f[4-(3-pyridinyl)-2-pyrimidinyllaminol-Λ/-r4-f(2-hvdroxy- propyl)amino]-3-(trifluoromethyl)phenvnbenzamide
Utilising the procedure described in Example 3, but employing (±)-1-[[4-amino-2-
(trifluoromethyl)phenyl]amino]-2-propanol (Tsutomu Mano, EP 299497) in lieu of 1 -(2- pyridyl)piperazine, afforded the title compound as a crystalline solid, m.p. 184-186°C.
Example 76: 4-Methyl-3-IT4-(3-pyridinyl)-2-pyrimidinvπamino1-/V-r4-fbis(2-methoxy- ethyl)amino]-3-(trifluoromethyl)phenyl1benzamide
Utilising the procedure described in Example 3, but employing Λ/,Λ/-bis(2-methoxyethyl)-2-
(trifluoromethyl)-l ,4-benzenediamine (Toshio Niwa, DE 3524519) in lieu of 1-(2- pyridyl)piperazine, afforded the title compound as a crystalline solid, m.p. 156-157°C.
Example 77: 4-Methyl-3-[ 4-(3-pyridinyl)-2-pyrimidinvnaminol-Λ/-[4-(4-methyl-1-piperazinyl)-3-
(trifluoromethyl)phenyl]benzamide
Utilising the procedure described in Example 3, but employing 4-(4-methyl-1 -piperazinyl)-3-
(trifluoromethyl)-benzenamine (Anthony David Baxter, WO 0119800) in lieu of 1-(2- pyridyl)piperazine, afforded the title compound as a crystalline solid, m.p.214-217°C.
Example 78: 4-Methyl-3-r[4-(3-pyridinyl)-2-pyrimidinyllaminol-Λ/-[4-(1 -piperidinyl)-3-
(trifluoromethyl)phenyllbenzamide
Utilising the procedure described in Example 3, but employing 4-(1 -piperidinyl)-3-
(trifluoromethyl)-benzenamine (Leping Li, WO 0151456) in lieu of 1-(2-pyridyl)piperazine, afforded the title compound as a crystalline solid, m.p.201-202°C.
Example 79: 4-Methyl-3-rf4-(3-pyridinyl -2-pyrimidinvnamino]-Λ/- 4-(1 -pyrrolidinyl)-3-
(trifluoromethyl)phenyllbenzamide
Utilising the procedure described in Example 3, but employing 4-(1-pyrrolidinyl)-3-
(trifluoromethyl)-benzenamine (Steven Lee Bender WO 0153274) in lieu of 1 -(2- pyridyl)piperazine afforded the title compound as a crystalline solid, m.p. 129-130°C. Example 80: 4-Methyl-3-ff4-(3-pyridinyl)-2-pyrimidinyl1amino'|-/v'-f4-(4-morpholinyl)-3-
(trifluoromethyl)phenyllbenzamide
Utilising the procedure described in Example 69, but employing 4-(4-morpholinyl)-3-
(trifluoromethyl)-benzenamine (Steven Lee Bender WO 0153274) in lieu of 3-[(1 -hydroxy-1 - methylethyl)]-5-(1 ,1 ,1-trifluoromethyl)benzeneamine, afforded the title compound as a crystalline solid, m.p. 216-218°C.
Example 81 : 4-Methyl-3-f[4-(3-pyridinyl)-2-pyrimidinyllamino1-Λ/-r4-phenyl-3-
(trifluoromethvDphenyllbenzamide
Utilising the procedure described in Example 3, but employing 4-(phenyl)-3-(trifluoromethyl)- benzenamine in lieu of 1 -(2-pyridyl)piperazine afforded the title compound as a crystalline solid, m.p. 172-174°C.
The aniline is prepared as follows:
Example 81 a: 4-(Phenyl)-3-(trifluoromethyl)benzenamine
Phenyl boronic acid (Aldrich, Buchs, Switzerland; 2.7 g, 22 mmol), Palladium II acetate (0.225 g, 1 mmol), tri-o-tolylphosphine (0.608 g, 2 mmol) and aqueous potassium carbonate solution (50 mL of 1 M) is added to a stirred solution of 2-bromo-5-nitrobenzotrifuoride (Lancaster Synthesis, GmbH; 5.4 g, 20 mmol) in dimethylformamide (200 mL) and heated at 120°C under an argon atmosphere for 1 h. The mixture is then evaporated to dryness under reduced pressure and the residue is treated with water (100 mL) and extracted with ethyl acetate (3 x 80 mL). The combined extracts are washed (brine), dried (MgSO4), filltered and the solvent is evorated off under reduced pressure to afford ^-nitro^'-^rifluoromethylJ-JI.I'- Biphenyl]. The biphenyl is dissolved in ethanol (200 mL) and hydrogenated at atmospheric pressure over Raney nickel (2 g) at 22°C. The calculated amount of hydrogen is taken up in 11 hours. The mixture is then filtered and the solvent is evaporated off under reduced pressure to yield the crude product which is purified by chromatograghy (silica gel; eluent ethyl acetate) to give the title compound as a brown oil.1 H-NMR (400 MHz, DMSO-d6): 5.62 (br.s, 2H), 6.80 (dd, 1 H), 6.96 (d, 1 H), 6.99 (d, 1 H), 7.19 - 7.23 (m, 2H), and 7.29 - 7.39 (m, 3H).
Example 82: 4-Methyl-3-r[4-(3-pyridinyl)-2-pyrimidinvnamino -N-[3-[4-(3-pyridinyl)-3- (trifluoromethvOphenyllmethyllbenzamide Utilising the procedure described in Example 69, but employing 4-(3-pyridinyl)-3- (trifluoromethyl)-benzenamine in lieu of 3-[(1-hydroxy-1-methylethyl)]-5-(1 ,1 ,1- trifluoromethyl)benzeneamine, afforded the title compound as a crystalline solid, m.p. 276- 280°C.
The aniline is prepared as follows:
Example 82a: 4-(3-Pyridinyl)-3-(trifluoromethyl)benzenamine
A stirred solution of 2-bromo-5-nitrobenzotrifuoride (Lancaster Synthesis, GmbH; 3.37 g,
12.5 mmol) and 3-(tri-n-butylstannyl)pyridine (Maybridge Chemical Co. Ltd., England; 5.0 g,
13.6 mmol) in xylene (75 mL) was purged with argon for 10 minutes at 20°C. Tetrakis(triphenylphosphine)palladium (0) (1.4 g, 1.25 mmol) is then added and the resulting mixture is heated at 130°C for 24 hours under an argon atmosphere. The mixture is then cooled, treated with an aqueous solution of sodium hydroxide (150 mL of 0.1 M) and purged with air for 2 hours. The resulting mixture is then diluted with ethylacetate (200 mL) and filtered. The orgainic phase is then sequentially washed with water (2 x 80 mL) and saturated aqueous sodium chloride (1 x 80 mL), dried (MgSO ), filtered and the solvent is evaporated off under reduced pressure to yield the crude product which is purified by column chromatography (silica gel, eluent 50% ethyl acetate in hexane) to afford 3-[(4-nitro-3-(trifluoromethyl)phenyl]pyridine. This product is dissolved in ethanol (200 mL) and hydrogenated at atmospheric pressure over Raney nickel (0.23 g) at 22°C. The calculated amount of hydrogen is taken up in 24 hours. The mixture is then filtered and the solvent is evaporated off under reduced pressure to yield the crude product which is purified by chromatography (silica gel; eluent 50% ethyl acetate in hexane) and recrystallised from ether - hexane to give the title compound as a colourless crystalline solid, m.p. 92-93°C.
Example 83: 4-Methyl-3-r 4-(3-pyridinyl)-2-pyrimidinvπamino1-Λ/-r4-(1 H-imidazol-1 -yl)-3-
(trifluoromethyl)phenvnbenzamide
Utilising the procedure described in Example 3, but employing 4-(1 H-imidazol-1 -yl)-3-
(trifluoromethyl)-benzenamine (Steven Lee Bender WO 0153274) in lieu of 1-(2- pyridyl)piperazine afforded the title compound as a crystalline solid, m.p. 226-229°C.
Example 84: 4-Methyl-3-fr4-(3-pyridinyl)-2-pyrimidinvnamino1-/v-r4-(2.4-dimethyl-1 H-imidazol- 1-yl)-3-(trifluoromethyl)phenyllbenzamide Utilising the procedure described in Example 69, but employing 4-(2,4-dimethyl-1 H-imidazol- 1-yl)-3-(trifluoromethyl)-benzenamine in lieu of 3-[(1-hydroxy-1-methylethyl)]-5-(1,1,1- trifluoromethyl)benzeneamine, afforded the title compound as an amorphous solid.
The aniline is prepared as follows:
Example 84a: 4-(2,4-dimethyl-1 H-imidazol-1 -yl)-3-(trif luoromethyl)-benzenamine A mixture of 2-bromo-5-nitrobenzotrifuoride (Lancaster Synthesis, GmbH; 6.0 g, 22 mmol) and 2,4-dimethylimidazole (10.6, 110 mmol) is heated at 120°C for 36 hours under an argon atmosphere. The mixture is then cooled and the residue is treated with water (150 mL) and extracted with ethyl acetate (3 x 80 mL). The combined extracts are washed (brine), dried (MgSO4), filtered and the solvent is evaporated off under reduced pressure to yield the crude product which is purified by column chromatography (silica gel, eluent ethyl acetate) to afford 1- [4-nitro-2-(trifluoromethyl)phenyl]-1 H-imidazole as yellow crystalline solid. This product is dissolved in ethanol (290 mL) and hydrogenated at atmospheric pressure over Raney nickel (1.15 g) at 25°C. The calculated amount of hydrogen is taken up in 14 hours. The mixture is then filtered and the solvent is evaporated off under reduced pressure to yield the crude product which is purified by recrystallisation from ether - hexane to give the title compound as a crystalline solid, m.p. 163-164°C.
Example 85: 4-Methyl-3-rf4-(3-pyridinvπ-2-pyrimidinvπamino]-Λ/-[4-(4-methyl-1 H-imidazol-1 - yl)-3-(trifluoromethyl)phenyr|benzamide
Utilising the procedure described in Example 69, but employing 4-(4-methyl-1 H-imidazol-1 - yl)-3-(trifluoromethyl)-benzenamine in lieu of 3-[(1-hydroxy-1-methylethyl)]-5-(1,1,1-trifluoro- methyl)benzeneamine, afforded the title compound as a crystalline solid, m.p. 154-163°C.
The aniline is prepared as follows:
Example 85a: 4-(4-Methyl-1 H-imidazol-1 -yl)-3-(trif luoromethyl)-benzenamine
Utilising the procedure described in Example 84a, but employing 4(5)-methyl-1 H-imidazole in lieu of 2,4-dimethylimidazole, afforded the title compound as a beige crystalline solid, m.p.
141-143°C. Example 86: 4-Methyl-3-ff4-(3-pyridinyl)-2-pyrimidinyl1amino]-A/-r4-(2-methyl-1 H-imidazol-1 - yl)-3-(trifluoromethyl)phenvπbenzamide
Utilising the procedure described in Example 69, but employing 4-(2-methyl-1 H-imidazol-1 - yl)-3-(trifluoromethyl)-benzenamine in lieu of 3-[(1-hydroxy-1-methylethyl)]-5-(1,1,1-trifluoro- methyl)benzeneamine, afforded the title compound as a crystalline solid, m.p. 154-163°C.
The aniline is prepared as follows:
Example 86a: 4-(2-Methyl-1 H-imidazol-1 -yl)-3-(trifluoromethyl)-benzenamine Utilising the procedure described in Example 84a, but employing 2-methyl-1 H-imidazole in lieu of 2,4-dimethylimidazole, afforded the title compound as a colourless crystalline solid, m.p. 117-119°C.
Example 87: 4-Methyl-3-fr4-(3-pyridinyl)-2-pyrimidinyl]aminol-Λ/-[3-(4-morpholinyl)-5- f(methylamino)carbonyl1phenyllbenzamide
Utilising the procedure described in Example 69, but employing 3-amino-5-(4-morpholinyl)-N-
(methyl)-benzamide in lieu of 3-[(1-hydroxy-1-methyIethyl)]-5-(1 ,1 ,1-trifluoromethyl)- benzeneamine, afforded the title compound as a crystalline solid, m.p. 153-156°C.
The aniline is prepared as follows:
Example 87a: 3-Bromo-5-nitro-benzoic acid, 1 ,1-dimethylethyl ester A solution of n-butyllithium in hexane (12.8 mL of 2.5 M, 32 mmol) is added with stirring to t- butanol (46 mL) at 25°C under an argon atmosphere. After 30 min the mixture is treated dropwise with a solution of 3-bromo-5-nitro-benzoyl chloride (J. Mindl, Collect. Czech. Chem. Commun. (1973), 38, 3496-505; 32 mmol) in dry THF (40 mL) and stirred for a further 17 h. The mixture is then treated with ether (250 mL) and washed with brine. The ether solution was dried (MgSO4) and the solvent is evaporated off under reduced pressure to give the crude product which is purified by column chromatography (silica gel, eluent 20% ethyl acetate in hexane) and recrystallised from ether - hexane to afford the title compound as colourless crystalline solid, m.p. 77-78°C.
Example 87b: 3-(4-Morpholinyl)-5-nitro-benzoic acid, 1 ,1-dimethylethyl ester A stirred mixture of 3-bromo-5-nitro-benzoic acid, 1,1-dimethylethyl ester (example 86a; 3.02 g, 10 mmol) and morpholine (1.22 mL, 14 mmol) in toluene (50 mL) is treated with sodium t- butylate (1.34 g, 14 mmol), tri-t-butylphosphine (3 mL, 1.5 mmol) and tris-(dibenzylidene- acetone)dipalladium[0] (0.45 g, 0.5 mmol) under an argon atmosphere, and then heated at 60°C for 18 h. The mixture is diluted with ethyl acetate (150 mL), filtered, washed with brine (2 x 50 mL), dried (MgSO4) and the solvent is evaporated off under reduced pressure to give the crude product which is purified by column chromatography (silica gel, eluent 15% ethyl acetate in hexane) and recrystallised from ethyl acetate - hexane to afford the title compound as colourless crystalline solid, m.p. 116-118°C.
Example 87c: 3-(4-Morpholinyl)-5-nitro-benzoic acid, methyl ester A mixture of 3-(4-morpholinyl)-5-nitro-benzoic acid, 1,1-dimethylethyl ester (Example 87b; 0.77 g, 2.5 mmol), 1 ,8-diazabicyclo[5,4,0]undec-7-ene (o.56 mL, 3.75 mL), and potassium bromide (1.09 g, 12.5 mmol) in methanol (25 mL) is stirred at 90 °C for 250 min. The cooled mixture is then added to hydrochloric acid (50 mL of 0.1 M) and extracted with ethyl acetate (3 x 100 mL). The combined extacts are washed with saturated aqueous sodium hydro- carbonate (2 x 25 mL), water (2 x 25 mL) and brine (2 x 50 mL), dried (MgSO ) and the solvent is evaporated off under reduced pressure to give the crude product which is purified by recrystallisation from ethyl acetate - hexane to afford the title compound as yellow crystalline solid.
Example 87d: 3-(4-Morpholinyl)-5-nitro-N-(methyl)-benzamide
A stirred solution of 3-(4-morpholinyl)-5-nitro-benzoic acid, methyl ester (Example 86c; 0.53 g, 2 mmol) in toluene (5 mL) under an argon atmosphere, is treated with a mixture of methylamine hydrochloride (0.27 g, 4 mmol), trimethylaluminium (2 mL of a 2 M solution in toluene, 4 mmol) in toluene (5 mL) and heated at 60 °C for 18 h. The cooled mixture is then treated with hydrochloric acid (10 mL of 2 M), stirred for 5 min and then treated with aqueous sodium hydroxide (5 mL of 4 M). The mixture is then treated with water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined extacts are washed with brine (2 x 50 mL), dried (MgSO4) and the solvent is evaporated off under reduced pressure to give the crude product which is purified by recrystallisation from ethyl acetate to afford the title compound as yellow crystalline solid, m.p.204-207°C.
Example 87e: 3-Amino-5-(4-Morpholinyl)-N-(methvl)-benzamide A solution of 3-(4-morpholinyl)-5-nitro-N-(methyl)-benzamide (Example 86d; 300 mg, 1.12 mmol) in ethanol (20 mL) is hydrogenated at atmospheric pressure over Raney nickel (0.2 g) at 25°C. The calculated amount of hydrogen is taken up in 19 hours. The mixture is then filtered and the solvent is evaporated off under reduced pressure to yield the crude product which is purified by recrystallisation from ethyl acetate to give the title compound as a beige crystalline solid, m.p. 201-204°C.
Example 88: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinvπamino]-Λ/-f3-[(methylamino)carbonyl1-5-
(trifluoromethyl)phenyllbenzamide
Utilising the procedure described in Example 69, but employing 3-amino-5-(trifluoromethyl)-
N-(methyl)-benzamide in lieu of 3-[(1-hydroxy-1-methylethyl)]-5-(1,1 ,1-trifluoromethyl)- benzeneamine, afforded the title compound as a crystalline solid, m.p. 245-249°C.
Example 88a: 3-Amino-5-(trifluoromethyl)-N-(methyl)-benzamide
Utilising the procedure described in Example 86e, but employing α,α,α-trifluoro-N-methyl-5- nitro-m-toluamide (Dean E. Welch, J. Med. Chem. (1969), 12, 299-303) in lieu of 3-(4- morpholinyl)-5-nitro-N-(methyl)-benzamide, afforded the title compound as a beige crystalline solid, m.p. 113-115°C.
Example 89: 4-Methyl-3-f[4-(3-pyridinyl)-2-pyrimidinyllaminol-Λ/-r5-(3-pyridinyl)-3-
(trifluoromethyl)phenyl benzamide
Utilising the procedure described in Example 69, but employing 5-(3-pyridinyl)-3-(trifluoro- methy -benzenamine in lieu of 3-[(1-hydroxy-1-methylethyl)]-5-(1 ,1 ,1-trifluoromethyI)- benzeneamine, afforded the title compound as a crystalline solid, m.p. 275-279°C.
The aniline is prepared as follows:
Example 89a: 5-(3-Pyridinyl)-3-(trifluoromethyl)benzenamine
A stirred solution of 3-amino-5-bromo-benzotrifuoride (Apollo, England; 1.12 g, 5 mmol) and 3-(tri-n-butylstannyl)pyridine (Maybridge Chemical Co. Ltd., England; 2.0 g, 5.4 mmol) in xylene (30 mL) was purged with argon for 10 minutes at 20°C. Tetrakis(triphenylphosphine)- palladium (0) (1.16 g, 1.0 mmol) is then added and the resulting mixture is heated at 140°C for 36 hours under an argon atmosphere. The mixture is then cooled, treated with an aqueous solution of sodium hydroxide (100 mL of 0.1 M) and purged with air for 2 hours. The resulting mixture is then diluted with ethylacetate (200 mL) and filtered. The orgainic phase is then sequentially washed with water (2 x 80 mL) and saturated aqueous sodium chloride (1 x 80 mL), dried (MgSO4), filtered and the solvent is evaporated off under reduced pressure to yield the crude product which is purified by column chromatography (silica gel, eluent ethyl acetate) to afford the title compound as a brown oil. 1 H-NMR (400 MHz, DMSO-d6, δ): 5.73 (br s, 2H), 6.83 (dd, 1 H), 6.99 (d, 1H), 7.04 (d, 1 H), 7.39 (dd, 1 H), 7.64 (d, 1 H), 8.42 (m, 1H) and 8.53 (dd, 1H).
Example 90: 4-Methyl-3-|"f4-(3-pyridinyl)-2-pyrimidinyllamino1-/v'-f5-(4-morpholinyl)-3-
(trifluoromethyl)phenyllbenzamide
Utilising the procedure described in Example 69, but employing 5-(4-morpholinyl)-3-
(trifluoromethyl)-benzenamine in lieu of 3-[(1-hydroxy-1-methyIethyl)]-5-(1 ,1 ,1-trifluoro- methyl)benzeneamine, afforded the title compound as a crystalline solid, m.p. 208-211°C.
The aniline is prepared as follows:
Example 90a: [3-Bromo-5-(trifluoromethyl)phenyl]-carbamic acid, 1,1-dimethylethyl ester A mixture of 3-amino-5-bromo-benzotrifuoride (Apollo, England; 12 g, 50 mmol), di-t-butyl- dicarbonate (12 g, 55 mmol) and 4-dimethylaminopyridine (0.61 g, 5 mmol) in acetonitrile (100 mL) is stirred at 60°C for 8 h. The solvent is then evaporated off under reduced pressure to yield the crude product which is purified by column chromatography (silica gel, eluent 10% ethyl acetate in hexane) and recrystallised from hexane to afford the title compound as a colourless crystalline solid, m.p. 113-115°C.
Example 90b: [3-(4-Morpholinyl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1 ,1-dimethylethyl ester
Utilising the procedure described in Example 86b but employing [3-bromo-5-(trifluoromethyl)- phenylj-carbamic acid, 1,1-dimethylethyl ester (Example 90a) in lieu of 3-bromo-5-nitro- benzoic acid, 1,1-dimethylethyl ester, afforded the title compound as a crystalline solid, m.p.
146-148°C.
Example 90c: 5-(4-Morpholinyl)-3-(trifluoromethyl)-benzenamine
[3-(4-morpholinyl)-5-(trifluoromethyI)phenyl]-carbamic acid, 1,1-dimethylethyl ester (Example 90b; 1.7 g, 5 mmol) is treated with a solution of hydrogen chloride in isopropanol (30 mL of 4 M) and heated at 60°C for 5 h. The solvent is evaporated off under reduced pressure and the residue is treated with aqueous sodium hydrogen carbonate solution (80 mL) and extracted with ethyl acetate (3 x 80 mL). The combined extacts are washed with brine (2 x 50 mL), dried (MgSO ) and the solvent is evaporated off under reduced pressure to give the crude product which is purified by recrystallisation from ether - hexane to afford the title compound as yellow crystalline solid, m.p. 96-97°C.
Example 91 : 4-Methyl-3-fr4-(3-pyridinyl)-2-pyrimidinvπamino]-Λ/-f5-(2-methyl-1 H-imidazol-1 - vD-3-(trifluoromethvDphenyllbenzamide
Utilising the procedure described in Example 69, but employing 5-(2-methyl-1 H-imidazol-1 - yl)-3-(trifluoromethyl)-benzenamine in lieu of 3-[(1-hydroxy-1-methylethyl)]-5-(1,1 ,1-trifluoro- methyl)benzeneamine, afforded the title compound as a crystalline solid, m.p. 242-247°C.
The was aniline is prepared as follows:
Example 91a: 3-(2-Methyl-1 H-imidazol-1 -yl)-5-(trif luoromethyl)-benzonitrile A mixture of 3-fluoro-5-(trifIuoromethyl)-benzonitrile (Lancaster Synthesis GmbH; 17 g, 89 mmol) and 2-methylimidazole (Fluka, Buchs, Switzerland; 22.2 g, 270 mmol) in N,N- dimethylacetamide (80 mL) is stirred at 145°C for 19 h. The solvent is evaporated off under reduced pressure and the residue is dissolved in ethyl acetate (200 mL). The solution is washed with brine (200 mL), dried (Na2SO4) and the solvent is evaporated off under reduced pressure to give the crude product which is purified by recrystallisation from ether - hexane to afford the title compound as yellow crystalline solid, m.p. 132-134°C.
Example 91 b: 3-(2-Methyl-1 H-imidazol-1 -yl)-5-(trifluoromethyl)-benzoic acid A solution of 3-(2-methyl-1 H-imidazol-1 -yl)-5-(trif luoromethyl)-benzonitrile (Example 91 a; 16.7 g, 66 mmol) in dioxane (300 mL) is added to an aqueous solution of sodium hydroxide (275 mL of 1 M) and the mixture is heated at 95°C for 18 h.The solvent is evaporated off under reduced pressure and the residue is neutralised with hydrochloric acid (1 M) and extracted with butanol (2 x 250 mL). The solvent is evaporated of under reduced pressure to give the title compound. 1H-NMR (400 MHz, DMSO-d6, δ): 7.17 (s, 1H); 8.03 (s, 1 H); 8.12 (s, 1H); 8.35 (s, 1H); 8.41 (s, 1H); 8.53 (s, 1H); 13.90 (br., 1H). Example 91c: [3-(2-methyI-1 H-imidazol-1 -yl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1,1- dimethylethyl ester
Triethylamine (5.23 mL, 37.5 mmol) is added to a stirred suspension of 3-(2-methyl-1 H- imidazol-1 -yl)-5-(trif Iuoromethyl)-benzoic acid (Example 91 b; 6.8 g, 25 mmol) in t-butanol (200 mL). Diphenylphosphorylazide (7.6 g, 27.5 mmol) is added to the resulting solution and the mixture is heated 80°C for 16 h. The solvent is evaporated off under reduced pressure and the residue is treated with water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined extracts are washed with brine (100 mL), dried (Na2SO4) and the solvent is evaporated off under reduced pressure to give the crude product which is purified by column chromatography (silica gel, eluent 2% ethanol in ethyl acetate) and recrystallised from ether - hexane to afford the title compound as a colourless crystalline solid, m.p. 203-208°C.
Example 91 d: 5-(2-Methyl-1 H-imidazol-1 -yl)-3-(trif luoromethyl)-benzenamine Utilising the procedure described in Example 90c but employing [3-(2-methyl-1 H-imidazol-1 - yl)-5-(trifIuoromethyl)phenyl]-carbamic acid, 1,1-dimethylethyl ester (Example 91c) in lieu of [3-(4-morpholinyl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1 ,1-dimethylethyl ester, afforded the title compound as a yellow crystalline solid, m.p. 130-133°C.
Example 92: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyllaminol-Λ/-r5-(4-methyl-1 H-imidazol-1 - yl)-3-(trifluoromethyl)phenyr]benzamide
Utilising the procedure described in Example 69, but employing 5-(4-methyl-1 H-imidazol-1 - yl)-3-(trifluoromethyl)-benzenamine in lieu of 3-[(1-hydroxy-1-methylethyl)]-5-(1,1,1-trifluoro- methyl)benzeneamine, afforded the title compound as a crystalline solid, m.p.235-236°C.
The was aniline is prepared as follows:
Example 92a: 3-(4-Methyl-1 H-imidazol-1 -yl)-5-(trifluoromethyl)-benzonitrile
Utilising the procedure described in Example 91a, but employing 4-methyl-1 H-imidazole in lieu of 2-methylimidazole, afforded the title compound as a crystalline solid, m.p. 127-128°C.
Example 92b: 3-(4-Methyl-1 H-imidazol-1 -yl)-5-(trif luoromethyl)-benzoic acid Utilising the procedure described in Example 91b, but employing 3-(4-methyl-1 H-imidazol-1 - yl)-5-(trifluoromethyl)-benzonitrile (Example 92a) in lieu of 3-(2-methyl-1 H-imidazol-1 -yl)-5- (trifluoromethyl)-benzonitrile, afforded the title compound as a crystalline solid, m.p. > 300°C. Example 92c: [3-(4-Methyl-1 H-imidazol-1 -yl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1 ,1- dimethylethyl ester
Utilising the procedure described in Example 91 c, but employing 3-(4-methyl-1 H-imidazol-1 - yl)-5-(trifluoromethyl)-benzoic acid (Example 92b) in lieu of 3-(2-methyl-1 H-imidazol-1 -yl)-5- (trifluoromethyl)-benzoic acid, afforded the title compound as a crystalline solid, m.p. 186- 188°C.
Example 92d: 5-(2-Methyl-1 H-imidazol-1 -yl)-3-(trif luoromethyl)-benzenamine Utilising the procedure described in Example 91 d, but employing [3-(4-methyl-1 H-imidazol-1 - yl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1,1-dimethylethyl ester (Example 92c) in lieu of [3-(2-methyl-1 H-imidazol-1 -yl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1 ,1-dimethylethyl ester, afforded the title compound as a colourless crystalline solid, m.p. 127-131 °C.
Example 93: 4-Methyl-3-fr4-(3-pyridinyl)-2-pyrimidinyl]aminol-Λ/-[5-(5-methyl-1 H-imidazol-1 - yl)-3-(trifluoromethyl)phenvπbenzamide
Utilising the procedure described in Example 3, but employing 5-(5-methyl-1 H-imidazol-1 -yl)-
3-(trifluoromethyl)-benzenamine in lieu of 1 -(2-pyridyl)piperazine, afforded the title compound as a crystalline solid, m.p. 231-233°C.
The aniline is prepared as follows:
Example 93a: 3-(5-Methyl-1 H-imidazol-1 -yl)-5-(trif luoromethyl)-benzonitrile
Utilising the procedure described in Example 91 a, but employing 4-methyl-1 H-imidazole in lieu of 2-methylimidazole, afforded the title compound as a crystalline solid, m.p. 99-101 °C.
Example 93b: 3-(5-MethyI-1 H-imidazol-1 -yl)-5-(trifluoromethyl)-benzoic acid Utilising the procedure described in Example 91b, but employing 3-(5-methyl-1 H-imidazol-1 - yl)-5-(trifluoromethyl)-benzonitrile (Example 93a) in lieu of 3-(2-methyl-1 H-imidazol-1 -yl)-5- (trifluoromethyl)-benzonitrile, afforded the title compound as a colourless crystalline solid, m.p. 243-245°C.
Example 93c: [3-(5-Methyl-1 H-imidazol-1 -yl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1,1- dimethylethyl ester Utilising the procedure described in Example 91 c, but employing 3-(5-methyl-1 H-imidazol-1 - yl)-5-(trifluoromethyl)-benzoic acid (Example 93b) in lieu of 3-(2-methyl-1 H-imidazol-1 -yl)-5- (trifluoromethyl)-benzoic acid, afforded the title compound as a crystalline solid, m.p. 169- 171°C.
Example 93d: 5-(5-Methyl-1 H-imidazol-1 -yl)-3-(trifluoromethyl)-benzenamine Utilising the procedure described in Example 91 d, but employing [3-(5-methyl-1 H-imidazol-1 - yl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1,1-dimethylethyl ester (Example 93c) in lieu of [3-(2-methyl-1 H-imidazol-1 -yl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1 ,1-dimethylethyl ester, afforded the title compound as a colourless crystalline solid, m.p. 131-133°C.
Example 94: 4-Methyl-3-fr4-(3-pyridinyl)-2-pyrimidinvnaminol-Λ/-f3-(4-methyl-1-piperazinyl)-5-
(trifluoromethyl)phenyl]benzamide
Utilising the procedure described in Example 69, but employing 3-(4-methyl-1-piperazinyl)-5-
(trifluoromethyl)-benzenamine in lieu of 3-[(1-hydroxy-1-methylethyl)]-5-(1,1,1-trifluoro- methyl)benzeneamine, afforded the title compound as a crystalline solid, m.p. 192-194°C.
The aniline is prepared as follows:
Example 94a: [3-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1,1- dimethylethyl ester
Utilising the procedure described in Example 87b, but employing 1 -methyl-1 -piperazine in lieu of morpholine, afforded the title compound as a crystalline solid, m.p.225°C.
Example 94b: 3-(4-methyl-1 -piperazinyl)-5-(trifluoromethyl)-benzenamine Utilising the procedure described in Example 90c, but employing [3-(4-methyl-1 -piperazinyl)- 5-(trifluoromethyl)phenyl]-carbamic acid, 1,1-dimethylethyl ester (Example 94a) in lieu of [3- (4-morpholinyl)-5-(trifluoromethyl)phenyl]-carbamic acid, 1,1-dimethylethyl ester, afforded the title compound as oil. 1 H-NMR (400 MHz, DMSO-d6): 2.20 (s, 3H), 2.42 (m, 4H), 3.07 (m, 4H), 3.32 (br s, 2H), 5.34 (s, 1H) and 6.31 (s, 2H).
Example 95: 4-Methyl-3- |"4-(3-pyridinyl)-2-pyrimidinyllaminol-/V-r2-(1 -pyrrolidinyl)-5- (trifluoromethyl)phenyllbenzamide Utilising the procedure described in Example 3, but employing 2-(1-pyrrolidinyI)-5- (trifluoromethyl)-benzenamine (Lancaster Synthesis Ltd.; Yasuhiro Ohtake et al., WO 9965874) in lieu of 1 -(2-pyridyl)piperazine, afforded the title compound as a crystalline solid. 1 H-NMR (400 MHz, DMSO-d6): 1.77-1.82 (m, 4H); 2.34 (s, 3H); 3.31-3.37 (m, 4H); 6.86 (d, 1H); 7.34-7.44 (m, 2H); 7.47 (d, 1 H); 7.49-7.53 (m, 1H); 7.73 (dd, 1 H); 8.27 (d, 1 H); 8.43 (dt, 1 H); 8.53 (d, 1 H); 8.69 (dd, 1 H); 9.13 (s, 1 H); 9.27 (d, 1 H); 9.96 (s, 1 H).
Example 96: 3-fr4-(3-pyridinyl)-2-pyrimidinyllaminol-Λ/-r5-(4-methyl-1 H-imidazol-1 -yl)-3-
(trifluoromethyl)phenvnbenzamide
Utilising the procedure described in example 1. but employing 3-fr4-(3-pyridinyl)-2- pyrimidinyllaminol-benzoic acid in lieu of 4-methyl-3-[f4-(3-pyridinyl)-2-pyrimidinvπaminol- benzoic acid and 5-(4-methyl-1 H-imidazol-1 -yl)-3-(trifluoromethv0-benzenamine in lieu of furfurylamine, afforded the title compound as as pale-yellow crystalline solid, m.p. 264-
266°C.
Example 96a: 3-[(Aminoiminomethyl)amino]-benzoic acid ethyl ester mononitrate Utilising the procedure described in example 1 a but employing 3-amino-benzoic acid ethyl ester (Fluka, Buchs, Switzerland) in lieu of 3-amino-4-methylbenzoic acid ethyl ester, afforded the title compound as a crystalline solid, m.p. 170-172°C.
Example 96b: 3-f[4-(3-pyridinyl)-2-pyrimidinyllaminol-benzoic acid ethyl ester
Utilising the procedure described in example 1 b but employing 3-[(aminoiminomethyl)amino]- benzoic acid ethyl ester mononitrate in lieu of 3-[(aminoiminomethyl)amino]-4-methyl-benzoic acid ethyl ester mononitrate, afforded the title compound as a crystalline solid, m.p. 197-
199°C.
Example 96c: 3-[f4-(3-pyridinyl)-2-pyrimidinyllaminol-benzoic acid
Utilising the procedure described in example 1 c but employing 3-[f4-(3-pyridinyl)-2- pyrimidinyllaminol-benzoic acid ethyl ester in lieu of 4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]-benzoic acid ethyl ester, afforded the title compound as a crystalline solid, m.p. 291-295°C.
Example 97: Soft Capsules
5000 soft gelatin capsules, each comprising as active ingredient 0.05 g of one of the compounds of formula I mentioned in the preceding Examples, are prepared as follows: 250 g pulverized active ingredient is suspended in 2L Lauroglykol® (propylene glycol laurate, Gattefosse S.A., Saint Priest, France) and ground in a wet pulverizer to produce a particle size of about 1 to 3 μm. 0.419 g portions of the mixture are then introduced into soft gelatin capsules using a capsule-filling machine.
Example 98: Pharmacokinetic data:
The compound of formula I to be tested is formulated for administration to female OF1 mice from IFACREDO, France, by first dissolving in NMP, and then by diluting with PEG300 to a final concentration of 10 % v/v NMP: 90 % v/v PEG300, producing a clear solution of the compound. The concentrations were adjusted to deliver a constant volume of 10 mL/kg body weight. The compound is prepared immediately before use. The formulated compound is administered perorally by gavage to provide dosages of 50 mg/kg. At the allotted time points mice (4 at each time) are anesthetized with 3 % isoflurane in medical oxygen and blood samples are obtained by heart puncture into heparinized tubes (ca. 30 lU/mL). The animals are subsequently killed without recovering from the anesthetic. Plasma is prepared from the blood by centrifugation (10,000 g, 5 min) and either analyzed immediately or stored frozen at - 70 °C.
The plasma samples (10 - 250 μL) are e.g. spiked with 5//L of internal standard, mixed with 200 μL 0.1 M NaOH and 500 μL chloroform in a 1.5 mL Eppendorf tube and shaken vigorously for 10 minutes on an Eppendorf mixer. Thereafter, the mixture is centrifuged (3 min at 10'000xg), the organic phase transferred to a second Eppendorf tube and evaporated to dryness in a vacuum centrifuge (Speedvac 5301). The dry residue e.g. is dissolved in 250 μL of 10 % v/v Acetonitrile in water containing 0.1 % formic acid. The subsequent analysis is carried out e.g. by HPLC/MS-MS using an Agilent 1100 Series (Agilent, Palo Alto, CA, USA) HPLC system with vacuum degasser, binary pump, and thermostated column compartment combined with a cooled autosampier system (HTS PAL, CTC Analytics, Zwingen, Switzerland). The sample (5-15 μL) is injected e.g. onto an Ultra Phenyl column (particle size 3 μm, 50 x1 mm; Restek, Bellefonte, USA) with a guard column (4 x 2 mm) of the same material (Phenomenex, Torrance, USA). After equilibration e.g. with water and a latency period of 1 min the sample is eluted e.g. by a linear gradient of 0 - 100 % acetonitrile in water containing 0.2 % v/v formic acid over a period of 11 min at a flow rate of 60 //L/min. The column is prepared for the next sample e.g. by re-equilibrating for 3 min with 100 % water to the starting conditions. The separation is performed e.g. at a column temperature of 40 °C. The column effluent is introduced e.g. directly into the ion source of a triple stage quadropole mass spectrometer (Quattro Ultima™, Micromass, Manchester, UK) controlled by Masslynx™ 3.5 software (Micromass, Manchester, UK ) using as ionization technique electrospray ionization positive mode (ESI +). The compound is detected by MS/MS following fragmentation of the parent ions. The limit of quantitation is determined at e.g. 0.002 nmol/L. A calibration curve is constructed with known amounts of compound including a fixed amount of internal standard in plasma which is processed as described above. The concentration of unknown samples is calculated from a plot of the peak area ratio of the selected daughter ion of the analyte to the product of its internal standard (ordinate) against the nominal concentration (abscissa). Regression analysis is performed using Quanlynx ™, Masslynx™ software 3.5 (Micromass, Manchester, UK).
Example 99: In vitro inhibition data:
Enzymatic (c-Abl, KDR, Flt3) in vitro inhibition data are presented as % inhibition at 10 μM.
The measurements are made as described above in the general description.
Figure imgf000070_0001
Figure imgf000071_0001

Claims

WHAT IS CLAIMED IS:
1. A compound of formula
Figure imgf000072_0001
wherein
R-i represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, carboxy- lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl;
R2 represents hydrogen, lower alkyl, optionally substituted by one or more identical or different radicals R3, cycloalkyl, benzcycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; and
R3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N- mono- or N,N-disubstituted carbamoyl, amino, mono- or disubstituted amino, cycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; or wherein
R1 and R2 together represent alkylene with four, five or six carbon atoms optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, oxo, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms; oxaalkylene with one oxygen and three or four carbon atoms; or azaalkylene with one nitrogen and three or four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N-disubstituted carbamoyl- lower alkyl, cycloalkyl, lower alkoxycarbonyl, carboxy, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl;
R4 represents hydrogen, lower alkyl, or halogen; and a N-oxide or a pharmaceutically acceptable salt of such a compound.
2. A compound of formula 1 according to claim 1 wherein i represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, carboxy- lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl;
R2 represents hydrogen, lower alkyl, optionally substituted by one or two identical or different radicals R3, cycloalkyl, benzcycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising one, two or three nitrogen atoms or one sulfur atom, which aryl and heteroaryl groups in each case are unsubstituted or mono- or polysubstituted; and
R3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N- mono- or N,N-disubstituted carbamoyl, amino, mono- or disubstituted amino, cycloalkyl, heterocyclyl, an aryl group, furanoyl, thienoyl, or a mono- or bicyclic heteroaryl group comprising one, two or three ring nitrogen atoms, zero or one ring oxygen atom and zero or one ring sulphur atom, which aryl and heteroaryl groups in each case are unsubstituted or mono- or polysubstituted; or wherein i and R2 together represent alkylene with four or five carbon atoms, optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms in the alkylene group; oxaalkylene with one oxygen and three or four carbon atoms, or azaalkylene with one nitrogen and three or four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N- disubstituted carbamoyl-lower alkyl, cycloalkyl, lower alkoxycarbonyl, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl;
R4 represents hydrogen, lower alkyl, or halogen; and a N-oxide or a pharmaceutically acceptable salt of such a compound.
3. A compound of formula I according to claim 1 wherein
RT represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl;
R2 represents hydrogen, lower alkyl, optionally substituted by one or two identical or different radicals R3, cyclopentyl, benzcyclopentyl, cylcohexyl, pyrrolidinyl, oxazolinyl, piperidinyl, N- substituted piperidinyl, morpholinyl, azepinyl, oxo-azepinyl, oxazepinyl, phenyl, naphthalinyl, tetrahydronaphthalinyl or a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which phenyl, naphthalinyl and heteroaryl groups in each case are unsubstituted or mono- or polysubstituted, thienyl, or lower alkoxycarbonyl-lower alkylthienyl; and
R3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N- mono- or N,N-disubstituted carbamoyl, amino, lower alkylamino, di-lower alkylamino, phenylamino, N-lower alkyl-N-phenylamino, pyrrolidino, oxopyrrolidino, piperidino, morpholino, imidazolino, oxoimidazolino, cycloalkyl, heterocyclyl, furyl, phenyl, naphthalinyl, tetrahydronaphthalinyl, or a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which phenyl, naphthalinyl and heteroaryl group are unsubstituted or mono- or polysubstituted; or wherein
Ri and R2 together represent alkylene with four or five carbon atoms, optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms in the alkylene group; oxaalkylene with one oxygen and four carbon atoms; or azaalkylene with one nitrogen and four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N-disubstituted carbamoyl- lower alkyl, cycloalkyl, lower alkoxycarbonyl, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl;
R represents hydrogen, lower alkyl, or halogen; and a N-oxide or a pharmaceutically acceptable salt of such a compound.
4. A compound of formula I according to claim 1 wherein
Ri represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl;
R2 represents hydrogen; lower alkyl, optionally substituted by one radical R3, by two phenyl groups, by two lower alkoycarbonyl groups, by phenyl and lower alkoxycarbonyl, or by hydroxyphenyl and lower alkoxycarbonyl; cyclopentyl; benzcyclopentyl; cylcohexyl; pyrrolidinyl; oxazolinyl; piperidinyl; N-lower alkylpiperidinyl; N-benzylpiperidinyl; N- pyrimidinylpiperidinyl; morpholinyl; azepinyl; oxo-azepinyl; oxazepinyl; phenyl, naphthalinyl, tetrahydronaphthalinyl or a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which phenyl, naphthalinyl and heteroaryl groups in each case are unsubstituted or substituted by one or two substituents selected from the group consisting of lower alkyl, trifluoro-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, amino- lower alkyl, lower alkylamino-lower alkyl, di-lower alkylamino-lower alkyl, N-cyclohexyl-N- lower alkylamino-lower alkyl, lower alkoxycarbonylpiperidino-lower alkyl, N-lower alkylpiperazino-lower alkyl, lower alkoxycarbonyl-lower alkyl, hydroxy, lower alkoxy, trifluoro-lower alkoxy, 1 H-imidazolyl-lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, lower alkyl carbamoyl, amino, lower alkanoylamino, benzoylamino, amino mono- or disubstituted by lower alkyl, by hydroxy-lower alkyl or by lower alkoxy-lower alkyl, 1 H-imidazolyl, mono- or di-lower alkyl-1 H-imidazolyl, pyrrolidino, piperidino, piperazino, N-lower alkylpiperazino, morpholino, sulfamoyl, lower alkylsulfonyl, phenylsulfonyl, lower alkylsulfinyl, phenylsulfinyl, lower alkylthio, phenylthio, phenyl, pyridyl, halogenyl, or benzoyl; thienyl; or lower alkoxycarbonyl-lower alkylthienyl; and
R3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, carbamoyl mono-or disubstituted by lower alkyl, phenyl or lower alkylene, amino, lower alkylamino, di-lower alkylamino, phenylamino, N-lower alkyl-N-phenylamino, pyrrolidino, oxopyrrolidino, piperidino, morpholino, imidazolino, oxoimidazolino, cycloalkyl, heterocyclyl, furyl; phenyl, naphthalinyl, tetrahydronaphthalinyl, or a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which phenyl, naphthalinyl and heteroaryl group is unsubstituted or substituted by one or two substituents selected from the group consisting of lower alkyl, trifluoro-lower alkyl, lower alkoxycarbonyl-lower alkyl, hydroxy, lower alkoxy, trifluoro-lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, amino, lower alkanoylamino, benzoylamino, amino mono- or disubstituted by lower alkyl, by hydroxy-lower alkyl or by loweralkoxy-lower alkyl, pyrrolidino, piperidino, morpholino, piperazino, N-lower alkylpiperazino, N-lower alkoxycarbonylpiperazino, phenyl, pyridyl, 1 H-imidazolyl, lower alkyl-1 H-imidazolyl, sulfamoyl, lower alkylsulfonyl, phenylsulfonyl, lower alkylsulfinyl, phenylsulfinyl, lower alkylthio, phenylthio, halogenyl, or benzoyl; or wherein
Ri and R2 together represent alkylene with four or five carbon atoms, optionally mono- or disubstituted by lower alkyl, cycloalkyl, phenyl, hydroxy, lower alkoxy, amino, benzoylamino, piperidino, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms in the alkylene group; oxaalkylene with one oxygen and four carbon atoms; or azaalkylene with one nitrogen and four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy- lower alkyl, carbamoyl-lower alkyl, carbamoyl-lower alkyl N-mono- or N,N-disubstituted by lower alkyl, phenyl, lower alkylene or oxa-lower alkylene, cycloalkyl, lower alkoxycarbonyl, phenyl, methoxyphenyl, trifluoromethylphenyl, trifluoromethoxyphenyl, pyridinyl, pyrimidinyl, or pyrazinyl; R4 represents hydrogen or lower alkyl; and a N-oxide or a pharmaceutically acceptable salt of such a compound.
5. A compound of formula I according to claim 1 wherein
Ri represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, or benzyl;
R2 represents lower alkyl, optionally substituted by one radical R3 , by two phenyl groups, by two lower alkoycarbonyl groups, by phenyl and lower alkoxycarbonyl, or by hydroxyphenyl and lower alkoxycarbonyl; cyclopentyl; benzcyclopentyl; cylcohexyl; pyrrolidinyl; piperidinyl; N-lower alkylpiperidinyl; N-benzylpiperidinyl; N-pyrimidinylpiperidinyl; morpholinyl; azepinyl; oxoazepinyl; phenyl; naphthalinyl; tetrahydronaphthalinyl; pyridyl; lower alkyl-pyridyl; quinolinyl; thienyl; lower alkoxycarbonylmethylthienyl; or phenyl substituted by one or two substituents selected from the group consisting of lower alkyl, trifluoro-lower alkyl, hydroxy- lower alkyl, amino-lower alkyl, lower alkylamino-lower alkyl, di-lower alkylamino-lower alkyl, N-cyclohexyl-N-lower alkylamino-lower alkyl, lower alkoxycarbonylpiperidino-lower alkyl, N- lower alkylpiperazino-lower alkyl, lower alkoxycarbonyl-lower alkyl, hydroxy, lower alkoxy, trifluoro-lower alkoxy, 1 H-imidazolyl-lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, amino, lower alkanoylamino, benzoylamino, amino mono- or disubstituted by lower alkyl, by hydroxy-lower alkyl or by loweralkoxy-lower alkyl, 1 H-imidazolyl, lower alkyl-1 H-imidazolyl, pyrrolidino, piperidino, piperazino, N-lower alkylpiperazino, morpholino, sulfamoyl, lower alkylsulfonyl, phenyl, pyridyl, halogenyl, or benzoyl; and
R3 represents hydroxy, lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, amino, lower alkylamino, di-lower alkylamino, phenylamino, N- lower alkyl-N-phenylamino, pyrrolidino, oxopyrrolidino, piperidino, morpholino, imidazolino, oxoimidazolino, cyclopropyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, phenyl, naphthalinyl, tetrahydronaphthalinyl, furyl, a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which heteroaryl group is unsubstituted or mono- or disubstituted by lower alkyl, hydroxy and lower alkoxy, or phenyl substituted by one or two substituents selected from the group consisting of lower alkyl, trifluoro-lower alkyl, lower alkoxycarbonyl-lower alkyl, hydroxy, lower alkoxy, trifluoro-lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, amino, lower alkanoylamino, benzoylamino, amino mono- or disubstituted by lower alkyl, by hydroxy-lower alkyl or by loweralkoxy-lower alkyl, pyrrolidino, piperidino, morpholino, piperazino, N-lower alkylpiperazino, N-lower alkoxycarbonylpiperazino, phenyl, pyridyl, 1 H-imidazolyl, lower alkyl-1 H-imidazolyl, sulfamoyl, lower alkylsulfonyl, halogenyl, or benzoyl; or wherein
Ri and R2 together represent alkylene with four or five carbon atoms, optionally mono- or disubstituted by phenyl, hydroxy, amino, benzoylamino, or piperidino; benzalkylene with four or five carbon atoms in the alkylene group; oxaalkylene with one oxygen and four carbon atoms; or azaalkylene with one nitrogen and four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carbamoyl-lower alkyl, pyrrolidinocarbonyl-lower alkyl, morpholinocarbonyl-lower alkyl, cyclopentyl, lower alkoxycarbonyl, phenyl, methoxyphenyl, trifluoromethylphenyl, pyridinyl; pyrimidinyl, or pyrazinyl;
R4 represents hydrogen or methyl; and a N-oxide or a pharmaceutically acceptable salt of such a compound.
6. A compound of formula I according to claim 1 wherein Ri represents hydrogen;
R2 represents phenyl substituted by trifluoromethyl and optionally a further substituent selected from the group consisting of hydroxy-lower alkyl, lower alkylamino, hydroxy-lower alkylamino, di-lower alkylamino, 1 H-imidazolyl, lower alkyl-1 H-imidazolyl, carbamoyl, lower alkylcarbamoyl, pyrrolidino, piperidino, piperazino, lower alkylpiperazino, morpholino, lower alkoxy, trifluoro-lower alkoxy, phenyl, pyridyl, and halogenyl;
R4 represents methyl; and a N-oxide or a pharmaceutically acceptable salt of such a compound.
7. A compound of formula I according to claim 1 wherein Ri represents hydrogen;
R2 represents phenyl substituted by 3-trifluoromethyl and optionally a further substituent selected from the group consisting of 1-hydroxy-1-methylethyl, methylamino, ethylamino, 2- hydroxy-1 -propylamino, 2-hydroxy-2-propylamino, diethylamino, 1 H-imidazolyl, 2- and 4- methyl-1 H-imidazolyl, carbamoyl, methylcarbamoyl, pyrrolidino, piperidino, piperazino, 4- methylpiperazino, morpholino, methoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenyl, 2-, 3- and 4-pyridyl, chloro, and fluoro;
R represents methyl; and a N-oxide or a pharmaceutically acceptable salt of such a compound.
8. The compound of formula I according to claim 1 wherein R-i represents hydrogen;
R2 represents 3-(1 -hydroxy-1 -methylethyl)-5-(trif luoromethyl)phenyl;
R4 represents methyl; and a N-oxide or a pharmaceutically acceptable salt of such a compound.
9. A compound according to any one of claim 1 wherein Ri is hydrogen;
R2 represents phenyl which is mono- or disubstituted by imidazol-lower alkoxy, lower alkyl amino, trifluoromethyl, hydroxy lower alkyl amino, bis-(lower alkoxy lower alkyl) amino, lower alkyl piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, phenyl, pyridyl, imidazolyl which is unsubstituted or mono- or disubstituted by lower alkyl or N-lower alkyl carbamoyl;
R4 is lower alkyl; and a N-oxide or a pharmaceutically acceptable salt of such a compound.
10. A compound of formula
Figure imgf000078_0001
wherein R4 is methyl or hydrogen.
11. A process for the synthesis of a compound of the formula
Figure imgf000079_0001
or an N-oxide or a salt thereof, wherein the symbols R^ R2 and R4 are as defined in claim 1 , characterized in that a compound of formula II
Figure imgf000079_0002
wherein R4 is as defined for a compound of formula I, or a derivative thereof wherein the carboxy group -COOH is in activated form, is reacted with an amine of the formula III
R NH-R2 (III)
wherein RT and R2 are as defined for a compound of the formula I, optionally in the presence of a dehydrating agent and an inert base and/or a suitable catalyst, and optionally in the presence of an inert solvent; where the above starting compounds II and III may also be present with functional groups in protected form if necessary and/or in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible; any protecting groups in a protected derivative of a compound of the formula I are removed; and, if so desired, an obtainable compound of formula I is converted into another compound of formula I or a N-oxide thereof, a free compound of formula I is converted into a salt, an obtainable salt of a compound of formula I is converted into the free compound or another salt, and/or a mixture of isomeric compounds of formula I is separated into the individual isomers.
12. A pharmaceutical composition comprising as an active ingredient a compound of formula I according to any one of claims 1 to 10 or a N-oxide or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.
13. A method for the treatment of a disease which responds to an inhibition of protein kinase activity, which comprises administering a compound of formula I according to any one of claims 1 to 10 or a N-oxide or a pharmaceutically acceptable salt thereof.
14. The use of a compound of formula I according to any one of claims 1 to 10 or a N-oxide or a possible tautomer thereof or of a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of a disease which responds to an inhibition of protein kinase activity.
PCT/EP2003/007198 2002-07-05 2003-07-04 Inhibitors of tyrosine kinases WO2004005281A1 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
GBGB0215676.8A GB0215676D0 (en) 2002-07-05 2002-07-05 Organic compounds
CA002491632A CA2491632C (en) 2002-07-05 2003-07-04 Pyrimidinylaminobenzamide derivatives and their use as inhibitors of tyrosine kinases
US10/520,359 US7169791B2 (en) 2002-07-05 2003-07-04 Inhibitors of tyrosine kinases
BRPI0312464A BRPI0312464B8 (en) 2002-07-05 2003-07-04 tyrosine kinase inhibitor compounds, pharmaceutical compositions comprising them, processes for manufacturing and uses thereof
CNA2007101077481A CN101045727A (en) 2002-07-05 2003-07-04 Inhibitors of tyrosine kinases
KR1020057000159A KR100733639B1 (en) 2002-07-05 2003-07-04 Inhibitors of tyrosine kinases
NZ537396A NZ537396A (en) 2002-07-05 2003-07-04 Inhibitors of tyrosine kinases
AU2003249962A AU2003249962C9 (en) 2002-07-05 2003-07-04 Inhibitors of tyrosine kinases
JP2004518718A JP4110140B2 (en) 2002-07-05 2003-07-04 Inhibitor of tyrosine kinase
MXPA05000328A MXPA05000328A (en) 2002-07-05 2003-07-04 Inhibitors of tyrosine kinases.
DE60324805T DE60324805D1 (en) 2002-07-05 2003-07-04 INHIBITORS OF TYROSINE KINASES
SI200331512T SI1532138T1 (en) 2002-07-05 2003-07-04 Inhibitors of tyrosine kinases
DK03762632T DK1532138T3 (en) 2002-07-05 2003-07-04 Inhibitors of tyrosine kinases
EP03762632A EP1532138B1 (en) 2002-07-05 2003-07-04 Inhibitors of tyrosine kinases
ZA200410322A ZA200410322B (en) 2002-07-05 2004-12-22 Inhibitors of tyrosine kinases
IL165977A IL165977A (en) 2002-07-05 2004-12-23 Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
NO20050636A NO331166B1 (en) 2002-07-05 2005-02-04 Inhibitors of tyrosine kinases, process for their preparation, pharmaceutical preparation and use of the compounds
HK05109671.2A HK1077811A1 (en) 2002-07-05 2005-10-31 Inhibitors of tyrosine kinases
US11/607,542 US20070093506A1 (en) 2002-07-05 2006-12-01 Inhibitors of tyrosine kinases
US12/061,334 US7569566B2 (en) 2002-07-05 2008-04-02 Inhibitors of tyrosine kinases
IL198996A IL198996A (en) 2002-07-05 2009-05-27 Use of an inhibitor of tyrosine kinases for preparation of a pharmaceutical composition
US12/489,049 US7956053B2 (en) 2002-07-05 2009-06-22 Inhibitors of tyrosine kinases
US13/106,582 US20110218187A1 (en) 2002-07-05 2011-05-12 Inhibitors of tyrosine kinases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0215676.8A GB0215676D0 (en) 2002-07-05 2002-07-05 Organic compounds
GB0215676.8 2002-07-05
GBGB0229893.3A GB0229893D0 (en) 2002-07-05 2002-12-20 Organic compounds
GB0229893.3 2002-12-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10520359 A-371-Of-International 2003-07-04
US11/607,542 Continuation US20070093506A1 (en) 2002-07-05 2006-12-01 Inhibitors of tyrosine kinases

Publications (2)

Publication Number Publication Date
WO2004005281A1 true WO2004005281A1 (en) 2004-01-15
WO2004005281A8 WO2004005281A8 (en) 2004-05-06

Family

ID=32178870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/007198 WO2004005281A1 (en) 2002-07-05 2003-07-04 Inhibitors of tyrosine kinases

Country Status (31)

Country Link
US (5) US7169791B2 (en)
EP (4) EP2368889A1 (en)
JP (4) JP4110140B2 (en)
KR (2) KR100864740B1 (en)
CN (2) CN1324022C (en)
AR (1) AR040390A1 (en)
AT (1) ATE414699T1 (en)
AU (1) AU2003249962C9 (en)
BR (1) BRPI0312464B8 (en)
CA (3) CA2677315C (en)
CO (1) CO5680432A2 (en)
CY (1) CY1108813T1 (en)
DE (1) DE60324805D1 (en)
DK (1) DK1532138T3 (en)
EC (1) ECSP055525A (en)
ES (2) ES2318164T3 (en)
GB (2) GB0215676D0 (en)
HK (2) HK1077811A1 (en)
IL (2) IL165977A (en)
MX (1) MXPA05000328A (en)
MY (1) MY143466A (en)
NO (1) NO331166B1 (en)
NZ (1) NZ537396A (en)
PE (1) PE20040647A1 (en)
PL (3) PL406680A1 (en)
PT (2) PT2357182E (en)
RU (2) RU2348627C2 (en)
SI (1) SI1532138T1 (en)
TW (1) TWI313603B (en)
WO (1) WO2004005281A1 (en)
ZA (1) ZA200410322B (en)

Cited By (305)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039586A1 (en) * 2003-10-27 2005-05-06 Novartis Ag Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders
WO2005049032A1 (en) * 2003-11-18 2005-06-02 Novartis Ag Inhibitors of the mutant form of kit
WO2005063720A1 (en) * 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. Amide derivative and medicine
WO2005113494A2 (en) * 2004-05-07 2005-12-01 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
WO2006069525A1 (en) * 2004-12-31 2006-07-06 Piaoyang Sun Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
WO2006079539A2 (en) * 2005-01-28 2006-08-03 Novartis Ag Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
WO2006089781A1 (en) * 2005-02-25 2006-08-31 Novartis Ag Pharmaceutical combination of bcr-abl and raf inhibitors
WO2006119154A1 (en) 2005-05-02 2006-11-09 Novartis Ag Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis
WO2006117185A1 (en) * 2005-05-02 2006-11-09 Novartis Ag Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
WO2006132930A1 (en) * 2005-06-03 2006-12-14 Novartis Ag Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
WO2006135641A2 (en) * 2005-06-09 2006-12-21 Novartis Ag PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE
WO2006135640A2 (en) 2005-06-09 2006-12-21 Novartis Ag Process for the synthesis of organic compounds
WO2006135619A1 (en) * 2005-06-09 2006-12-21 Novartis Ag Process for the synthesis of 5- (methyl- 1h-imidazol-1-yl) -3- (trifluoromethyl) -benzeneamine
WO2007010013A2 (en) * 2005-07-20 2007-01-25 Novartis Ag Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases
WO2007010012A2 (en) * 2005-07-20 2007-01-25 Novartis Ag Combination of a pyrimidylaminobenzamide and an mtor kinase inhibitor
KR100674813B1 (en) * 2005-08-05 2007-01-29 일양약품주식회사 N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
WO2007015870A2 (en) 2005-07-20 2007-02-08 Novartis Ag Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
WO2007015871A1 (en) 2005-07-20 2007-02-08 Novartis Ag Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
WO2007022044A2 (en) * 2005-08-11 2007-02-22 Novartis Ag Combination of organic compounds
WO2007022042A2 (en) * 2005-08-11 2007-02-22 Novartis Ag Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
WO2007042465A2 (en) * 2005-10-07 2007-04-19 Novartis Ag Combinati0n of nilotinib with farnesyl transferase inhibitors
WO2007051862A1 (en) * 2005-11-07 2007-05-10 Novartis Ag Combination of organic compounds
WO2007065898A1 (en) 2005-12-06 2007-06-14 Novartis Ag Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
WO2007137981A1 (en) * 2006-05-25 2007-12-06 Novartis Ag Inhibitors of tyrosine kinases
EP1885352A2 (en) * 2004-11-24 2008-02-13 Novartis AG Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008058037A1 (en) * 2006-11-03 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2008137605A1 (en) * 2007-05-04 2008-11-13 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
WO2007116029A3 (en) * 2006-04-07 2008-12-11 Novartis Ag Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
WO2008153974A1 (en) 2007-06-07 2008-12-18 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
JP2008546698A (en) * 2005-06-14 2008-12-25 タイゲン バイオテクノロジー カンパニー，リミテッド Pyrimidine compounds
EP2012787A2 (en) * 2006-04-05 2009-01-14 Novartis AG Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
WO2009082662A1 (en) 2007-12-21 2009-07-02 Novartis Ag Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia
EP2100874A1 (en) * 2006-11-13 2009-09-16 Toray Fine Chemicals Co., Ltd. Process for production of 2,2'-bis(trifluoromethyl)- 4,4'-diaminobiphenyl
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
WO2010019540A1 (en) * 2008-08-13 2010-02-18 Novartis Ag Treatment of pulmonary arterial hypertension
WO2010018895A1 (en) * 2008-08-14 2010-02-18 Il-Yang Pharm. Co., Ltd. Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives
WO2010054056A2 (en) * 2008-11-05 2010-05-14 Teva Pharmaceutical Industries Ltd. Nilotinib hci crystalline forms
EP2186514A1 (en) 2008-11-14 2010-05-19 Novartis AG Treatment of Malignant Peripheral Nerve Sheath Tumors
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
WO2010072776A1 (en) 2008-12-23 2010-07-01 Boehringer Ingelheim International Gmbh Salt forms of organic compound
WO2010079197A1 (en) 2009-01-07 2010-07-15 Boehringer Ingelheim International Gmbh Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2010086411A1 (en) 2009-01-29 2010-08-05 Boehringer Ingelheim International Gmbh Dpp-iv inhibitors for treatment of diabetes in paediatric patients
WO2010092163A2 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
WO2010100248A1 (en) 2009-03-06 2010-09-10 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)
US7795279B2 (en) 2005-10-18 2010-09-14 Janssen Pharmaceutica Nv Method of inhibiting FLT3 kinase
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US7834022B2 (en) 2007-06-13 2010-11-16 Incyte Corporation Metabolites of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP2251042A2 (en) 2006-09-22 2010-11-17 Novartis AG Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
WO2010135621A1 (en) 2009-05-22 2010-11-25 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
WO2010141427A1 (en) 2009-06-02 2010-12-09 Novartis Ag Treatment of ophthalmologic disorders mediated by albha-carbonic anhydrase isoforms
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
WO2011008487A1 (en) 2009-06-29 2011-01-20 Incyte Corporation Pyrimidinones as pi3k inhibitors
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011033307A1 (en) 2009-09-17 2011-03-24 Generics [Uk] Limited Nilotinib dihydrochloride salt
WO2011039367A2 (en) 2009-10-02 2011-04-07 Boehringer Ingelheim International Gmbh Therapeutic uses of pharmaceutical compositions
WO2011044001A1 (en) 2009-10-09 2011-04-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2011044481A1 (en) 2009-10-09 2011-04-14 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2011050120A1 (en) 2009-10-23 2011-04-28 Novartis Ag Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
WO2011062927A1 (en) 2009-11-17 2011-05-26 Novartis Ag Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
WO2011064352A1 (en) 2009-11-27 2011-06-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011067306A1 (en) 2009-12-03 2011-06-09 Novartis Ag Cyclohexane derivatives as inhibitors of acetyl-coa carboxylase (acc)
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
EP2343298A1 (en) 2005-12-13 2011-07-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
WO2011083124A1 (en) 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists for the treatment or the prevention of pain disorders
WO2011086085A1 (en) 2010-01-12 2011-07-21 Ab Science Thiazole and oxazole kinase inhibitors
WO2011086541A1 (en) 2010-01-15 2011-07-21 Generics [Uk] Limited Novel polymorph of nilotinib monohydrochloride monohydrate
WO2011103423A1 (en) 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
WO2011112662A1 (en) 2010-03-10 2011-09-15 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CN101184748B (en) * 2005-06-09 2011-09-28 诺瓦提斯公司 Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
WO2011128434A2 (en) 2010-04-16 2011-10-20 Novartis Ag Treatment of endocrine resistant breast cancer
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
EP2385035A1 (en) * 2008-12-25 2011-11-09 Harbin Gloria Pharmaceuticals Co., Ltd. Preparation method of dihydroindene amide compounds their pharmaceutical compositions containg compounds thereof and use as protein kinases inhibitor
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
WO2011146808A2 (en) 2010-05-21 2011-11-24 Incyte Corporation Topical formulation for a jak inhibitor
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
CN102321073A (en) * 2011-08-12 2012-01-18 西安交通大学 Preparation method of nilotinib
WO2012013716A1 (en) 2010-07-29 2012-02-02 Novartis Ag Bicyclic acetyl-coa carboxylase inhibitors
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8182792B2 (en) 2004-03-23 2012-05-22 Novartis Ag Pharmaceutical compositions
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
WO2012065993A1 (en) 2010-11-15 2012-05-24 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AU2011202833B2 (en) * 2006-04-07 2012-05-24 Novartis Ag Combination comprising a) a pyrimidylaminobenzamide compound, and b) a Thr315lle kinase inhibitor
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
US8288540B2 (en) 2007-08-22 2012-10-16 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
US8293757B2 (en) 2007-08-22 2012-10-23 Irm Llc 5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
US8309718B2 (en) 2007-11-16 2012-11-13 Incyte Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
US8338417B2 (en) 2007-05-04 2012-12-25 Irm Llc Compounds and compositions as c-kit and PDGFR kinase inhibitors
WO2012177606A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8367686B2 (en) 2007-06-07 2013-02-05 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
WO2013026025A1 (en) 2011-08-18 2013-02-21 Incyte Corporation Cyclohexyl azetidine derivatives as jak inhibitors
WO2013033569A1 (en) 2011-09-02 2013-03-07 Incyte Corporation Heterocyclylamines as pi3k inhibitors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063000A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013068836A1 (en) 2011-11-07 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
US20130158059A1 (en) * 2010-06-21 2013-06-20 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof
WO2013098372A1 (en) 2011-12-29 2013-07-04 Boehringer Ingelheim International Gmbh Subcutaneous therapeutic use of dpp-4 inhibitor
US8481564B2 (en) 2006-04-20 2013-07-09 Janssen Pharmaceutica, N.V. Inhibitors of c-fms kinase
US8497376B2 (en) 2007-10-17 2013-07-30 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
EP2626355A1 (en) 2012-02-09 2013-08-14 Natco Pharma Limited Process for the preparation of nilotinib hydrochloride
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
US20130245052A1 (en) * 2010-11-26 2013-09-19 Hetero Research Foundation Novel polymorph of nilotinib hydrochloride
WO2013151930A1 (en) 2012-04-02 2013-10-10 Incyte Corporation Bicyclic azaheterocyclobenzylamines as pi3k inhibitors
US8557830B2 (en) 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use
US8557847B2 (en) 2005-06-10 2013-10-15 Janssen Pharmaceutica, N.V. Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor
WO2013161853A1 (en) 2012-04-24 2013-10-31 中外製薬株式会社 Quinazolinedione derivative
WO2013161851A1 (en) 2012-04-24 2013-10-31 中外製薬株式会社 Benzamide derivative
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2013171642A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013171640A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
WO2013171639A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174768A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014011284A1 (en) 2012-07-11 2014-01-16 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
WO2014060449A1 (en) * 2012-10-19 2014-04-24 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
WO2014071031A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
US8722718B2 (en) 2006-04-20 2014-05-13 Janssen Pharmaceutica Nv Inhibitors of C-FMS kinase
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2014107209A2 (en) 2013-01-07 2014-07-10 Arog Pharmaceuticals, Llc Crenolanib for treating flt3 mutated proliferative disorders
US20140227260A1 (en) * 2009-06-09 2014-08-14 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
WO2014134426A1 (en) 2013-03-01 2014-09-04 Incyte Corporation USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2014186706A1 (en) 2013-05-17 2014-11-20 Incyte Corporation Bipyrazole derivatives as jak inhibitors
AU2012203844B2 (en) * 2005-07-20 2014-12-11 Novartis Ag Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
WO2015026818A1 (en) 2013-08-20 2015-02-26 Incyte Corporation Survival benefit in patients with solid tumors with elevated c-reactive protein levels
KR20150027158A (en) * 2012-06-05 2015-03-11 길리어드 파마셋 엘엘씨 Synthesis of antiviral compound
WO2015060373A1 (en) 2013-10-23 2015-04-30 中外製薬株式会社 Quinazolinone and isoquinolinone derivative
US9023880B2 (en) 2012-09-21 2015-05-05 Arog Pharmaceuticals, Llc Method of inhibiting constitutively active phosphorylated FLT3 kinase
US9029352B2 (en) 2012-08-07 2015-05-12 Janssen Pharmaceutica Nv Process for the preparation of C-FMS kinase inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
WO2015131031A1 (en) 2014-02-28 2015-09-03 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015157257A1 (en) 2014-04-08 2015-10-15 Incyte Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
WO2015168246A1 (en) 2014-04-30 2015-11-05 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
AU2013205820B2 (en) * 2005-06-09 2015-11-26 Novartis Ag Process for the synthesis of organic compounds
WO2016016370A1 (en) 2014-07-31 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists
EP2990037A1 (en) 2008-08-06 2016-03-02 Boehringer Ingelheim International GmbH Treatment for diabetes in patients inappropriate for metformin therapy
WO2016035023A1 (en) 2014-09-03 2016-03-10 Novartis Ag Pharmaceutical combinations and their use
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
US9303046B2 (en) 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
WO2016057841A1 (en) 2014-10-08 2016-04-14 Novartis Ag Compositions and methods of use for augmented immune response and cancer therapy
US9315489B2 (en) 2012-05-15 2016-04-19 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
EP3042655A1 (en) 2008-10-02 2016-07-13 Incyte Holdings Corporation Janus kinase inhibitors for treatment of dry eye and other eye related diseases
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
WO2016138363A1 (en) 2015-02-27 2016-09-01 Incyte Corporation Salts of pi3k inhibitor and processes for their preparation
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183062A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
EP3095782A1 (en) 2015-05-18 2016-11-23 Esteve Química, S.A. New method for preparing 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017079519A1 (en) 2015-11-06 2017-05-11 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017120194A1 (en) 2016-01-05 2017-07-13 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
US9714233B2 (en) 2013-03-06 2017-07-25 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9718834B2 (en) 2011-09-07 2017-08-01 Incyte Corporation Processes and intermediates for making a JAK inhibitor
WO2017211937A1 (en) 2016-06-08 2017-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2018198076A1 (en) 2017-04-28 2018-11-01 Aduro Biotech, Inc. Bis 2'-5'-rr-(3'f-a)(3'f-a) cyclic dinucleotide compound and uses thereof
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
EP3501505A1 (en) 2017-12-20 2019-06-26 Zentiva K.S. A drug form comprising crystalline nilotinib
WO2019126505A1 (en) 2017-12-21 2019-06-27 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
EP3514179A1 (en) 2014-01-24 2019-07-24 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
WO2019191684A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
US10472419B2 (en) 2014-01-31 2019-11-12 Novartis Ag Antibody molecules to TIM-3 and uses thereof
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
WO2019226213A2 (en) 2018-03-08 2019-11-28 Incyte Corporation AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
WO2019227007A1 (en) 2018-05-25 2019-11-28 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
WO2019229658A1 (en) 2018-05-30 2019-12-05 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
JP2020007240A (en) * 2018-07-04 2020-01-16 住友化学株式会社 Method for producing benzamide compound
WO2020016232A1 (en) 2018-07-17 2020-01-23 Boehringer Ingelheim International Gmbh Cardiosafe antidiabetic therapy
WO2020016230A1 (en) 2018-07-17 2020-01-23 Boehringer Ingelheim International Gmbh Cardio- and renosafe antidiabetic therapy
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3626238A1 (en) 2008-08-15 2020-03-25 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020146237A1 (en) 2019-01-07 2020-07-16 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020159905A1 (en) 2019-01-29 2020-08-06 Incyte Corporation Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
WO2020168178A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US10894830B2 (en) 2015-11-03 2021-01-19 Janssen Biotech, Inc. Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
WO2021022172A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2021041360A1 (en) 2019-08-26 2021-03-04 Incyte Corporation Triazolopyrimidines as a2a / a2b inhibitors
US10940149B1 (en) 2018-06-15 2021-03-09 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021074138A1 (en) * 2019-10-14 2021-04-22 Esco Aster Pte. Ltd. Synthesis of 6-methyl-n1-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US11014923B2 (en) 2015-02-20 2021-05-25 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11078541B2 (en) 2016-11-02 2021-08-03 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
WO2021155254A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
US11091466B2 (en) 2017-03-17 2021-08-17 Cardio Therapeutics Pty Ltd Heterocyclic inhibitors of PCSK9
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
WO2021211864A1 (en) 2020-04-16 2021-10-21 Incyte Corporation Fused tricyclic kras inhibitors
EP3904342A1 (en) 2020-04-28 2021-11-03 Grindeks, A Joint Stock Company Process for the preparation of 3-(trifluoromethyl)-5-(4-methyl-1h-imidazole-1-yl)-benzeneamine hydrochloride
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
CN113717152A (en) * 2021-09-08 2021-11-30 上海皓鸿生物医药科技有限公司 Preparation method of specific MRK small molecule inhibitor
US11186580B2 (en) 2018-09-05 2021-11-30 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
US11192868B2 (en) 2005-05-10 2021-12-07 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2021247668A1 (en) 2020-06-02 2021-12-09 Incyte Corporation Processes of preparing a jak1 inhibitor
US11207302B2 (en) 2008-07-08 2021-12-28 Incyte Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
WO2022061351A1 (en) 2020-09-16 2022-03-24 Incyte Corporation Topical treatment of vitiligo
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11530214B2 (en) 2013-04-19 2022-12-20 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
WO2023283213A1 (en) 2021-07-07 2023-01-12 Incyte Corporation Tricyclic compounds as inhibitors of kras
WO2023287896A1 (en) 2021-07-14 2023-01-19 Incyte Corporation Tricyclic compounds as inhibitors of kras
US11590138B2 (en) 2019-06-10 2023-02-28 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2023034290A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
WO2023056421A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
WO2023091746A1 (en) 2021-11-22 2023-05-25 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
WO2023102184A1 (en) 2021-12-03 2023-06-08 Incyte Corporation Bicyclic amine compounds as cdk12 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
WO2023122134A1 (en) 2021-12-22 2023-06-29 Incyte Corporation Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
WO2023116884A1 (en) 2021-12-24 2023-06-29 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
WO2023172921A1 (en) 2022-03-07 2023-09-14 Incyte Corporation Solid forms, salts, and processes of preparation of a cdk2 inhibitor
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11833152B2 (en) 2018-02-16 2023-12-05 Incyte Corporation JAK1 pathway inhibitors for the treatment of cytokine-related disorders
WO2023245053A1 (en) 2022-06-14 2023-12-21 Incyte Corporation Solid forms of a jak inhibitor and process of preparing the same
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
WO2024015731A1 (en) 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
WO2024030600A1 (en) 2022-08-05 2024-02-08 Incyte Corporation Treatment of urticaria using jak inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11957661B2 (en) 2020-12-08 2024-04-16 Incyte Corporation JAK1 pathway inhibitors for the treatment of vitiligo
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
EP4364796A2 (en) 2013-03-15 2024-05-08 Boehringer Ingelheim International GmbH Use of linagliptin in cardio- and renoprotective antidiabetic therapy
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12029740B2 (en) 2022-07-18 2024-07-09 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2007059143A2 (en) * 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof
US20090306094A1 (en) * 2006-03-17 2009-12-10 Bristol-Myers Squibb Company Methods Of Identifying And Treating Individuals Exhibiting Mutant Bcr/Abl Kinase Polypeptides
EP2105442A4 (en) * 2006-12-21 2013-01-23 Astellas Pharma Inc Method for producing c-glycoside derivative and synthetic intermediate thereof
US8242271B2 (en) * 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
PT2200436E (en) 2007-09-04 2015-04-29 Scripps Research Inst Substituted pyrimidinyl-amines as protein kinase inhibitors
CN102316738A (en) * 2009-02-18 2012-01-11 盛泰萨路申有限公司 Amides as kinase inhibitors
BRPI1012159B1 (en) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compounds derived from n-(hetero)aryl-pyrrolidine of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors, compositions pharmaceuticals comprising said compounds and uses thereof
US8426418B2 (en) 2010-08-27 2013-04-23 CollabRx Inc. Method to treat melanoma in BRAF inhibitor-resistant subjects
CN103502217B (en) 2011-01-21 2015-11-25 太阳医药高级研究有限公司 Comprise the diaryl acetylene hydrazides of tyrosine kinase inhibitor
WO2012118599A1 (en) 2011-02-28 2012-09-07 Emory University C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication
EP2717883B1 (en) 2011-05-02 2017-03-22 Stichting VUmc Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg)
GB2496135B (en) 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis
BR112014011518A2 (en) * 2011-11-14 2017-05-16 Novartis Ag immediate release of the formulation 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoromethyl ) phenyl] benzamide
CN103172617A (en) * 2011-12-20 2013-06-26 天津市国际生物医药联合研究院 Application of 1,5-2 substituent-1,2,3-triazole trifluoromethyl compound
RU2650501C2 (en) 2012-03-01 2018-04-16 Эррэй Биофарма Инк. Serine/threonine kinase inhibitors
WO2014018932A2 (en) 2012-07-27 2014-01-30 Bunt Antonius Martinus Gustave Effluz inhibitor compositions and methods of treatment using the same
CN103910714A (en) * 2013-01-09 2014-07-09 天津泰瑞倍药研科技有限公司 Fluoro cyclobutyl imidazole compound
EP2988729A1 (en) 2013-04-25 2016-03-02 Sun Pharmaceutical Industries Limited Pharmaceutical gastro-retentive solid oral dosage form of nilotinib
GB2513615A (en) 2013-05-01 2014-11-05 Cancer Rec Tech Ltd Medical use
CN103288804A (en) * 2013-05-24 2013-09-11 苏州明锐医药科技有限公司 Preparation method of nilotinib
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2016033304A1 (en) 2014-08-28 2016-03-03 Codexis, Inc. Imidazoyl anilide derivatives and methods of use
CN104592122B (en) * 2014-12-09 2018-01-23 凯莱英医药集团（天津）股份有限公司 The preparation method of 3 (base of 4 methyl 1H imidazoles 1) 5 (trifluoromethyl) aniline
CN105985293B (en) * 2015-03-04 2018-04-03 埃斯特维华义制药有限公司 The preparation method of AMN107 intermediate
WO2016151304A1 (en) 2015-03-20 2016-09-29 Cipla Limited Novel polymorphic form x of nilotinib dihydrochloride hydrate
CN104860929B (en) * 2015-05-26 2017-10-31 凯莱英医药集团（天津）股份有限公司 The preparation method of AMN107
CN106905298A (en) * 2015-12-22 2017-06-30 江苏先声药业有限公司 The preparation method of hydrochloric acid AMN107 impurity
WO2017147700A1 (en) 2016-03-01 2017-09-08 Ontario Institute For Cancer Research (Oicr) Inhibitors of wdr5 protein-protein binding
EP3423437A4 (en) 2016-03-01 2019-07-24 Propellon Therapeutics Inc. Inhibitors of wdr5 protein-protein binding
CN105801559B (en) * 2016-04-28 2019-03-01 北京化工大学 The preparation method of 4- methyl -3- [[4- (3- pyridyl group) -2- pyrimidine radicals] amino] ethyl benzoate
WO2018002958A1 (en) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
US11426406B2 (en) 2017-02-09 2022-08-30 Georgetown University Compositions and methods for treating lysosomal storage disorders
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CN107188887A (en) * 2017-06-15 2017-09-22 苏州立新制药有限公司 A kind of AMN107 oxidative degradation impurity and preparation method thereof
CN108530364B (en) 2018-04-10 2020-01-21 江苏创诺制药有限公司 Crystal form of 3- (4-methyl-1H-imidazole-1-yl) -5-trifluoromethyl aniline monohydrochloride and application thereof
JP2020002108A (en) * 2018-06-29 2020-01-09 住友化学株式会社 Manufacturing method of benzoic acid compound
JPWO2020130125A1 (en) 2018-12-21 2021-11-04 第一三共株式会社 Combination of antibody-drug conjugate and kinase inhibitor
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US20230075170A1 (en) 2020-02-15 2023-03-09 Cipla Limited Novel salts of nilotinib and polymorphic forms thereof
CN112745300A (en) * 2021-01-21 2021-05-04 杭州浙中医药科技有限公司 Method for preparing N- (5-carboxyl-2-methylphenyl) -4- (3-pyridine) -2-pyrimidinamine
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0588762A1 (en) * 1992-08-31 1994-03-23 Ciba-Geigy Ag Use of pyrimidine derivatives as inhibitors of proteinkinase C and antitumor drugs
WO1995009853A1 (en) * 1993-10-01 1995-04-13 Ciba-Geigy Ag Pharmacologically active pyridine derivatives and processes for the preparation thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3524519A1 (en) 1984-07-11 1986-01-16 Mitsubishi Chemical Industries Ltd., Tokio/Tokyo Dyes for heat-sensitive sublimation transfer recording
US4788195A (en) * 1986-01-13 1988-11-29 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
US4871372A (en) 1987-07-17 1989-10-03 Kao Corporation Dye composition for keratinous fiber
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (en) * 1992-04-03 1994-06-21 Ciba Geigy Ag
EP0654529B1 (en) * 1993-03-29 2007-05-23 Kyowa Hakko Kogyo Kabushiki Kaisha alpha-2,8-SIALYLTRANSFERASE
JPH10182459A (en) 1996-12-26 1998-07-07 Otsuka Pharmaceut Co Ltd Cgmp phosphodiesterase inhibitor
JP2002179651A (en) 1998-06-19 2002-06-26 Wakamoto Pharmaceut Co Ltd Benzanilide derivative and medicine composition
EP3222619A1 (en) 1999-04-15 2017-09-27 Bristol-Myers Squibb Holdings Ireland Cyclic protein tyrosine kinase inhibitors
ES2234662T3 (en) 1999-09-16 2005-07-01 Curis, Inc. HEDGEHOG SIGNALING ROUTE MEDIATORS, COMPOSITIONS AND USES RELATED TO THEMSELVES.
DE60131138T2 (en) 2000-01-13 2008-08-14 Amgen Inc., Thousand Oaks ANTIBACTERIAL AGENTS
HN2001000008A (en) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals AMIDA COMPOSITE AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINASES, AND THE INSTRUCTIONS FOR USE
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
CN100343237C (en) * 2002-06-28 2007-10-17 日本新药株式会社 Amide derivative and medicine
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0588762A1 (en) * 1992-08-31 1994-03-23 Ciba-Geigy Ag Use of pyrimidine derivatives as inhibitors of proteinkinase C and antitumor drugs
WO1995009853A1 (en) * 1993-10-01 1995-04-13 Ciba-Geigy Ag Pharmacologically active pyridine derivatives and processes for the preparation thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PAUL R ET AL: "Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 36, no. 19, 17 September 1993 (1993-09-17), pages 2716 - 2725, XP002134022, ISSN: 0022-2623 *
ZIMMERMANN J ET AL: "Phenylamino-pyrimidine (PAP) - derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 6, no. 11, 4 June 1996 (1996-06-04), pages 1221 - 1226, XP004134858, ISSN: 0960-894X *
ZIMMERMANN J ET AL: "Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 7, no. 2, 21 January 1997 (1997-01-21), pages 187 - 192, XP004135990, ISSN: 0960-894X *

Cited By (716)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687512B2 (en) 2003-10-27 2010-03-30 Novartis Ag Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders
WO2005039586A1 (en) * 2003-10-27 2005-05-06 Novartis Ag Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders
US8017621B2 (en) 2003-11-18 2011-09-13 Novartis Ag Inhibitors of the mutant form of kit
WO2005049032A1 (en) * 2003-11-18 2005-06-02 Novartis Ag Inhibitors of the mutant form of kit
US8124611B2 (en) 2003-11-18 2012-02-28 Novartis Ag Inhibitors of the mutant form of kit
EP1917965A1 (en) 2003-11-18 2008-05-07 Novartis AG Inhibitors of the mutant form of KIT
WO2005063720A1 (en) * 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. Amide derivative and medicine
US8182792B2 (en) 2004-03-23 2012-05-22 Novartis Ag Pharmaceutical compositions
US8476434B2 (en) 2004-05-07 2013-07-02 Amgen Inc. Protein kinase modulators and method of use
US7880000B2 (en) 2004-05-07 2011-02-01 Amgen Inc. Protein kinase modulators and method of use
WO2005113494A2 (en) * 2004-05-07 2005-12-01 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
WO2005113494A3 (en) * 2004-05-07 2006-03-16 Amgen Inc Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
EP1885352A2 (en) * 2004-11-24 2008-02-13 Novartis AG Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
US8183242B2 (en) 2004-12-31 2012-05-22 Piaoyang Sun Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
JP2008526692A (en) * 2004-12-31 2008-07-24 ▲飄▼▲揚▼ ▲孫▼ Preparation method of aminopyrimidines and salts thereof and use of drugs
WO2006069525A1 (en) * 2004-12-31 2006-07-06 Piaoyang Sun Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
JP4698681B2 (en) * 2004-12-31 2011-06-08 ▲飄▼▲揚▼ ▲孫▼ Preparation method of aminopyrimidines and salts thereof and use of drugs
WO2006079539A2 (en) * 2005-01-28 2006-08-03 Novartis Ag Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
JP2008528531A (en) * 2005-01-28 2008-07-31 ノバルティス アクチエンゲゼルシャフト Use of pyrimidylaminobenzamide for treating diseases responsive to modulation of Tie-2 kinase activity
CN101203224B (en) * 2005-01-28 2010-11-03 诺瓦提斯公司 Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of Tie-2 kinase activity
JP2013213042A (en) * 2005-01-28 2013-10-17 Novartis Ag USE OF PYRIMIDYLAMINOBENZAMIDES FOR TREATMENT OF DISEASES THAT RESPOND TO MODULATION OF Tie-2 KINASE ACTIVITY
AU2006208638B2 (en) * 2005-01-28 2010-03-04 Novartis Ag Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
WO2006079539A3 (en) * 2005-01-28 2007-11-29 Novartis Ag Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
KR101325424B1 (en) 2005-01-28 2013-11-04 노파르티스 아게 Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
WO2006089781A1 (en) * 2005-02-25 2006-08-31 Novartis Ag Pharmaceutical combination of bcr-abl and raf inhibitors
WO2006119154A1 (en) 2005-05-02 2006-11-09 Novartis Ag Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis
JP2008540420A (en) * 2005-05-02 2008-11-20 ノバルティス アクチエンゲゼルシャフト Use of pyrimidylaminobenzamide derivatives for the treatment of systemic mastocytosis
KR101376875B1 (en) 2005-05-02 2014-03-27 노파르티스 아게 Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Systematic Mastocytosis
JP2008540358A (en) * 2005-05-02 2008-11-20 ノバルティス アクチエンゲゼルシャフト Pyrimidylaminobenzamide derivatives for eosinophilia syndrome
US7666874B2 (en) 2005-05-02 2010-02-23 Novartis Ag Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
US8673930B2 (en) 2005-05-02 2014-03-18 Novartis Ag Pyrimidylaminobenzamide derivatives for systemic mastocytosis
AU2006243395B2 (en) * 2005-05-02 2010-03-11 Novartis Ag Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
EP2266572A1 (en) 2005-05-02 2010-12-29 Novartis AG Use of pyrimidylaminobenzamide derivatives for the treatment of hypereosinophilic syndrome
WO2006117185A1 (en) * 2005-05-02 2006-11-09 Novartis Ag Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
US11192868B2 (en) 2005-05-10 2021-12-07 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2006132930A1 (en) * 2005-06-03 2006-12-14 Novartis Ag Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
AU2006255559B2 (en) * 2005-06-03 2009-12-17 Novartis Ag Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
JP2013035853A (en) * 2005-06-03 2013-02-21 Novartis Ag Combination of pyrimidylaminobenzamide compound and imatinib for treating or preventing proliferative disease
US7767688B2 (en) 2005-06-03 2010-08-03 Novartis Ag Combination of pyrimidylaminobenzamide compounds and imatinib for treating gastrointestinal stromal tumours
US8653093B2 (en) 2005-06-03 2014-02-18 Novartis Ag Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
JP2008542390A (en) * 2005-06-03 2008-11-27 ノバルティス アクチエンゲゼルシャフト Combination of pyrimidylaminobenzamide compound and imatinib for the treatment or prevention of proliferative diseases
KR101276425B1 (en) 2005-06-03 2013-06-19 노파르티스 아게 Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
AU2006258050B2 (en) * 2005-06-09 2010-12-09 Novartis Ag Process for the synthesis of organic compounds
JP2013035855A (en) * 2005-06-09 2013-02-21 Novartis Ag Method for synthesis of organic compounds
KR101283109B1 (en) 2005-06-09 2013-07-05 노파르티스 아게 Process for the Synthesis of Organic Compounds
EP2292607A2 (en) 2005-06-09 2011-03-09 Novartis AG Process for the synthesis of organic compounds
CN101184748B (en) * 2005-06-09 2011-09-28 诺瓦提斯公司 Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
WO2006135641A2 (en) * 2005-06-09 2006-12-21 Novartis Ag PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE
WO2006135640A2 (en) 2005-06-09 2006-12-21 Novartis Ag Process for the synthesis of organic compounds
CN101193866B (en) * 2005-06-09 2011-01-19 诺瓦提斯公司 Process for the synthesis of 5- (methyl-1H-imidazol-1-yl) -3- (trifluoromethyl) -benzeneamine
AU2010241374B2 (en) * 2005-06-09 2011-11-03 Novartis Ag Process for the synthesis of organic compounds
WO2006135619A1 (en) * 2005-06-09 2006-12-21 Novartis Ag Process for the synthesis of 5- (methyl- 1h-imidazol-1-yl) -3- (trifluoromethyl) -benzeneamine
KR101319071B1 (en) 2005-06-09 2013-10-17 노파르티스 아게 Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine
EP2266961A2 (en) 2005-06-09 2010-12-29 Novartis AG Process for the synthesis of organic compounds
JP2008545786A (en) * 2005-06-09 2008-12-18 ノバルティス アクチエンゲゼルシャフト Synthesis method of organic compounds
US8008504B2 (en) 2005-06-09 2011-08-30 Novartis Ag Process for the synthesis of organic compounds
JP2008545782A (en) * 2005-06-09 2008-12-18 ノバルティス アクチエンゲゼルシャフト Synthesis method of 5- (4-methyl-1H-imidazol-1-yl) -3- (trifluoromethyl) -benzenamine
WO2006135641A3 (en) * 2005-06-09 2007-03-29 Novartis Ag PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE
JP2008546645A (en) * 2005-06-09 2008-12-25 ノバルティス アクチエンゲゼルシャフト Synthesis method of organic compounds
KR101216249B1 (en) 2005-06-09 2012-12-28 노파르티스 아게 Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine
TWI380981B (en) * 2005-06-09 2013-01-01 Novartis Ag Process for the synthesis of organic compounds
AU2013205820B2 (en) * 2005-06-09 2015-11-26 Novartis Ag Process for the synthesis of organic compounds
US7709657B2 (en) 2005-06-09 2010-05-04 Novartis Ag Process for the synthesis of organic compounds
US8124763B2 (en) 2005-06-09 2012-02-28 Novartis Ag Process for the synthesis of 5-(methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine
KR101249199B1 (en) * 2005-06-09 2013-04-03 노파르티스 아게 Process for the Synthesis of Organic Compounds
US7781597B2 (en) 2005-06-09 2010-08-24 Novartis Ag Process for the synthesis of organic compounds
EP2266961A3 (en) * 2005-06-09 2011-07-27 Novartis AG Process for the synthesis of organic compounds
WO2006135640A3 (en) * 2005-06-09 2007-08-02 Novartis Ag Process for the synthesis of organic compounds
NO340743B1 (en) * 2005-06-09 2017-06-12 Novartis Ag Process for the synthesis of organic compounds
KR101514593B1 (en) * 2005-06-09 2015-04-22 노파르티스 아게 Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine
US8946416B2 (en) 2005-06-09 2015-02-03 Novartis Ag Process for the synthesis of 5-(methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine
EP2292607A3 (en) * 2005-06-09 2011-04-27 Novartis AG Process for the synthesis of organic compounds
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US8557847B2 (en) 2005-06-10 2013-10-15 Janssen Pharmaceutica, N.V. Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
JP2008546698A (en) * 2005-06-14 2008-12-25 タイゲン バイオテクノロジー カンパニー，リミテッド Pyrimidine compounds
TWI455934B (en) * 2005-07-20 2014-10-11 Novartis Ag Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP2253320A1 (en) 2005-07-20 2010-11-24 Novartis AG Combination of a pyrimidylaminobenzamide and a mTOR kinase inhibitor
NO341313B1 (en) * 2005-07-20 2017-10-09 Novartis Ag Monohydrochloride monohydrate salt of 4-methyl-N- [3- (4-methylimidazol-1-yl) -5-trifluoromethylphenyl] -3- (4-pyridin-3-yl-pyrimidin-2-ylamino) -benzamide
EP2535337A1 (en) 2005-07-20 2012-12-19 Novartis AG Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide sulfate and its amorphous form
EA013464B1 (en) * 2005-07-20 2010-04-30 Новартис Аг Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-2-ylamino)-benzamide
US8343984B2 (en) * 2005-07-20 2013-01-01 Novartis Ag Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
AU2012203844B2 (en) * 2005-07-20 2014-12-11 Novartis Ag Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EA016856B1 (en) * 2005-07-20 2012-08-30 Новартис Аг Crystalline forms of 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamide
EP2186808A1 (en) * 2005-07-20 2010-05-19 Novartis AG Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
KR101755137B1 (en) * 2005-07-20 2017-07-06 노파르티스 아게 Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP2543665A2 (en) 2005-07-20 2013-01-09 Novartis AG Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base
NO341930B1 (en) * 2005-07-20 2018-02-19 Novartis Ag Crystalline forms of 4-methyl-N- [3- (4-methylimidazol-1-yl) -5-trifluoromethylphenyl] -3- (4-pyridin-3-ylpyrimidin-2-ylamino) benzamide
JP2013018789A (en) * 2005-07-20 2013-01-31 Novartis Ag Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
WO2007015871A1 (en) 2005-07-20 2007-02-08 Novartis Ag Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
US8389537B2 (en) 2005-07-20 2013-03-05 Novartis Ag Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
WO2007015870A2 (en) 2005-07-20 2007-02-08 Novartis Ag Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
AU2006276205B2 (en) * 2005-07-20 2010-08-19 Novartis Ag Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
US8163904B2 (en) 2005-07-20 2012-04-24 Novartis Ag Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide
CN103804356A (en) * 2005-07-20 2014-05-21 诺瓦提斯公司 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
KR20080027853A (en) * 2005-07-20 2008-03-28 노파르티스 아게 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
WO2007010012A2 (en) * 2005-07-20 2007-01-25 Novartis Ag Combination of a pyrimidylaminobenzamide and an mtor kinase inhibitor
JP2009502796A (en) * 2005-07-20 2009-01-29 ノバルティス アクチエンゲゼルシャフト 4-methyl-N- [3- (4-methyl-imidazol-1-yl) -5-trifluoromethyl-phenyl] -3- (4-pyridin-3-yl-pyrimidin-2-ylamino) -benzamide salt
CN102358736A (en) * 2005-07-20 2012-02-22 诺瓦提斯公司 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP2284167B1 (en) 2005-07-20 2017-02-01 Novartis AG crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
WO2007010013A2 (en) * 2005-07-20 2007-01-25 Novartis Ag Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases
US9163005B2 (en) 2005-07-20 2015-10-20 Novartis Ag Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
JP2009502795A (en) * 2005-07-20 2009-01-29 ノバルティス アクチエンゲゼルシャフト Of 4-methyl-N- [3- (4-methyl-imidazol-1-yl) -5-trifluoromethyl-phenyl] -3- (4-pyridin-3-yl-pyrimidin-2-ylamino) -benzamide Crystal form
RU2509767C1 (en) * 2005-07-20 2014-03-20 Новартис Аг 4-methyl-n-[3-4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)benzamide salts
CN102267981A (en) * 2005-07-20 2011-12-07 诺瓦提斯公司 Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
JP2009501765A (en) * 2005-07-20 2009-01-22 ノバルティス アクチエンゲゼルシャフト Combination of pyrimidylaminobenzamide and mTOR kinase inhibitor
US8415363B2 (en) 2005-07-20 2013-04-09 Novartis Ag Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
US8829015B2 (en) 2005-07-20 2014-09-09 Novartis Ag Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
WO2007010013A3 (en) * 2005-07-20 2007-05-03 Novartis Ag Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases
US8580806B2 (en) 2005-07-20 2013-11-12 Novartis Ag Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
RU2483065C2 (en) * 2005-07-20 2013-05-27 Новартис Аг 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)benzamide salts
US20080269269A1 (en) * 2005-07-20 2008-10-30 Manley Paul W Crystalline Forms of 4-Methyl-N- [3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3- (4-Pyridin-3-Yl-Pyrimidin-2-Ylamino) -Benzamide
EP2543665A3 (en) * 2005-07-20 2013-05-29 Novartis AG Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base
WO2007015870A3 (en) * 2005-07-20 2007-06-07 Novartis Ag Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
KR101651288B1 (en) * 2005-07-20 2016-08-25 노파르티스 아게 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP2284168A2 (en) 2005-07-20 2011-02-16 Novartis AG Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP2284167A3 (en) * 2005-07-20 2011-03-02 Novartis AG crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
WO2007010012A3 (en) * 2005-07-20 2007-07-05 Novartis Ag Combination of a pyrimidylaminobenzamide and an mtor kinase inhibitor
EP2284168A3 (en) * 2005-07-20 2011-04-13 Novartis AG Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
TWI406661B (en) * 2005-07-20 2013-09-01 Novartis Ag Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
RU2605551C2 (en) * 2005-07-20 2016-12-20 Новартис Аг Salts of 4-methyl-n-[3-(4-methylimidazole-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridine-3-ylpyrimidine-2-ylamino)benzamide
AU2012201453B2 (en) * 2005-07-20 2013-09-05 Novartis Ag Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP1922309A1 (en) * 2005-08-05 2008-05-21 Il Yang Pharm. Co. Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
JP2009503060A (en) * 2005-08-05 2009-01-29 イル−ヤン ファーム カンパニー リミテッド N-phenyl-2-pyrimidin-amine derivative and process for its preparation
EA015103B1 (en) * 2005-08-05 2011-06-30 Ил-Янг Фарм. Ко., Лтд. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
KR100674813B1 (en) * 2005-08-05 2007-01-29 일양약품주식회사 N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
US7501424B2 (en) 2005-08-05 2009-03-10 Il-Yang Pharm. Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
EP1922309A4 (en) * 2005-08-05 2009-10-14 Il Yang Pharm Co Ltd N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
CN101155786B (en) * 2005-08-05 2012-08-29 一洋药品株式会社 N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
WO2007018325A1 (en) * 2005-08-05 2007-02-15 Il-Yang Pharm. Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
JP2009504673A (en) * 2005-08-11 2009-02-05 ノバルティス アクチエンゲゼルシャフト A combination comprising a protein kinase inhibitor which is a pyrimidylaminobenzamide compound and an HSP90 inhibitor such as 17-AAG
JP2013127001A (en) * 2005-08-11 2013-06-27 Novartis Ag Combination agent including protein kinase inhibitor of pyrimidylaminobenzamide compound and hsp90 inhibitor such as 17-aag
WO2007022044A3 (en) * 2005-08-11 2007-05-24 Novartis Ag Combination of organic compounds
US20110281902A1 (en) * 2005-08-11 2011-11-17 Manley Paul W Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-aag
WO2007022042A3 (en) * 2005-08-11 2008-03-20 Novartis Ag Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
US20080200489A1 (en) * 2005-08-11 2008-08-21 Peter Wisdom Atadja Combination of Organic Compounds
WO2007022042A2 (en) * 2005-08-11 2007-02-22 Novartis Ag Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
WO2007022044A2 (en) * 2005-08-11 2007-02-22 Novartis Ag Combination of organic compounds
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
US8563541B2 (en) 2005-09-22 2013-10-22 Incyte Corporation Azepine inhibitors of Janus kinases
US8835423B2 (en) 2005-09-22 2014-09-16 Incyte Corporation Azepine inhibitors of janus kinases
WO2007042465A2 (en) * 2005-10-07 2007-04-19 Novartis Ag Combinati0n of nilotinib with farnesyl transferase inhibitors
WO2007042465A3 (en) * 2005-10-07 2007-10-11 Novartis Ag Combinati0n of nilotinib with farnesyl transferase inhibitors
JP2009511450A (en) * 2005-10-07 2009-03-19 ノバルティス アクチエンゲゼルシャフト Combination of nilotinib and farnesyltransferase inhibitor
US7795279B2 (en) 2005-10-18 2010-09-14 Janssen Pharmaceutica Nv Method of inhibiting FLT3 kinase
WO2007051862A1 (en) * 2005-11-07 2007-05-10 Novartis Ag Combination of organic compounds
KR101413387B1 (en) * 2005-12-06 2014-06-27 노파르티스 아게 Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
EP2177222A1 (en) * 2005-12-06 2010-04-21 Novartis AG Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
RU2450814C2 (en) * 2005-12-06 2012-05-20 Новартис Аг Pyrimidylaminobenzamide derivatives for neurofibromatosis
AU2006323992B2 (en) * 2005-12-06 2010-07-08 Novartis Ag Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
CN101321532B (en) * 2005-12-06 2011-06-29 诺瓦提斯公司 Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
KR101498848B1 (en) * 2005-12-06 2015-03-05 노파르티스 아게 Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
US8604045B2 (en) 2005-12-06 2013-12-10 Novartis Ag Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis
WO2007065898A1 (en) 2005-12-06 2007-06-14 Novartis Ag Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
US10639310B2 (en) 2005-12-13 2020-05-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP2426129A1 (en) 2005-12-13 2012-03-07 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9814722B2 (en) 2005-12-13 2017-11-14 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
EP2343299A1 (en) 2005-12-13 2011-07-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP3184526A1 (en) 2005-12-13 2017-06-28 Incyte Holdings Corporation Pyrrolo[2,3-d]pyrimidine derivatives as janus kinase inhibitor
US9662335B2 (en) 2005-12-13 2017-05-30 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US11744832B2 (en) 2005-12-13 2023-09-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US8415362B2 (en) 2005-12-13 2013-04-09 Incyte Corporation Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US10398699B2 (en) 2005-12-13 2019-09-03 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US9079912B2 (en) 2005-12-13 2015-07-14 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
EP2474545A1 (en) 2005-12-13 2012-07-11 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP2455382A1 (en) 2005-12-13 2012-05-23 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9974790B2 (en) 2005-12-13 2018-05-22 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
EP2343298A1 (en) 2005-12-13 2011-07-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP3466953A1 (en) 2005-12-13 2019-04-10 Incyte Holdings Corporation Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor
EP3838903A1 (en) 2005-12-13 2021-06-23 Incyte Holdings Corporation Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor
EP2348023A1 (en) 2005-12-13 2011-07-27 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US11331320B2 (en) 2005-12-13 2022-05-17 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP2314297A1 (en) * 2006-04-05 2011-04-27 Novartis AG Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
AU2007234382B2 (en) * 2006-04-05 2011-06-09 Novartis Ag Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
EP2012787A2 (en) * 2006-04-05 2009-01-14 Novartis AG Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
AU2011202833B2 (en) * 2006-04-07 2012-05-24 Novartis Ag Combination comprising a) a pyrimidylaminobenzamide compound, and b) a Thr315lle kinase inhibitor
EP2574340A3 (en) * 2006-04-07 2013-04-17 Novartis AG Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor
WO2007116029A3 (en) * 2006-04-07 2008-12-11 Novartis Ag Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
EP2574340A2 (en) 2006-04-07 2013-04-03 Novartis AG Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor
RU2481840C2 (en) * 2006-04-07 2013-05-20 Новартис Аг COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR
US9526731B2 (en) 2006-04-20 2016-12-27 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
US9266866B2 (en) 2006-04-20 2016-02-23 Janssen Pharmaceutica Nv Inhibitors of C-FMS kinase
US8815867B2 (en) 2006-04-20 2014-08-26 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
US8481564B2 (en) 2006-04-20 2013-07-09 Janssen Pharmaceutica, N.V. Inhibitors of c-fms kinase
US8759347B2 (en) 2006-04-20 2014-06-24 Janssen Pharmaceutica Nv Inhibitors of C-FMS kinase
US8722718B2 (en) 2006-04-20 2014-05-13 Janssen Pharmaceutica Nv Inhibitors of C-FMS kinase
US8895584B2 (en) 2006-04-20 2014-11-25 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
US8859602B2 (en) 2006-04-20 2014-10-14 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
US9403804B2 (en) 2006-04-20 2016-08-02 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
US9394289B2 (en) 2006-04-20 2016-07-19 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
US9296726B2 (en) 2006-04-20 2016-03-29 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
US8933091B2 (en) 2006-04-20 2015-01-13 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
EP2351568A2 (en) 2006-05-04 2011-08-03 Boehringer Ingelheim International GmbH Uses of dpp-iv inhibitors
US8093259B2 (en) 2006-05-25 2012-01-10 Novartis Ag 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma
WO2007137981A1 (en) * 2006-05-25 2007-12-06 Novartis Ag Inhibitors of tyrosine kinases
EP2251042A2 (en) 2006-09-22 2010-11-17 Novartis AG Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
WO2008037716A3 (en) * 2006-09-27 2008-07-17 Novartis Ag Pharmaceutical compositions comprising nilotinib or its salt
US8501760B2 (en) 2006-09-27 2013-08-06 Novartis Ag Pharmaceutical compositions comprising nilotinib or its salt
EP3984528A1 (en) 2006-09-27 2022-04-20 Novartis AG Pharmaceutical compositions comprising nilotinib
AU2007301977B2 (en) * 2006-09-27 2011-09-08 Novartis Ag Pharmaceutical compositions comprising nilotinib or its salt
EP2068839B1 (en) 2006-09-27 2015-09-23 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
NO346639B1 (en) * 2006-09-27 2022-11-07 Novartis Ag Pharmaceutical preparations and method for their production
EP3009128A1 (en) 2006-09-27 2016-04-20 Novartis AG Pharmaceutical compositions comprising nilotinib
NO347404B1 (en) * 2006-09-27 2023-10-16 Novartis Ag Granules or granulated mixture, as well as pharmaceutical preparations comprising such
US8293756B2 (en) 2006-09-27 2012-10-23 Novartis Ag Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate
NO20220946A1 (en) * 2006-09-27 2009-04-24 Novartis Ag Granules or granulated mixture, as well as pharmaceutical preparations comprising such
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
AU2007317349B2 (en) * 2006-11-03 2011-10-20 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008058037A1 (en) * 2006-11-03 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2010509349A (en) * 2006-11-03 2010-03-25 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as protein kinase inhibitors
EP2100874A1 (en) * 2006-11-13 2009-09-16 Toray Fine Chemicals Co., Ltd. Process for production of 2,2'-bis(trifluoromethyl)- 4,4'-diaminobiphenyl
EP2100874A4 (en) * 2006-11-13 2014-04-09 Toray Finechemicals Co Ltd Process for production of 2,2'-bis(trifluoromethyl)- 4,4'-diaminobiphenyl
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
US8841318B2 (en) 2006-12-22 2014-09-23 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
EA017269B1 (en) * 2007-05-04 2012-11-30 Айрм Ллк PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS c-kit AND PDGFR KINASE INHIBITORS
US8268850B2 (en) 2007-05-04 2012-09-18 Irm Llc Pyrimidine derivatives and compositions as C-kit and PDGFR kinase inhibitors
US8338417B2 (en) 2007-05-04 2012-12-25 Irm Llc Compounds and compositions as c-kit and PDGFR kinase inhibitors
WO2008137605A1 (en) * 2007-05-04 2008-11-13 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
KR101122481B1 (en) * 2007-05-04 2012-02-29 아이알엠 엘엘씨 Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
WO2008153974A1 (en) 2007-06-07 2008-12-18 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
US8557830B2 (en) 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use
US9056837B2 (en) 2007-06-07 2015-06-16 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
US9062023B2 (en) 2007-06-07 2015-06-23 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
US8367686B2 (en) 2007-06-07 2013-02-05 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
US10610530B2 (en) 2007-06-13 2020-04-07 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8889697B2 (en) 2007-06-13 2014-11-18 Incyte Corporation Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10463667B2 (en) 2007-06-13 2019-11-05 Incyte Incorporation Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10016429B2 (en) 2007-06-13 2018-07-10 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US11213528B2 (en) 2007-06-13 2022-01-04 Incyte Holdings Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8829013B1 (en) 2007-06-13 2014-09-09 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP3495369A1 (en) 2007-06-13 2019-06-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
EP4011883A1 (en) 2007-06-13 2022-06-15 Incyte Holdings Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3-cyclopentylpropanenitrile
US9376439B2 (en) 2007-06-13 2016-06-28 Incyte Corporation Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP3070090A1 (en) 2007-06-13 2016-09-21 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
US7834022B2 (en) 2007-06-13 2010-11-16 Incyte Corporation Metabolites of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8822481B1 (en) 2007-06-13 2014-09-02 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP2740731A1 (en) 2007-06-13 2014-06-11 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8293757B2 (en) 2007-08-22 2012-10-23 Irm Llc 5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
US8288540B2 (en) 2007-08-22 2012-10-16 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
US8497376B2 (en) 2007-10-17 2013-07-30 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US8309718B2 (en) 2007-11-16 2012-11-13 Incyte Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
WO2009082662A1 (en) 2007-12-21 2009-07-02 Novartis Ag Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia
US8420629B2 (en) 2008-03-11 2013-04-16 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
US11207302B2 (en) 2008-07-08 2021-12-28 Incyte Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
WO2010009402A3 (en) * 2008-07-17 2010-08-26 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
EP2305667A2 (en) 2008-07-17 2011-04-06 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
EP3598974A1 (en) 2008-08-06 2020-01-29 Boehringer Ingelheim International GmbH Treatment for diabetes in patients inappropriate for metformin therapy
EP2990037A1 (en) 2008-08-06 2016-03-02 Boehringer Ingelheim International GmbH Treatment for diabetes in patients inappropriate for metformin therapy
WO2010019540A1 (en) * 2008-08-13 2010-02-18 Novartis Ag Treatment of pulmonary arterial hypertension
WO2010018895A1 (en) * 2008-08-14 2010-02-18 Il-Yang Pharm. Co., Ltd. Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives
EP3626238A1 (en) 2008-08-15 2020-03-25 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
EP3042655A1 (en) 2008-10-02 2016-07-13 Incyte Holdings Corporation Janus kinase inhibitors for treatment of dry eye and other eye related diseases
US8592442B2 (en) 2008-11-05 2013-11-26 Teva Pharmaceutical Industries Ltd. Nilotinib HCl crystalline forms
WO2010054056A3 (en) * 2008-11-05 2010-09-16 Teva Pharmaceutical Industries Ltd. Nilotinib hci crystalline forms
EP2530081A3 (en) * 2008-11-05 2013-04-10 Teva Pharmaceutical Industries, Ltd. Nilotinib HCI crystalline forms
US8227477B2 (en) 2008-11-05 2012-07-24 Greta Sterimbaum Nilotinib HCl crystalline forms
WO2010054056A2 (en) * 2008-11-05 2010-05-14 Teva Pharmaceutical Industries Ltd. Nilotinib hci crystalline forms
EP2186514A1 (en) 2008-11-14 2010-05-19 Novartis AG Treatment of Malignant Peripheral Nerve Sheath Tumors
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
WO2010072776A1 (en) 2008-12-23 2010-07-01 Boehringer Ingelheim International Gmbh Salt forms of organic compound
EP2385035A1 (en) * 2008-12-25 2011-11-09 Harbin Gloria Pharmaceuticals Co., Ltd. Preparation method of dihydroindene amide compounds their pharmaceutical compositions containg compounds thereof and use as protein kinases inhibitor
EP2385035A4 (en) * 2008-12-25 2013-07-10 Harbin Gloria Pharmaceuticals Co Ltd Preparation method of dihydroindene amide compounds their pharmaceutical compositions containg compounds thereof and use as protein kinases inhibitor
WO2010079197A1 (en) 2009-01-07 2010-07-15 Boehringer Ingelheim International Gmbh Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2010086411A1 (en) 2009-01-29 2010-08-05 Boehringer Ingelheim International Gmbh Dpp-iv inhibitors for treatment of diabetes in paediatric patients
WO2010092163A2 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
WO2010100248A1 (en) 2009-03-06 2010-09-10 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)
WO2010135621A1 (en) 2009-05-22 2010-11-25 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
US9623029B2 (en) 2009-05-22 2017-04-18 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
EP3643312A1 (en) 2009-05-22 2020-04-29 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
WO2010141427A1 (en) 2009-06-02 2010-12-09 Novartis Ag Treatment of ophthalmologic disorders mediated by albha-carbonic anhydrase isoforms
US20120088776A1 (en) * 2009-06-02 2012-04-12 Claudiu Supuran Treatment of mammalian disorders mediated by alpha-anhydrase isoforms
TWI565466B (en) * 2009-06-02 2017-01-11 芬蘭坦帕雷大學 Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms
US9623025B2 (en) * 2009-06-02 2017-04-18 Claudiu Supuran Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms
US10568965B2 (en) * 2009-06-09 2020-02-25 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
US20140227260A1 (en) * 2009-06-09 2014-08-14 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
US10428087B2 (en) 2009-06-29 2019-10-01 Incyte Corporation Pyrimidinones as PI3K inhibitors
US11401280B2 (en) 2009-06-29 2022-08-02 Incyte Holdings Corporation Pyrimidinones as PI3K inhibitors
US9975907B2 (en) 2009-06-29 2018-05-22 Incyte Holdings Corporation Pyrimidinones as PI3K inhibitors
US10829502B2 (en) 2009-06-29 2020-11-10 Incyte Corporation Pyrimidinones as PI3K inhibitors
WO2011008487A1 (en) 2009-06-29 2011-01-20 Incyte Corporation Pyrimidinones as pi3k inhibitors
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
US9605041B2 (en) 2009-08-05 2017-03-28 Intra-Cellular Therapies, Inc. Regulatory proteins and inhibitors
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011033307A1 (en) 2009-09-17 2011-03-24 Generics [Uk] Limited Nilotinib dihydrochloride salt
EP4209210A1 (en) 2009-10-02 2023-07-12 Boehringer Ingelheim International GmbH Pharmaceutical compositions comprising bi-1356 and metformin
WO2011039367A2 (en) 2009-10-02 2011-04-07 Boehringer Ingelheim International Gmbh Therapeutic uses of pharmaceutical compositions
WO2011044481A1 (en) 2009-10-09 2011-04-14 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US9512161B2 (en) 2009-10-09 2016-12-06 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2011044001A1 (en) 2009-10-09 2011-04-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2011050120A1 (en) 2009-10-23 2011-04-28 Novartis Ag Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
EP2501384B1 (en) 2009-11-17 2016-02-17 Novartis AG Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
JP2013511524A (en) * 2009-11-17 2013-04-04 ノバルティス アーゲー Methods of treating proliferative disorders and other pathologies caused by BCR-ABL, C-KIT, DDR1, DDR2 or PDGF-R kinase activity
WO2011062927A1 (en) 2009-11-17 2011-05-26 Novartis Ag Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
TWI498116B (en) * 2009-11-17 2015-09-01 Novartis Ag Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
US9061029B2 (en) 2009-11-17 2015-06-23 Novartis Ag Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
AU2010322102B2 (en) * 2009-11-17 2014-08-28 Novartis Ag Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
KR101743315B1 (en) * 2009-11-17 2017-06-15 노파르티스 아게 Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
JP2015180636A (en) * 2009-11-17 2015-10-15 ノバルティス アーゲー Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
RU2625835C2 (en) * 2009-11-17 2017-07-19 Новартис Аг Method for treating proliferative disorders and other pathological conditions mediated by activity of kinase bcr-abl, c-kit, ddr1, ddr2 or pdgf-r
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011064352A1 (en) 2009-11-27 2011-06-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011067306A1 (en) 2009-12-03 2011-06-09 Novartis Ag Cyclohexane derivatives as inhibitors of acetyl-coa carboxylase (acc)
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
WO2011083124A1 (en) 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists for the treatment or the prevention of pain disorders
WO2011086085A1 (en) 2010-01-12 2011-07-21 Ab Science Thiazole and oxazole kinase inhibitors
US8962665B2 (en) 2010-01-12 2015-02-24 Ab Science Thiazole and oxazole kinase inhibitors
WO2011086541A1 (en) 2010-01-15 2011-07-21 Generics [Uk] Limited Novel polymorph of nilotinib monohydrochloride monohydrate
WO2011103423A1 (en) 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
EP4036088A1 (en) 2010-03-10 2022-08-03 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US11285140B2 (en) 2010-03-10 2022-03-29 Incyte Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
EP3715347A1 (en) 2010-03-10 2020-09-30 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US10695337B2 (en) 2010-03-10 2020-06-30 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
WO2011112662A1 (en) 2010-03-10 2011-09-15 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP3050882A1 (en) 2010-03-10 2016-08-03 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP3354652A1 (en) 2010-03-10 2018-08-01 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US9999619B2 (en) 2010-03-10 2018-06-19 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
WO2011128434A2 (en) 2010-04-16 2011-10-20 Novartis Ag Treatment of endocrine resistant breast cancer
WO2011128434A3 (en) * 2010-04-16 2011-12-22 Novartis Ag Treatment of endocrine resistant breast cancer
WO2011136399A1 (en) 2010-04-30 2011-11-03 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
WO2011146808A2 (en) 2010-05-21 2011-11-24 Incyte Corporation Topical formulation for a jak inhibitor
US11219624B2 (en) 2010-05-21 2022-01-11 Incyte Holdings Corporation Topical formulation for a JAK inhibitor
US10869870B2 (en) 2010-05-21 2020-12-22 Incyte Corporation Topical formulation for a JAK inhibitor
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
US11571425B2 (en) 2010-05-21 2023-02-07 Incyte Corporation Topical formulation for a JAK inhibitor
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
US11590136B2 (en) 2010-05-21 2023-02-28 Incyte Corporation Topical formulation for a JAK inhibitor
US8937082B2 (en) * 2010-06-21 2015-01-20 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US9090598B2 (en) 2010-06-21 2015-07-28 Teva Pharmaceutical Industries, Ltd. Nilotinib salts and crystalline forms thereof
US20130158059A1 (en) * 2010-06-21 2013-06-20 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
WO2012013716A1 (en) 2010-07-29 2012-02-02 Novartis Ag Bicyclic acetyl-coa carboxylase inhibitors
WO2012065993A1 (en) 2010-11-15 2012-05-24 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
US10640506B2 (en) 2010-11-19 2020-05-05 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US20130245052A1 (en) * 2010-11-26 2013-09-19 Hetero Research Foundation Novel polymorph of nilotinib hydrochloride
US8703788B2 (en) * 2010-11-26 2014-04-22 Bandi Parthasaradhi Reddy Polymorph of nilotinib hydrochloride
US9815839B2 (en) 2010-12-20 2017-11-14 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
EP3660016A1 (en) 2010-12-20 2020-06-03 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
US9611269B2 (en) 2011-06-20 2017-04-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US11214573B2 (en) 2011-06-20 2022-01-04 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
WO2012177606A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
US10513522B2 (en) 2011-06-20 2019-12-24 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
EP3517539A1 (en) 2011-07-15 2019-07-31 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
CN102321073A (en) * 2011-08-12 2012-01-18 西安交通大学 Preparation method of nilotinib
WO2013026025A1 (en) 2011-08-18 2013-02-21 Incyte Corporation Cyclohexyl azetidine derivatives as jak inhibitors
US11433071B2 (en) 2011-09-02 2022-09-06 Incyte Corporation Heterocyclylamines as PI3K inhibitors
US10092570B2 (en) 2011-09-02 2018-10-09 Incyte Holdings Corporation Heterocyclylamines as PI3K inhibitors
US9730939B2 (en) 2011-09-02 2017-08-15 Incyte Holdings Corporation Heterocyclylamines as PI3K inhibitors
US11819505B2 (en) 2011-09-02 2023-11-21 Incyte Corporation Heterocyclylamines as PI3K inhibitors
US10376513B2 (en) 2011-09-02 2019-08-13 Incyte Holdings Corporation Heterocyclylamines as PI3K inhibitors
EP3513793A1 (en) 2011-09-02 2019-07-24 Incyte Holdings Corporation Heterocyclylamines as pi3k inhibitors
WO2013033569A1 (en) 2011-09-02 2013-03-07 Incyte Corporation Heterocyclylamines as pi3k inhibitors
US9707233B2 (en) 2011-09-02 2017-07-18 Incyte Holdings Corporation Heterocyclylamines as PI3K inhibitors
US10646492B2 (en) 2011-09-02 2020-05-12 Incyte Corporation Heterocyclylamines as PI3K inhibitors
EP3196202A1 (en) 2011-09-02 2017-07-26 Incyte Holdings Corporation Heterocyclylamines as pi3k inhibitors
US9718834B2 (en) 2011-09-07 2017-08-01 Incyte Corporation Processes and intermediates for making a JAK inhibitor
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063000A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013068836A1 (en) 2011-11-07 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
WO2013098372A1 (en) 2011-12-29 2013-07-04 Boehringer Ingelheim International Gmbh Subcutaneous therapeutic use of dpp-4 inhibitor
EP2626355A1 (en) 2012-02-09 2013-08-14 Natco Pharma Limited Process for the preparation of nilotinib hydrochloride
US9440959B2 (en) 2012-02-15 2016-09-13 Natco Pharma Limited Process for the preparation of nilotinib
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
WO2013151930A1 (en) 2012-04-02 2013-10-10 Incyte Corporation Bicyclic azaheterocyclobenzylamines as pi3k inhibitors
US9944646B2 (en) 2012-04-02 2018-04-17 Incyte Holdings Corporation Bicyclic azaheterocyclobenzylamines as PI3K inhibitors
US10259818B2 (en) 2012-04-02 2019-04-16 Incyte Corporation Bicyclic azaheterocyclobenzylamines as PI3K inhibitors
US9695118B2 (en) 2012-04-24 2017-07-04 Chugai Seiyaku Kabushiki Kaisha Benzamide derivative
US9567304B2 (en) 2012-04-24 2017-02-14 Chugai Seiyaku Kabushiki Kaisha Quinazolinedione derivative
WO2013161853A1 (en) 2012-04-24 2013-10-31 中外製薬株式会社 Quinazolinedione derivative
WO2013161851A1 (en) 2012-04-24 2013-10-31 中外製薬株式会社 Benzamide derivative
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
AP3613A (en) * 2012-05-15 2016-02-29 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 abl1abl2 bcr-abl1
AU2013261128B2 (en) * 2012-05-15 2015-11-12 Novartis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US9315489B2 (en) 2012-05-15 2016-04-19 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
EA024391B1 (en) * 2012-05-15 2016-09-30 Новартис Аг Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
WO2013171642A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
AU2013261127B2 (en) * 2012-05-15 2015-03-12 Novartis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US8829195B2 (en) 2012-05-15 2014-09-09 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
WO2013171640A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
KR102091893B1 (en) 2012-05-15 2020-03-23 노파르티스 아게 Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
US9278981B2 (en) 2012-05-15 2016-03-08 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
WO2013171639A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
US9896444B2 (en) 2012-05-15 2018-02-20 Novartis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US9340537B2 (en) 2012-05-15 2016-05-17 Novatis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
KR20150020170A (en) * 2012-05-15 2015-02-25 노파르티스 아게 Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
CN104302638A (en) * 2012-05-15 2015-01-21 诺华股份有限公司 Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
US9458112B2 (en) 2012-05-15 2016-10-04 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013174768A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
KR102206434B1 (en) 2012-06-05 2021-01-22 길리애드 파마셋 엘엘씨 Synthesis of antiviral compound
KR20150027158A (en) * 2012-06-05 2015-03-11 길리어드 파마셋 엘엘씨 Synthesis of antiviral compound
US11840534B2 (en) 2012-06-13 2023-12-12 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
WO2014011284A1 (en) 2012-07-11 2014-01-16 Novartis Ag Method of treating gastrointestinal stromal tumors
US9303046B2 (en) 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
US9029352B2 (en) 2012-08-07 2015-05-12 Janssen Pharmaceutica Nv Process for the preparation of C-FMS kinase inhibitors
US9023880B2 (en) 2012-09-21 2015-05-05 Arog Pharmaceuticals, Llc Method of inhibiting constitutively active phosphorylated FLT3 kinase
US11738017B2 (en) 2012-09-21 2023-08-29 Arog Pharmaceuticals, Inc. Method of inhibiting constitutively active phosphorylated FLT3 kinase
US10780086B2 (en) 2012-09-21 2020-09-22 Arog Pharmaceuticals, Inc. Method of inhibiting constitutively active phosphorylated FLT3 kinase
US9801869B2 (en) 2012-09-21 2017-10-31 Arog Pharmaceuticals, Inc. Method of inhibiting constitutively active phosphorylated FLT3 kinase
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
WO2014060449A1 (en) * 2012-10-19 2014-04-24 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
CN104736531A (en) * 2012-10-19 2015-06-24 巴斯夫欧洲公司 Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
US9567317B2 (en) 2012-10-19 2017-02-14 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
AU2013333953B2 (en) * 2012-10-19 2017-08-31 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
RU2652121C2 (en) * 2012-10-19 2018-04-25 Басф Се Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
US9908895B2 (en) 2012-11-01 2018-03-06 Incyte Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US9181271B2 (en) 2012-11-01 2015-11-10 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US10370387B2 (en) 2012-11-01 2019-08-06 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
WO2014071031A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
US9777017B2 (en) 2012-11-01 2017-10-03 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US11161855B2 (en) 2012-11-01 2021-11-02 Incyte Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US10874616B2 (en) 2012-11-15 2020-12-29 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11576864B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11896717B2 (en) 2012-11-15 2024-02-13 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US11337927B2 (en) 2012-11-15 2022-05-24 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US11576865B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11007188B2 (en) 2013-01-07 2021-05-18 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders
WO2014107209A2 (en) 2013-01-07 2014-07-10 Arog Pharmaceuticals, Llc Crenolanib for treating flt3 mutated proliferative disorders
US9393240B2 (en) 2013-01-07 2016-07-19 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders
US9101624B2 (en) 2013-01-07 2015-08-11 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders
US9801870B2 (en) 2013-01-07 2017-10-31 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders
US11458131B2 (en) 2013-01-07 2022-10-04 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders
US10213423B2 (en) 2013-01-07 2019-02-26 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
EP4233869A2 (en) 2013-03-01 2023-08-30 Incyte Holdings Corporation Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
US9932341B2 (en) 2013-03-01 2018-04-03 Incyte Corporation Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders
EP3632442A1 (en) 2013-03-01 2020-04-08 Incyte Holdings Corporation Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
WO2014134426A1 (en) 2013-03-01 2014-09-04 Incyte Corporation USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS
US9714233B2 (en) 2013-03-06 2017-07-25 Incyte Corporation Processes and intermediates for making a JAK inhibitor
EP4364796A2 (en) 2013-03-15 2024-05-08 Boehringer Ingelheim International GmbH Use of linagliptin in cardio- and renoprotective antidiabetic therapy
US11530214B2 (en) 2013-04-19 2022-12-20 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9382231B2 (en) 2013-05-17 2016-07-05 Incyte Corporation Bipyrazole derivatives as JAK inhibitors
EP3527263A1 (en) 2013-05-17 2019-08-21 Incyte Corporation Bipyrazole derivatives as jak inhibitors
US11001571B2 (en) 2013-05-17 2021-05-11 Incyte Corporation Bipyrazole derivatives as JAK inhibitors
US11591318B2 (en) 2013-05-17 2023-02-28 Incyte Corporation Bipyrazole derivatives as JAK inhibitors
EP3786162A1 (en) 2013-05-17 2021-03-03 Incyte Corporation Bipyrazole derivatives as jak inhibitors
US11905275B2 (en) 2013-05-17 2024-02-20 Incyte Corporation Bipyrazole derivatives as JAK inhibitors
WO2014186706A1 (en) 2013-05-17 2014-11-20 Incyte Corporation Bipyrazole derivatives as jak inhibitors
US10435392B2 (en) 2013-05-17 2019-10-08 Incyte Corporation Bipyrazole derivatives as JAK inhibitors
US9926301B2 (en) 2013-05-17 2018-03-27 Incyte Corporation Bipyrazole derivatives as JAK inhibitors
EP3231801A1 (en) 2013-05-17 2017-10-18 Incyte Corporation Bipyrazole salt as jak inhibitor
EP4275756A2 (en) 2013-05-17 2023-11-15 Incyte Holdings Corporation Bipyrazole derivatives as jak inhibitors
EP3721873A1 (en) 2013-08-07 2020-10-14 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
US11045421B2 (en) 2013-08-07 2021-06-29 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US10561616B2 (en) 2013-08-07 2020-02-18 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
WO2015026818A1 (en) 2013-08-20 2015-02-26 Incyte Corporation Survival benefit in patients with solid tumors with elevated c-reactive protein levels
US11708412B2 (en) 2013-09-26 2023-07-25 Novartis Ag Methods for treating hematologic cancers
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
KR20160073413A (en) 2013-10-23 2016-06-24 추가이 세이야쿠 가부시키가이샤 Quinazolinone and isoquinolinone derivative
US10005739B2 (en) 2013-10-23 2018-06-26 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
WO2015060373A1 (en) 2013-10-23 2015-04-30 中外製薬株式会社 Quinazolinone and isoquinolinone derivative
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
US10752687B2 (en) 2014-01-24 2020-08-25 Novartis Ag Antibody molecules to PD-1 and uses thereof
US11827704B2 (en) 2014-01-24 2023-11-28 Novartis Ag Antibody molecules to PD-1 and uses thereof
EP3514179A1 (en) 2014-01-24 2019-07-24 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
US10472419B2 (en) 2014-01-31 2019-11-12 Novartis Ag Antibody molecules to TIM-3 and uses thereof
EP4324518A2 (en) 2014-01-31 2024-02-21 Novartis AG Antibody molecules to tim-3 and uses thereof
US11155620B2 (en) 2014-01-31 2021-10-26 Novartis Ag Method of detecting TIM-3 using antibody molecules to TIM-3
US10981990B2 (en) 2014-01-31 2021-04-20 Novartis Ag Antibody molecules to TIM-3 and uses thereof
WO2015131031A1 (en) 2014-02-28 2015-09-03 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP3660050A1 (en) 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
US10064866B2 (en) 2014-04-08 2018-09-04 Incyte Corporation Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors
WO2015157257A1 (en) 2014-04-08 2015-10-15 Incyte Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
EP3795152A1 (en) 2014-04-08 2021-03-24 Incyte Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
US10675284B2 (en) 2014-04-08 2020-06-09 Incyte Corporation Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors
US10450325B2 (en) 2014-04-30 2019-10-22 Incyte Corporation Processes of preparing a JAK1 inhibitor and new forms thereto
WO2015168246A1 (en) 2014-04-30 2015-11-05 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
US9802957B2 (en) 2014-04-30 2017-10-31 Incyte Corporation Processes of preparing a JAK1 inhibitor and new forms thereto
US11130767B2 (en) 2014-06-11 2021-09-28 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US11999751B2 (en) 2014-06-11 2024-06-04 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US10479803B2 (en) 2014-06-11 2019-11-19 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016016370A1 (en) 2014-07-31 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists
WO2016035023A1 (en) 2014-09-03 2016-03-10 Novartis Ag Pharmaceutical combinations and their use
EP3925622A1 (en) 2014-09-13 2021-12-22 Novartis AG Combination therapies
EP3659621A1 (en) 2014-09-13 2020-06-03 Novartis AG Combination therapies for cancer
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
EP3662903A2 (en) 2014-10-03 2020-06-10 Novartis AG Combination therapies
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
WO2016057841A1 (en) 2014-10-08 2016-04-14 Novartis Ag Compositions and methods of use for augmented immune response and cancer therapy
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP4245376A2 (en) 2014-10-14 2023-09-20 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
US10022387B2 (en) 2015-02-09 2018-07-17 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US10596184B2 (en) 2015-02-09 2020-03-24 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US11014923B2 (en) 2015-02-20 2021-05-25 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11667635B2 (en) 2015-02-20 2023-06-06 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10336759B2 (en) 2015-02-27 2019-07-02 Incyte Corporation Salts and processes of preparing a PI3K inhibitor
EP3831833A1 (en) 2015-02-27 2021-06-09 Incyte Corporation Processes for the preparation of a pi3k inhibitor
US12024522B2 (en) 2015-02-27 2024-07-02 Incyte Corporation Salts and processes of preparing a PI3K inhibitor
US11084822B2 (en) 2015-02-27 2021-08-10 Incyte Corporation Salts and processes of preparing a PI3K inhibitor
WO2016138363A1 (en) 2015-02-27 2016-09-01 Incyte Corporation Salts of pi3k inhibitor and processes for their preparation
EP4183789A1 (en) 2015-02-27 2023-05-24 Incyte Holdings Corporation Salts of pi3k inhibitor and processes for their preparation
US11040053B2 (en) 2015-03-10 2021-06-22 Chinook Therapeutics, Inc. Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
WO2016183062A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US10125150B2 (en) 2015-05-11 2018-11-13 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
EP3095782A1 (en) 2015-05-18 2016-11-23 Esteve Química, S.A. New method for preparing 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US10894830B2 (en) 2015-11-03 2021-01-19 Janssen Biotech, Inc. Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
US11773102B2 (en) 2015-11-06 2023-10-03 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
WO2017079519A1 (en) 2015-11-06 2017-05-11 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
US11091491B2 (en) 2015-11-06 2021-08-17 Incyte Corporation Heterocyclic compounds as PI3K-y inhibitors
US10065963B2 (en) 2015-11-06 2018-09-04 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US10472368B2 (en) 2015-11-06 2019-11-12 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
EP4086259A1 (en) 2015-11-06 2022-11-09 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017120194A1 (en) 2016-01-05 2017-07-13 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
EP3792256A1 (en) 2016-01-05 2021-03-17 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
US11352340B2 (en) 2016-01-05 2022-06-07 Incyte Corporation Pyridine and pyridimine compounds as PI3K-gamma inhibitors
US11952367B2 (en) 2016-01-05 2024-04-09 Incyte Corporation Pyridine and pyridimine compounds as PI3K-gamma inhibitors
WO2017211937A1 (en) 2016-06-08 2017-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
EP4233840A2 (en) 2016-06-10 2023-08-30 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
US10479795B2 (en) 2016-06-24 2019-11-19 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
US10975088B2 (en) 2016-06-24 2021-04-13 Incyte Corporation Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US11078541B2 (en) 2016-11-02 2021-08-03 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
US11897868B2 (en) 2017-03-17 2024-02-13 Cardio Therapeutics Pty Ltd Heterocyclic inhibitors of PCSK9
US11091466B2 (en) 2017-03-17 2021-08-17 Cardio Therapeutics Pty Ltd Heterocyclic inhibitors of PCSK9
US10975114B2 (en) 2017-04-28 2021-04-13 Chinook Therapeutics, Inc. Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof
WO2018198076A1 (en) 2017-04-28 2018-11-01 Aduro Biotech, Inc. Bis 2'-5'-rr-(3'f-a)(3'f-a) cyclic dinucleotide compound and uses thereof
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
EP4006034A1 (en) 2017-10-18 2022-06-01 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
US10738057B2 (en) 2017-10-18 2020-08-11 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
US11225486B2 (en) 2017-10-18 2022-01-18 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11278541B2 (en) 2017-12-08 2022-03-22 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3501505A1 (en) 2017-12-20 2019-06-26 Zentiva K.S. A drug form comprising crystalline nilotinib
US11306079B2 (en) 2017-12-21 2022-04-19 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
WO2019126505A1 (en) 2017-12-21 2019-06-27 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US11833152B2 (en) 2018-02-16 2023-12-05 Incyte Corporation JAK1 pathway inhibitors for the treatment of cytokine-related disorders
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
WO2019226213A2 (en) 2018-03-08 2019-11-28 Incyte Corporation AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
US11926616B2 (en) 2018-03-08 2024-03-12 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors
EP4056560A1 (en) 2018-03-08 2022-09-14 Incyte Corporation Aminopyrazine diol compounds as pi3k-y inhibitors
US10669262B2 (en) 2018-03-08 2020-06-02 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors
WO2019191684A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US12024517B2 (en) 2018-05-04 2024-07-02 Incyte Corporation Salts of an FGFR inhibitor
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11873304B2 (en) 2018-05-18 2024-01-16 Incyte Corporation Fused pyrimidine derivatives as A2A/A2B inhibitors
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
US11713317B2 (en) 2018-05-25 2023-08-01 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
US10947227B2 (en) 2018-05-25 2021-03-16 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
WO2019227007A1 (en) 2018-05-25 2019-11-28 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
WO2019229658A1 (en) 2018-05-30 2019-12-05 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US11007195B2 (en) 2018-06-15 2021-05-18 Handa Oncology, Llc Kinase inhibitor salts, and compositions thereof
US11052088B2 (en) 2018-06-15 2021-07-06 Handa Oncology, Llc Kinase inhibitor salts, and compositions thereof
US10940149B1 (en) 2018-06-15 2021-03-09 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
US11160805B2 (en) 2018-06-15 2021-11-02 Handa Onocology, Llc Kinase inhibitor salts and compositions thereof
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
JP2020007240A (en) * 2018-07-04 2020-01-16 住友化学株式会社 Method for producing benzamide compound
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US11999740B2 (en) 2018-07-05 2024-06-04 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
WO2020016232A1 (en) 2018-07-17 2020-01-23 Boehringer Ingelheim International Gmbh Cardiosafe antidiabetic therapy
WO2020016230A1 (en) 2018-07-17 2020-01-23 Boehringer Ingelheim International Gmbh Cardio- and renosafe antidiabetic therapy
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
US11912722B2 (en) 2018-07-31 2024-02-27 Incyte Corporation Tricyclic heteroaryl compounds as sting activators
US11427597B2 (en) 2018-07-31 2022-08-30 Incyte Corporation Heteroaryl amide compounds as sting activators
US11008344B2 (en) 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
EP4338801A2 (en) 2018-09-05 2024-03-20 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
US11186580B2 (en) 2018-09-05 2021-11-30 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11866432B2 (en) 2018-10-11 2024-01-09 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US12006320B2 (en) 2018-11-13 2024-06-11 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020146237A1 (en) 2019-01-07 2020-07-16 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020159905A1 (en) 2019-01-29 2020-08-06 Incyte Corporation Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
US11884665B2 (en) 2019-01-29 2024-01-30 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020168178A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11602536B2 (en) 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor
US11590138B2 (en) 2019-06-10 2023-02-28 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021022172A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2021041360A1 (en) 2019-08-26 2021-03-04 Incyte Corporation Triazolopyrimidines as a2a / a2b inhibitors
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021074138A1 (en) * 2019-10-14 2021-04-22 Esco Aster Pte. Ltd. Synthesis of 6-methyl-n1-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021155254A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
US11998548B2 (en) 2020-01-31 2024-06-04 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
US11389450B2 (en) 2020-01-31 2022-07-19 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
US12016861B2 (en) 2020-01-31 2024-06-25 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
WO2021211864A1 (en) 2020-04-16 2021-10-21 Incyte Corporation Fused tricyclic kras inhibitors
EP3904342A1 (en) 2020-04-28 2021-11-03 Grindeks, A Joint Stock Company Process for the preparation of 3-(trifluoromethyl)-5-(4-methyl-1h-imidazole-1-yl)-benzeneamine hydrochloride
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US11559485B2 (en) 2020-04-30 2023-01-24 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
WO2021247668A1 (en) 2020-06-02 2021-12-09 Incyte Corporation Processes of preparing a jak1 inhibitor
US11685731B2 (en) 2020-06-02 2023-06-27 Incyte Corporation Processes of preparing a JAK1 inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
WO2022061351A1 (en) 2020-09-16 2022-03-24 Incyte Corporation Topical treatment of vitiligo
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
US11957661B2 (en) 2020-12-08 2024-04-16 Incyte Corporation JAK1 pathway inhibitors for the treatment of vitiligo
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2023283213A1 (en) 2021-07-07 2023-01-12 Incyte Corporation Tricyclic compounds as inhibitors of kras
WO2023287896A1 (en) 2021-07-14 2023-01-19 Incyte Corporation Tricyclic compounds as inhibitors of kras
WO2023034290A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
CN113717152A (en) * 2021-09-08 2021-11-30 上海皓鸿生物医药科技有限公司 Preparation method of specific MRK small molecule inhibitor
CN113717152B (en) * 2021-09-08 2022-06-17 上海皓鸿生物医药科技有限公司 Preparation method of specific MRK small molecule inhibitor
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
WO2023056421A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
WO2023091746A1 (en) 2021-11-22 2023-05-25 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
WO2023102184A1 (en) 2021-12-03 2023-06-08 Incyte Corporation Bicyclic amine compounds as cdk12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
WO2023122134A1 (en) 2021-12-22 2023-06-29 Incyte Corporation Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
WO2023116884A1 (en) 2021-12-24 2023-06-29 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
WO2023172921A1 (en) 2022-03-07 2023-09-14 Incyte Corporation Solid forms, salts, and processes of preparation of a cdk2 inhibitor
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
WO2023245053A1 (en) 2022-06-14 2023-12-21 Incyte Corporation Solid forms of a jak inhibitor and process of preparing the same
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
WO2024015731A1 (en) 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
US12029740B2 (en) 2022-07-18 2024-07-09 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
WO2024030600A1 (en) 2022-08-05 2024-02-08 Incyte Corporation Treatment of urticaria using jak inhibitors

Also Published As

Publication number Publication date
PT2357182E (en) 2014-09-02
EP2368889A1 (en) 2011-09-28
ES2318164T3 (en) 2009-05-01
US20090286821A1 (en) 2009-11-19
RU2348627C2 (en) 2009-03-10
JP4110140B2 (en) 2008-07-02
KR20060126847A (en) 2006-12-08
ES2475066T3 (en) 2014-07-10
US20080188451A1 (en) 2008-08-07
PL395096A1 (en) 2011-10-24
CA2677313A1 (en) 2004-01-15
KR100864740B1 (en) 2008-10-22
KR100733639B1 (en) 2007-06-29
IL198996A (en) 2017-02-28
ATE414699T1 (en) 2008-12-15
CO5680432A2 (en) 2006-09-29
GB0215676D0 (en) 2002-08-14
US20110218187A1 (en) 2011-09-08
PT1532138E (en) 2009-02-25
NO331166B1 (en) 2011-10-24
AU2003249962C9 (en) 2022-06-30
JP2013227358A (en) 2013-11-07
JP2005533827A (en) 2005-11-10
IL198996A0 (en) 2011-08-01
TW200403060A (en) 2004-03-01
RU2005102917A (en) 2005-10-27
MY143466A (en) 2011-05-31
CN1675195A (en) 2005-09-28
CY1108813T1 (en) 2014-04-09
IL165977A (en) 2010-12-30
WO2004005281A8 (en) 2004-05-06
MXPA05000328A (en) 2005-03-31
JP2011219495A (en) 2011-11-04
PL374583A1 (en) 2005-10-31
RU2445309C2 (en) 2012-03-20
BR0312464A (en) 2005-05-03
DE60324805D1 (en) 2009-01-02
BRPI0312464B1 (en) 2017-07-04
TWI313603B (en) 2009-08-21
EP2357182A1 (en) 2011-08-17
IL165977A0 (en) 2006-01-15
CN101045727A (en) 2007-10-03
CN1324022C (en) 2007-07-04
BRPI0312464B8 (en) 2021-05-25
US7569566B2 (en) 2009-08-04
JP4895976B2 (en) 2012-03-14
CA2677315C (en) 2013-01-08
ECSP055525A (en) 2005-03-10
CA2491632C (en) 2009-11-10
HK1160859A1 (en) 2012-08-17
EP2100891A1 (en) 2009-09-16
RU2008137927A (en) 2010-03-27
PL219723B1 (en) 2015-07-31
SI1532138T1 (en) 2009-04-30
GB0229893D0 (en) 2003-01-29
AU2003249962A1 (en) 2004-01-23
EP2357182B1 (en) 2014-05-21
NZ537396A (en) 2006-11-30
EP1532138B1 (en) 2008-11-19
JP2008044968A (en) 2008-02-28
AR040390A1 (en) 2005-03-30
CA2677315A1 (en) 2004-01-15
CA2677313C (en) 2012-01-24
HK1077811A1 (en) 2006-02-24
AU2003249962C1 (en) 2022-06-09
AU2003249962B2 (en) 2008-02-28
US7169791B2 (en) 2007-01-30
DK1532138T3 (en) 2009-03-23
ZA200410322B (en) 2006-07-26
EP1532138A1 (en) 2005-05-25
KR20050018952A (en) 2005-02-28
PL406680A1 (en) 2014-03-31
US20060167015A1 (en) 2006-07-27
NO20050636L (en) 2005-02-04
US20070093506A1 (en) 2007-04-26
US7956053B2 (en) 2011-06-07
PE20040647A1 (en) 2004-11-15
CA2491632A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
AU2003249962C9 (en) Inhibitors of tyrosine kinases
EP1546127B1 (en) Novel pyrimidineamide derivatives and the use thereof
AU2008202194B2 (en) Inhibitors of tyrosine kinases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200500148

Country of ref document: VN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NI NO NZ OM PG PH PL PT RO RU SC SE SG SK SY TJ TM TN TR TT UA US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 03/2004 UNDER (30) REPLACE "BG" BY "GB"

WWE Wipo information: entry into national phase

Ref document number: 2003249962

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004/10322

Country of ref document: ZA

Ref document number: 200410322

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 537396

Country of ref document: NZ

Ref document number: 165977

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 3003/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020057000159

Country of ref document: KR

Ref document number: 374583

Country of ref document: PL

Ref document number: 2491632

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004518718

Country of ref document: JP

Ref document number: PA/a/2005/000328

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 05001801

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2003762632

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038187280

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2005102917

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020057000159

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1-2005-500004

Country of ref document: PH

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2003762632

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006167015

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10520359

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10520359

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 198996

Country of ref document: IL